

第1日

D A Y 1

7月18日(木)

Thursday, July 18, 2019

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)

Special Presidential Session / 会長特別企画

- SPS1** A New Approach to Summarizing Treatment Effects: Are Conventional Methods for Analyzing OS and PFS Always Appropriate?
臨床試験における治療効果の要約方法の新しいアプローチ：OSやPFSを分析するために使われる統計学的手法は万能か？ 117

ASCO/JSMO Joint Symposium / ASCO/JSMO 合同シンポジウム

- AJS** Precision Oncology: How Do We Use a Panel Gene Test? 111

ESMO/JSMO Joint Symposium / ESMO/JSMO 合同シンポジウム

- EJS** Hereditary Cancer Treatment in Cancer Genome Era 112

Joint Symposium / 合同シンポジウム

- JS1** Role of Radiation Therapy in Cancer Patients
担癌患者に対する放射線治療の役割 119
- JS2** Rare Cancer in Asia: Current Status and Construction of Medical Network
アジアでの希少がん：現状及び診療のネットワーク構築について 122
- JS3** Cardio-Oncology Learned from Case Discussion
症例提示で学ぶ腫瘍循環器学 124

Presidential Symposium / 会長企画シンポジウム

- PSY1** Regulatory Science in an Era of Precision Medicine 111
- PSY2** Future Tracks of Clinical Oncology and Development in South-East Asia 118
- PSY3** Issues and Perspectives for Genomic Medicine in Oncology in General Hospitals
一般病院におけるがん領域のゲノム診療の課題と展望 118

Symposium / シンポジウム

- SY1** The Challenge of Translational Research
Translational Researchの課題とその克服 91
- SY2** Treatment Development Through Investigator-initiated Registration-directed Trials and the Advanced Medical Care System in Japanese Cancer Cooperative Groups
多施設共同試験グループにおける医師主導治験 / 先進医療を通じた治療開発の取り組み 92
- SY3** Clinical Trial in Supportive and Palliative Care
支持・緩和療養領域の今後の研究のありかた 95
- SY4** New Evidences of Chemotherapy in Biliary Tract and Pancreatic Cancers and Introduction them to the Practice
膵癌・胆道癌の新たな標準療法のエビデンスと臨床への影響 103

SY5	Immune Therapy for Hematologic Malignancies 造血器腫瘍に対する免疫療法	121
SY6	Cancer Immunotherapy: A Paradigm Shift in the First-line Treatment of Lung Cancer 肺癌薬物療法のパラダイムシフト～初回治療総入れ替え元年	124
SY7	Future Prospects of Immune Checkpoint Inhibitors 免疫チェックポイント阻害薬の展望	125

Mini Symposium / ミニシンポジウム

MS1	Development of Combination Therapy Using I-O Agent for Upper GI Tract Cancer 上部消化管癌における免疫チェックポイント阻害薬併用療法の開発	103
MS2	How to Integrate Molecular Biomarker in Clinic for CRC?	109

Panel Discussion / パネルディスカッション

PD1	The Role of Multidisciplinary Staffs on the Support to Decision Making for Patients with Cancer 治療方針決定支援プロセスにおける多職種役割	95
------------	--	----

Workshop / ワークショップ

WS1	How Do We Properly Use Various Regimens in Chemotherapy for Advanced HCC? 肝細胞癌の薬物療法の使い分け	121
------------	---	-----

Educational Lecture / 教育講演

EL1	腫瘍生物学の基礎 I	87
EL2	腫瘍生物学の基礎 II	87
EL3	腫瘍生物学の基礎 III	87
EL4	腫瘍免疫学の基礎	88
EL5	抗がん薬の臨床薬理・化学療法の基本的理論	88
EL6	化学療法総論 I: 殺細胞性抗がん剤の種類	88
EL7	化学療法総論 II: 分子標的薬剤の種類	88
EL8	副作用とその対策, 支持療法	89
EL9	オンコロジー・エマーゼンシー・腫瘍随伴症候群	89
EL10	高齢者のがん治療	89
EL11	がん緩和医療	89
EL12	サイコオンコロジー・ACP (Advanced Care Planning)	90
EL13	利益相反	90
EL14	個人情報保護・臨床研究法	90
EL15	頭頸部癌・甲状腺癌	91
EL16	食道癌・胃癌	94

Distinguished Expert Lecture

DL1	My Lung Cancer World: Yesterday, Today and Tomorrow	127
------------	---	-----

DL2	Precision Medicine in Triple Negative Breast Cancer: The Future is Coming.....	128
DL3	Breast Cancer in Young and Premenopausal Women	128
DL4	Checkpoint Inhibition and Other Immunotherapies in the Management of Sarcomas: Are We There Yet?	128
DL5	Challenges of Current Management in Nasopharyngeal Carcinoma from a Perspective of a High Incidence Developing Country	128
DL6	International Collaboration in Cancer Clinical Trials: The Australasian Gastrointestinal Cancer Trials Group Experience	129

Meet the Experts

ME1	Targeting Biliary Tract Cancers	130
ME2	Evolving Strategies for Enhancing the Impact of Immunotherapy in Breast Cancer	130
ME3	Frailty and Challenges of Immunotherapy in Older Patients	130
ME4	New Therapeutic Strategies for EGFR Mutant Lung Cancer	130
ME5	Development of Immunotherapy in Gastro-esophageal Cancer in the Worldwide Arena	131
ME6	Treatment Strategies for Newly Diagnosed Elderly Patients with Multiple Myeloma	131

国立京都国際会館 1階 メインホール

9:00-10:15 Oral Abstract Session 1-1

O1-1 Hematologic Malignancies

血液

Chairs : Priscilla B. Caguioa (University of Santo Tomas Hospital, St. Lukes Medical Center Quezon City)
Itaru Matsumura (Department of Hematology and Rheumatology Kindai University Faculty of Medicine)

Discussant : Wataru Munakata (Department of Hematology, National Cancer Center Hospital)

司会 : Priscilla B. Caguioa (University of Santo Tomas Hospital, St. Lukes Medical Center Quezon City)
松村 到 (近畿大学医学部 血液・膠原病内科)

ディスカッサント: 棟方 理 (国立がん研究センター中央病院 血液腫瘍科)

O1-1-1 Prediction of toxicity in R/R DLBCL treated with Axicabtagene Cleioleucel (19-28z CAR T)

Hiroshi Kotani (Clinical Science Division, H. Lee Moffitt Cancer Center and Research Institute)
小谷 浩 (Clinical Science Division, H. Lee Moffitt Cancer Center and Research Institute)

O1-1-2 Analysis of Japanese Patients from the AUGMENT Phase 3 Study of Lenalidomide+Rituximab vs Rituximab+Placebo in R/R iNHL

Yosuke Minami (Department of Hematology, National Cancer Center Hospital East, Chiba, Japan)

O1-1-3 A Phase 1b/2 Study of Blinatumomab in Japanese Subjects with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)

Keizo Horibe (National Hospital Organization Nagoya Medical Center)
堀部 敬三 (独立行政法人国立病院機構 名古屋医療センター臨床研究センター)

O1-1-4 Unmanipulated haploidentical stem cell transplantation for high-risk hematologic malignancies

Kazuhiro Ikegame (Division of Hematology, Department of Medicine, Hyogo College of Medicine)
池亀 和博 (兵庫医科大学 内科学講座 血液内科)

10:15-11:30 Oral Abstract Session 1-2

O1-2 Head and Neck Cancer

頭頸部がん

Chairs : Yasushi Shimizu (Hokkaido University Hospital Department of Medical Oncology)
Voon Pei Jye (Radiotherapy and Oncology Department, Hospital Umum Sarawak)
Discussant : Ryuji Yasumatsu (Department of Otolaryngology, Graduate of Medical Sciences, Kyushu University)

司会 : 清水 康 (北海道大学病院 腫瘍内科)

Voon Pei Jye (Radiotherapy and Oncology Department, Hospital Umum Sarawak)

ディスカッサント: 安松 隆治 (九州大学大学院医学研究院 耳鼻咽喉科学分野)

O1-2-1 Phase 1 study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma

Makoto Tahara (Department of Head and Neck Medical Oncology, National Cancer Center Hospital East)
田原 信 (国立がん研究センター東病院 頭頸部内科)

O1-2-2 Post-marketing survey of safety and efficacy of nivolumab for recurrent or metastatic head and neck cancer in Japan

Naomi Kiyota (Kobe University Hospital Cancer Center)
清田 尚臣 (神戸大学医学部附属病院 腫瘍センター)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
4/F
Annex 1
Annex 2
Room A
Room B-1
Room D
Room E
5<5
5/F
6/F
7/F
8/F
Room C-1
Room C-2
Room B-2
Room 104

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) 4/27-28/ Annex 1 Annex 2 Room A Room B-1 Room D Room E 6<5> スラッ 04/11/04 04-21/04 04-21/04 04-21/04 Room C-1 Room C-2 Room B-2 Room 104

01-2-3 Japanese Subgroup Analysis of KEYNOTE-048: Ph3 Study of 1L Pembrolizumab for R/M Head and Neck Squamous Cell Carcinoma
 Shunji Takahashi (Cancer Institute Hospital, Japanese Foundation for Cancer Research)
 高橋 俊二 (がん研究会有明病院 総合腫瘍科)

01-2-4 Efficacy of nivolumab for head and neck cancer arising from subsites which were not included in CheckMate 141
 Yuri Ueda (Department of Head and Neck Medical Oncology, National Cancer Center East, Japan)
 上田 百合 (国立がん研究センター東病院 頭頸部内科)

13:40-15:40 Presidential Session 1

PS1 Presidential Session 1

Chairs : Yuichiro Ohe (National Cancer Center Hospital, Dept. Thoracic Oncology)
 Yoon-Sim Yap (National Cancer Centre Singapore, Singapore)
 司会 : 大江 裕一郎 (国立がん研究センター中央病院 呼吸器内科)
 Yoon-Sim Yap (National Cancer Centre Singapore, Singapore)

PS1-1 Phase III study of CBDCA/PEM followed by PEM versus DOC in elderly pts with advanced non-sq NSCLC (JCOG1210/WJOG7813L)
 Hiroshi Nokihara (Tokushima University Hospital)
 軒原 浩 (徳島大学病院)

Discussant : James CH Yang (National Taiwan University College of Medicine, Taiwan)

PS1-2 RELAY: Global Ph3 study of erlotinib + ramucirumab or placebo in metastatic NSCLC with EGFR mutation - East Asian subset
 Makoto Nishio (Department of Thoracic Medical Oncology, The Cancer Institute Hospital of JFCR)
 西尾 誠人 (公益財団法人がん研究会有明病院 呼吸器内科)

Discussant : Tetsuya Mitsudomi (Thoracic Surgery, Kindai University Faculty of Medicine)
 ディスカッション: 光富 徹哉 (近畿大学医学部 外科学講座呼吸器外科部門)

PS1-3 Alpelisib (ALP) +fulvestrant (FUL) in patients from Japan with advanced breast cancer: Subgroup analysis of SOLAR-1 trial
 Hiroji Iwata (Department of Breast Oncology, Aichi Cancer Center Hospital)
 岩田 広治 (愛知県がんセンター中央病院 乳腺部)

Discussant : Yukinori Ozaki (Toranomon Hospital)
 ディスカッション: 尾崎 由記範 (虎の門病院 臨床腫瘍科)

PS1-4 KEYNOTE-048: 1st-line (1L) pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
 Makoto Tahara (National Cancer Center Hospital East, Kashiwa, Japan)

Discussant : Shunji Takahashi (Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research)
 ディスカッション: 高橋 俊二 (がん研究会有明病院 総合腫瘍科)

15:40-16:55 Oral Abstract Session 1-3

01-3 Lung Cancer/Thoracic Cancer1 (Lung Cancer1)
呼吸器 1 (肺がん 1)

Chairs : Nobuyuki Katakami (Department of Medical Oncology, Takarazuka City Hospital)
Naiyarat Prasongsook (Pramongkutkloa Hospital)

Discussant : Satoru Miura (Niigata Cancer Center Hospital)

司会 : 片上 信之 (宝塚市立病院 腫瘍内科)
Naiyarat Prasongsook (Pramongkutkloa Hospital)

マイカサント : 三浦 理 (新潟県立がんセンター新潟病院)

01-3-1 **A randomized phase III study of maintenance Bev with or without Pem after CBDCA, Pem, and Bev for nSQ-NSCLC (WJOG5610L)**

Koichi Azuma (Division of Respiriology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine)
東 公一 (久留米大学)

01-3-2 **Randomized Phase III Study of PEM/CDDP and VNR/CDDP for completely resected stage II-IIIa non-squamous NSCLC: JIPANG**

Akira Okada (Department of Chest Surgery, Niigata Cancer Center Hospital)
岡田 英 (新潟県立がんセンター新潟病院 呼吸器外科)

01-3-3 **KEYNOTE-042 Final Analysis: Pembrolizumab vs Chemotherapy in First-Line PD-L1-Positive Locally Advanced/Metastatic NSCLC**

Kaoru Kubota (Nippon Medical School Hospital, Tokyo, Japan)

01-3-4 **Pembrolizumab in Elderly Patients With PD-L1-positive Advanced NSCLC: A Pooled Analysis from KEYNOTE-010, -024, and -042**

Yukio Hosomi (Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan)

16:55-18:10 Oral Abstract Session 1-4

01-4 Lung Cancer/Thoracic Cancer2 (Lung Cancer2)
呼吸器 2 (肺がん 2)

Chairs : Hideo Saka (Departments of Medical Oncology and Respiratory Medicine)
Tomoyasu Mimori (Saiseikai Kawaguchi General Hospital Respiratory medicine)

Discussant : Motoko Tachihara (Division of Respiratory Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine)

司会 : 坂 英雄 (名古屋医療センター 名古屋がんセンター臨床腫瘍科・呼吸器科)
三森 友靖 (埼玉県済生会川口総合病院 呼吸器内科)

マイカサント : 立原 素子 (神戸大学大学院医学研究科内科学講座呼吸器内科学分野)

01-4-1 **Effects of Dose Modifications on Safety and Efficacy of Dacomitinib for EGFR⁺ NSCLC in ARCHER 1050 Japanese Subset**

Terufumi Kato (Kanagawa Cancer Center, Japan)

01-4-2 **Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK+ NSCLC from ALTA-1L**

James CH Yang (National Taiwan University Hospital, Taiwan)

01-4-3 **Therapeutic and prognostic impacts of specific gene alterations for squamous cell lung cancer in LC-SCRUM-Japan**

Haruko Daga (Department of Medical Oncology, Osaka City General Hospital)
駄賀 晴子 (大阪市立総合医療センター 腫瘍内科)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
キッズビル
Annex 1
Annex 2
Room A
Room B-1
Room D
Room E
さくら
スライ
D441111-1
D-211-1
F-11111-1
Room C-1
Room C-2
Room B-2
Room 104

01-4-4 **Clinical development of molecular-targeted therapies for non-small cell lung cancer through LC-SCRUM-Japan**

Kei Kunimasa (Department of Thoracic Oncology, Osaka International Cancer Institute)

國政 啓 (大阪国際がんセンター 呼吸器内科)

9:00-9:30 Educational Lecture 1 / 教育講演 1 : 入門編

EL1 腫瘍生物学の基礎 I

Chair : Takuma Onoe (Division of Medical Oncology, Hyogo Cancer Center)
 司会 : 尾上 琢磨 (兵庫県立がんセンター 腫瘍内科)

Translational Research Based on Molecular Pathology of Cancer

Yataro Daigo (Department of Medical Oncology and Cancer Center, Shiga University of Medical Science/Center for Antibody and Vaccine Therapy, Research Hospital, Institute of Medical Science Hospital, The University of Tokyo)

がんの分子病態に基づいたトランスレーショナルリサーチ

醍醐 弥太郎 (滋賀医科大学臨床腫瘍学講座・腫瘍内科・腫瘍センター / 東京大学医科学研究所附属病院抗体・ワクチンセンター)

9:30-10:00 Educational Lecture 2 / 教育講演 2 : 入門編

EL2 腫瘍生物学の基礎 II

Chair : Koichi Akashi (Department of Medicine and Biosystemic Science, Graduate School of Medical Science, Kyushu University)
 司会 : 赤司 浩一 (九州大学大学院 医学研究院病態修復内科学講座)

Introduction to the Basics of Tumor Biology II

Osamu Maeda (Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital)

腫瘍生物学の基礎II

前田 修 (名古屋大学医学部附属病院)

10:00-10:30 Educational Lecture 3 / 教育講演 3 : 入門編

EL3 腫瘍生物学の基礎 III

Chair : Akihiko Gemma (Nippon Medical School)
 司会 : 弦間 昭彦 (日本医科大学)

The Overview of Molecular Analyses and Companion Diagnostics

Hiroya Taniguchi (National Cancer Center Hospital East)

腫瘍生物学 (III) - 分子生物学的解析法とコンパニオン診断薬

谷口 浩也 (国立がん研究センター東病院)

Day 1 (Thu)
 Day 2 (Fri)
 Day 3 (Sat)
 4/27(木)
 Annex 1
 Annex 2
 Room A
 Room B-1
 Room D
 Room E
 5<5
 5<5
 5<5
 D-1111-1
 D-1111-1
 5-1111-1
 Room C-1
 Room C-2
 Room B-2
 Room 104

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
Annex 1
Annex 2
Room A
Room B-1
Room D
Room E
さくら
スラッ
D-111-1
D-211-1
F-111-1
Room C-1
Room C-2
Room B-2
Room 104

10:30-11:00 Educational Lecture 4 / 教育講演 4 : 入門編

EL4 腫瘍免疫学の基礎

Chair : Hideo Harigae (Dep. Hematology and Rheumatology, Tohoku University Graduate School of Medicine)
司会 : 張替 秀郎 (東北大学 大学院 医学系研究科 血液・免疫病学分野)

Recent Findings in Tumor Immunology

Shigehisa Kitano (Department of Experimental Therapeutics, National Cancer Center Hospital)

腫瘍免疫領域における最近の知見

北野 滋久 (国立がん研究センター中央病院 先端医療科)

11:00-11:30 Educational Lecture 5 / 教育講演 5 : 入門編

EL5 抗がん薬の臨床薬理・化学療法の基本的理論

Chair : Masahiro Goto (Osaka Medical College Hospital, Cancer Chemotherapy Center)
司会 : 後藤 昌弘 (大阪医科大学附属病院 化学療法センター)

Clinical Pharmacology of Anticancer Drugs and Theory of Chemotherapy

Tomoya Shimokata (Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital)

抗がん薬の臨床薬理・化学療法の基本的理論

下方 智也 (名古屋大学医学部附属病院 化学療法部)

13:40-14:10 Educational Lecture 6 / 教育講演 6 : 入門編

EL6 化学療法総論 I : 殺細胞性抗がん剤の種類

Chair : Keita Kirito (Department of Hematology&Oncology, University of yamanashi)
司会 : 桐戸 敬太 (山梨大学医学部附属病院 血液・腫瘍内科)

Cytotoxic Anticancer Agents

Nagio Takigawa (Kawasaki Medical School)

殺細胞性抗がん薬

瀧川 奈義夫 (川崎医科大学)

14:10-14:40 Educational Lecture 7 / 教育講演 7 : 入門編

EL7 化学療法総論 II : 分子標的薬剤の種類

Chair : Toshihiro Kudo (Osaka International Cancer Institute)
司会 : 工藤 敏啓 (大阪国際がんセンター 腫瘍内科)

Categories and Characteristics of Molecular Targeting Agents

Jiichiro Sasaki (Division of Clinical Oncology, Department of Comprehensive Medicine, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine)

分子標的薬剤の分類と特徴

佐々木 治一郎 (北里大学医学部附属新世紀医療開発エンター 横断的医療領域開発部門 臨床腫瘍学)

14:40-15:10 Educational Lecture 8 / 教育講演 8 : 入門編

EL8 副作用とその対策、支持療法

Chair : Satoshi Iyama (Department of Hematology, Sapporo Medical University School of Medicine)
司会 : 井山 諭 (札幌医科大学附属病院 血液内科)

Management of Adverse Events and Supportive Care of Cancer Chemotherapy

Hisateru Yasui (Department of Medical Oncology, Kobe City Medical Center General Hospital)

副作用とその対策、支持療法

安井 久晃 (神戸市立医療センター中央市民病院腫瘍内科)

15:10-15:40 Educational Lecture 9 / 教育講演 9 : 入門編

EL9 オンコロジー・エマージェンシー・腫瘍随伴症候群

Chair : Norifumi Tsukamoto (Oncology Center, Gunma University Hospital)
司会 : 塚本 憲史 (群馬大学医学部附属病院 腫瘍センター)

Oncologic Emergency / Paraneoplastic Syndrome

Rumiko Okamoto (Medical Oncology Department, Chibanishi General Hospital)

がん救急 / 腫瘍随伴症候群

岡元 るみ子 (千葉西総合病院)

15:40-16:10 Educational Lecture 10 / 教育講演 10 : 入門編

EL10 高齢者のがん治療

Chair : Michio Nakamura (Department of Gastroenterology, Sapporo City General Hospital)
司会 : 中村 路夫 (市立札幌病院 消化器内科)

Cancer therapy for geriatric patients

Chiyoe Kitagawa (NHO Nagoya Medical Center)

高齢者のがん治療

北川 智余恵 (名古屋医療センター)

16:10-16:40 Educational Lecture 11 / 教育講演 11 : 入門編

EL11 がん緩和医療

Chair : Nobukazu Fujimoto (Department of Medical Oncology, Okayama Rosai Hospital)
司会 : 藤本 伸一 (岡山労災病院 腫瘍内科)

Update of Palliative Medicine in Oncology

Hiroto Ishiki (National Cancer Center Hospital)

がん緩和医療 Update

石木 寛人 (国立がん研究センター中央病院)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
Avenue
Annex 1
Annex 2
Room A
Room B-1
Room D
Room E
E&S
Sロン
D4/F/H/A
D-7/A
F-H/A
Room C-1
Room C-2
Room B-2
Room 104

16:40-17:10 Educational Lecture 12 / 教育講演 12 : 入門編

EL12 サイコオンコロジー・ACP (Advanced Care Planning)

Chair : Akihiro Bessho (Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital)
司会 : 別所 昭宏 (岡山赤十字病院 呼吸器内科)

Psycho-Oncology, Advance Care Planning

Asao Ogawa (Department of Psycho-Oncology Service, National Cancer Center Hospital East / Division of Psycho-Oncology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center)

サイコオンコロジー、アドバンス・ケア・プランニング

小川 朝生 (国立がん研究センター東病院 精神腫瘍科 / 国立がん研究センター 先端医療開発センター 精神腫瘍学開発分野)

17:10-17:40 Educational Lecture 13 / 教育講演 13 : 入門編

EL13 利益相反

Chair : Shiro Akinaga (AccuRna, Inc., CEO)
司会 : 秋永 士朗 (アキュルナ株式会社 代表取締役社長)

Conflict of Interest

Narikazu Boku (National Cancer Center Hospital)

利益相反

朴 成和 (国立がん研究センター中央病院)

17:40-18:10 Educational Lecture 14 / 教育講演 14 : 入門編

EL14 個人情報保護・臨床研究法

Chair : Emiko Ohki (Medical Affairs, Oncology, Pfizer Japan Inc.)
司会 : 大木 恵美子 (ファイザー株式会社 オンコロジー部門 メディカル・アフェアーズ部)

Act on the Protection of Personal Information and Clinical Trial Act

Tsunakuni Ikka (Healthcare Law Section, Bioethics and Healthcare Law Division, Center for Public Health Sciences, National Cancer Center Japan)

個人情報保護法と臨床研究法について

一家 綱邦 (国立がん研究センター社会と健康研究センター生命倫理・医事法研究部医事法研究室)

国立京都国際会館 1階 Annex2

9:00-11:00 Symposium 1 / シンポジウム 1

SY1 The Challenge of Translational Research Translational Research の課題とその克服

Chairs : Yasuhiro Koh (Internal Medicine III, Wakayama Medical University)
Sadakatsu Ikeda (Tokyo Medical and Dental University Cancer Center)
司会 : 洪 泰浩 (和歌山県立医科大学 内科学第三講座)
池田 貞勝 (東京医科歯科大学 腫瘍センター)

SY1-1 Tumor Mutation Burden in lung cancer

David P. Carbone (James Thoracic Oncology Center, Ohio State University, United States)

SY1-2 Development of redox metabolic imaging for early evaluation of cancer treatment

Masayuki Matsuo (Department of Radiology, Gifu University)

腫瘍レドックス代謝可視化による診断開発

松尾 政之 (岐阜大学 放射線科)

SY1-3 Development of novel strategies to overcome resistance to targeted therapies

Susumu Kobayashi (Division of Transnational Genomics, NCC-EPOC)

分子標的治療抵抗性腫瘍の治療開発

小林 進 (国立がん研究センター 先端医療開発センター)

SY1-4 High-throughput functional evaluation of variants of unknown significance in oncogene

Encore Shinji Kohsaka (Division of Cellular Signaling, National Cancer Center Research Institute)

がん遺伝子における意義不明バリエーションのハイスループット機能解析法

高阪 真路 (国立がん研究センター 研究所 細胞情報学分野)

11:00-11:30 Educational Lecture 15 / 教育講演 15 : 応用編

EL15 頭頸部癌・甲状腺癌

Chair : Yusuke Onozawa (Division of Clinical Oncology, Shizuoka Cancer Center)
司会 : 小野澤 祐輔 (静岡県立静岡がんセンター 原発不明科)

Anti-cancer Drugs for Head and Neck Cancer and Thyroid Cancer

Makoto Tahara (Department of Head and Neck Medical Oncology, National Cancer Center Hospital East)

頭頸部がん・甲状腺がんの薬物療法

田原 信 (国立がん研究センター 東病院)

13:30-15:40 Symposium 2 / シンポジウム 2

SY2

Treatment Development Through Investigator-initiated Registration-directed Trials and the Advanced Medical Care System in Japanese Cancer Cooperative Groups

多施設共同試験グループにおける医師主導治験 / 先進医療を通じた治療開発の取り組み

Chairs : Tomomi Hata (International Trial Management Section, Research Management Division, Clinical Research Support Office, National Cancer Center Hospital)
Haruhiko Fukuda (Data Management Division / JCOG Data Center, Clinical Research Support Office, National Cancer Center Hospital)

司会 : 秦 友美 (国立がん研究センター中央病院 臨床研究支援部門 研究企画推進部 国際研究支援室)
福田 治彦 (国立がん研究センター中央病院 臨床研究支援部門データ管理部 / JCOGデータセンター)

SY2-1 西日本がん研究機構 (WJOG) における医師主導治験の取り組みと問題点

Koji Takeda (West Japan Oncology Group)

武田 晃司 (西日本がん研究機構)

SY2-2 Challenge and issues for investigator initiated clinical trial and advanced medical care from the standpoint of TORG

Yukiko Nakamura (Department of Respiratory Medicine, Yokohama Municipal Citizen's Hospital)

TORGにおける医師主導治験 / 先進医療の取り組みと問題点

中村 有希子 (横浜国立大学市民病院 呼吸器内科)

SY2-3 Investigator-Initiated Registration Directed Trials, or Advanced Medical Care conducted by GOTIC and NRG-Oncology Japan

Keiichi Fujiwara (Saitama Medical University International Medical Center)

GOTIC/NRG-Japanが行う国際・国内共同医師主導治験 / 先進医療への取り組みと問題点

藤原 恵一 (埼玉医科大学国際医療センター 包括的がんセンター)

SY2-4 Investigator-initiated clinical trials of Chiken and Advanced Medical Care B in the Japan Clinical Oncology Group

Junko Eba (Clinical Research Support Office, National Cancer Center Hospital)

JCOGにおける医師主導治験 / 先進医療の取り組みと問題点

江場 淳子 (国立がん研究センター中央病院 臨床研究支援部門)

15:40-16:50 Oral Abstract Session 1-5

O1-5

Translational Research
TR

Chairs : Masakazu Toi (Kyoto University Hospital)
Ichiro Kinoshita (Hokkaido University Hospital, Division of Clinical Cancer Genomics)

Discussant : Tohru Ohmori (Div Allergol & Resp Med Dept Int Med Showa Univ Sch Med)

司会 : 戸井 雅和 (京都大学医学部附属病院 乳腺外科)
木下 一郎 (北海道大学病院 がん遺伝子診断部)
大森 亨 (昭和大学 医学部 内科学講座 呼吸器アレルギー教室)

O1-5-1 Phenotypic and Genetic Dissection of HCC Based on Tumor Evolutionary Trait

Yosuke Hirotsu (Genome Analysis Center, Yamanashi Central Hospital)

弘津 陽介 (山梨県立中央病院ゲノム解析センター)

O1-5-2 Circulating tumor DNA molecular profiling in rare cancer patients from the MASTER KEY Project

Hitomi Okuma (National Cancer Center Hospital)

大熊 ひとみ (国立がん研究センター中央病院)

01-5-3	<p>190 検体のMSI 検査とミスマッチ修復酵素免疫染色のペア解析 ～不一致例で見られたMSI statusの腫瘍内不均一性～ Kenji Amemiya (Genome Analysis Center, Yamanashi Central Hospital) 両宮 健司 (山梨県立中央病院ゲノム解析センター)</p>
01-5-4	<p>Genetic Alterations in Cerebrospinal Fluid Predict Clinical Outcomes of Brain/Leptomeningeal Metastases among NSCLC Mei-Mei Zheng (Guangdong Provincial People's Hospital, School of Medicine, South China University of Technology, China / Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences)</p>
16:50-17:40 Mini-Oral Abstract Session 1-1	
MO1-1	Gynecologic Cancer 婦人科
Chair : Hidetaka Nomura (Cancer Institute Hospital of JFCR) 司会 : 野村 秀高 (がん研究会有明病院 婦人科)	
MO1-1-1	<p>Pre-operative paraspinal muscle index is a prognostic factor for survival in patients with epithelial ovarian cancer WANKYU EO (Kyung Hee University Hospital at Gangdong, Seoul, Korea)</p>
MO1-1-2	<p>Safety and efficacy of carboplatin desensitization protocol in patients with ovarian cancer Meiko Nishimura (Department of Medical Oncology, Hyogo Cancer Center) 西村 明子 (兵庫県立がんセンター 腫瘍内科)</p>
MO1-1-3	<p>Awareness about Cervical Cancer and Its Prevention among the Female Respondents of General Hospital in Bangladesh Nur-E- Alam (Biotechnology and Genetic Engineering Department, Faculty of Life Science, Mawlana Bhashani Science and Technology University, Bangladesh)</p>
MO1-1-4	<p>Evaluation of HPV DNA and mRNA testing for Cervical Cancer Screening in National Cancer Institute, Thailand Supakorn Pitakkarnkul (Gynecologic oncology Division, National Cancer Institute, Thailand)</p>
MO1-1-5	<p>Prevalence and determinants of high-risk HPV infection among 11549 women in Hubei Province, China Wu-Xufeng (Hubei Maternal and Child Health Hospital, China)</p>
MO1-1-6	<p>HER3 protein expression is risk factors for postoperative recurrence in patients with carcinoma of the cervix Yukiko Sugiura (Department of Breast and Medical Oncology, National Cancer Center Hospital / Department of Gynecology, National Cancer Center Hospital) 杉浦 由紀子 (国立がん研究センター中央病院 乳腺腫瘍内科 / 国立がん研究センター中央病院 婦人腫瘍科)</p>

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
Annex 1
Annex 2
Room A
Room B-1
Room D
Room E
Room C-1
Room C-2
Room B-2
Room 104

EL16 食道癌・胃癌

Chair : Kentaro Yamazaki (Division of Gastrointestinal Oncology, Shizuoka Cancer Center)
司会 : 山崎 健太郎 (静岡県立静岡がんセンター 消化器内科)

Current Progress of Chemotherapy for Gastric and Esophageal Cancer

Ken Kato (National Cancer Center Hospital)

胃癌食道癌に対する最近の化学療法

加藤 健 (国立がん研究センター中央病院)

SY3	Clinical Trial in Supportive and Palliative Care 支持・緩和療領域の今後の研究のありかた
Chairs :	Akira Inoue (Tohoku University School of Medicine, Department of Palliative Medicine) Masanori Mori (Palliative Care Team, Seirei Mikatahara General Hospital)
司会 :	井上 彰 (東北大学大学院 医学系研究科緩和医療学分野) 森 雅紀 (聖隷三方原病院 緩和ケアチーム)
SY3-1	Supportive and Palliative care research guideline (General remarks) Sadamoto Zenda (National Cancer Center Hospital East) 支持療法・緩和治療領域研究ポリシーについて 全田 貞幹 (国立がん研究センター東病院)
SY3-2	Endpoints and assessment measures in supportive and palliative care studies Takuhiro Yamaguchi (Biostatistics, Tohoku University Graduate School of Medicine) 支持療法・緩和治療領域研究における研究デザイン エンドポイントと評価尺度を中心に 山口 拓洋 (東北大学大学院医学系研究科 医学統計学分野)
SY3-3	Conduction of the multicenter clinical trial of the supportive care with multi-medical division and multi-medical staff Masakazu Abe (Gynecologic Oncology, Shizuoka Cancer Center) 多科・多職種・多施設による支持療法臨床試験の実施体制の構築 ~J-FORCE STUDYの経験から~ 安部 正和 (静岡県立静岡がんセンター 婦人科)
SY3-4 Encore	Smartphone psychotherapy to reduce fear of recurrence: a randomised controlled trial Tatsuo Akechi (Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences) がん患者の精神症状に対するスマートフォン・アプリの有用性-eConsentとePROを用いたデータ管理システムを用いた臨床試験 明智 龍男 (名古屋市立大学大学院医学研究科)
SY3-5	Learned during the conduct of a clinical trial for cancer patients with palliative care settings Tomofumi Miura (Department of Palliative Medicine, National Cancer Center Hospital East) 緩和ケア主体の時期のがん患者の症状緩和における臨床試験を通じて得られたこと 三浦 智史 (国立がん研究センター東病院 緩和医療科)
13:40-15:40 Panel Discussion 1 / パネルディスカッション 1	
PD1	The Role of Multidisciplinary Staffs on the Support to Decision Making for Patients with Cancer 治療方針決定支援プロセスにおける多職種の役割
Chairs :	Shinji Ohno (Breast Oncology Center, Cancer Institute Hospital) Chikako Shimizu (Comprehensive Cancer Center, National Center for Global Health and Medicine)
司会 :	大野 真司 (がん研究会 有明病院 乳腺センター) 清水 千佳子 (国立国際医療研究センター病院 がん総合診療センター 乳腺腫瘍内科)
PD1-1	What is "Shared Decision Making"? Takeo Nakayama (School of Public Health, Kyoto University) Shared Decision Making <SDM> の可能性 中山 健夫 (京都大学大学院医学研究科 社会健康医学系専攻健康情報学分野)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Annex 1 Annex 2 Room A Room B-1 Room D Room E 6<5> スラッ Day1/1/1-4 Day2/1/1-4 Room C-1 Room C-2 Room B-2 Room 104

PD1-2	Communication skill and multidisciplinary care for oncology practice Noriyuki Katsumata (Nippon Medical School Musashikosugi Hospital) がん診療で求められるコミュニケーションスキルとチーム医療 勝俣 範之 (日本医科大学武蔵小杉病院)
PD1-3	Social worker's role in decision-making Support building consensus and preparing the environment as patient desire Yumiko Hayasaka (Kitasato University Hospital Total Support Centaer) 意思決定支援における医療ソーシャルワーカーの役割 ～合意形成に向けての支援と患者の望む療養環境を整えるために～ 早坂 由美子 (北里大学病院 トータルサポートセンター)
PD1-4	Impact of pharmacist counseling on decision making of cancer patients Encore Kanako Azuma (Tokyo Medical University Hospital) がん患者の意思決定における薬剤師の服薬カウンセリングの影響 東 加奈子 (東京医科大学病院)
PD1-5	The nursing role in the medical choice of hereditary breast cancer Megumi Okawa (Nursing Department, St Luke's International Hospital) 遺伝性乳がんの医療選択における看護師の役割 大川 恵 (聖路加国際病院看護部)
PD1-6	Supporting AYA cancer patients in decision making Chikako Shimizu (Comprehensive Cancer Center, National Center for Global Health and Medicine) 思春期・若年がん患者における意思決定の支援 清水 千佳子 (国立国際医療研究センター病院 がん総合診療センター 乳腺腫瘍内科)
15:40-16:55 Oral Abstract Session 1-6	
O1-6	Patient Advocacy/Suivorship 患者支援・サバイバーシップ
Chairs :	Harue Arao (Osaka University Graduate School of Medicine) Toshiyuki Kozuki (National Hospital Organization Shikoku Cancer Center)
Discussant :	Hirofumi Mukai (National Cancer Center Hospital East)
司会 :	荒尾 晴恵 (大阪大学大学院医学系研究科 保健学専攻) 上月 稔幸 (国立病院機構 四国がんセンター 臨床研究センター)
ディスカサント :	向井 博文 (国立がん研究センター東病院)
O1-6-1	Factors that affect distress faced by adolescents and young adults with cancer Takatoshi Hirayama (Department of Psycho-Oncology, National Cancer Center Hospital, Japan) AYA世代がん患者のつらさに影響を与える因子の検討 平山 貴敏 (国立がん研究センター中央病院 精神腫瘍科)
O1-6-2	A questionnaire survey about psychosocial effects due to appearance change among Japanese cancer patients Hitomi Sakai (Department of Medical Oncology, Kindai University Faculty of Medicine) 日本人がん患者における外見変化の心理社会的影響の質問紙調査 酒井 瞳 (近畿大学医学部内科学腫瘍内科)
O1-6-3	Psychological Intervention for Adolescence and Young Adult Cancer Survivors: A Multilevel Meta-analysis Nutthaporn Chandeyng (Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, Faculty of Medicine Vajira hospital, Navamindradhiraj University, Thailand)

01-6-4 **Growth hormone deficiency and replacement therapy in pediatric and adolescent brain tumor survivors**

Fumiyuki Yamasaki (Department of Neurosurgery, Hiroshima University Hospital)

小児、AYA世代の脳腫瘍サバイバーにおける成長ホルモン分泌不全と補充療法

山崎 文之 (広島大学病院 脳神経外科)

16:55-18:10 Oral Abstract Session 1-7

01-7 Palliative Care/Symptom Management
緩和ケア・支持療法

Chairs : Naoki Inui (Hamamatsu University School of Medicine, Department of Clinical Pharmacology and Therapeutics)

Hideki Katayama (Dept. of Palliative and Supportive Care)

Discussant : Tateaki Naito (Shizuoka Cancer Center)

司会 : 乾 直輝 (浜松医科大学 臨床薬理学)

片山 英樹 (岡山大学病院 緩和支援医療科)

アシカサト: 内藤 立暁 (静岡県立がんセンター呼吸器内科)

01-71 **D-index-guided early antifungal therapy for persistent FN in patients with hematological malignancies (CEDMIC trial)**

Encore

Emiko Sakaida (Department of Hematology, Chiba University)

血液腫瘍患者の発熱性好中球減少症に対するD-Indexを用いた早期真菌療法介入の有用性—経済効果に関する解析—CEDMIC試験

堺田 恵美子 (千葉大学医学部附属病院 血液内科)

01-72 **Prevalence of venous thromboembolism for patients with advanced solid tumor in prospective observational study**

Encore

Takahiro Tsushima (Division of Gastrointestinal Oncology, Shizuoka Cancer Center)

進行固形がん患者における静脈血栓塞栓症に関する多施設共同前向き観察研究

対馬 隆浩 (静岡県立静岡がんセンター 消化器内科)

01-73 **Incidence of VTE at the time of lung cancer diagnosis: A multicenter, prospective observational trial (Rising-VTE/NEJ037)**

Encore

Atsushi Nakamura (Department of Pulmonary Medicine, Sendai Kousei Hospital)

進行再発肺癌診断時の静脈血栓塞栓症合併率と患者背景に関する多施設共同前向き観察研究 (Rising-VTE/NEJ037 study)

中村 敦 (仙台厚生病院 呼吸器内科)

01-74 **A phase III trial evaluating olanzapine 5mg combined with standard antiemetic therapy for cisplatin-based chemotherapy**

Encore

Kazuhisa Nakashima (Division of Thoracic Oncology, Shizuoka Cancer Center)

中島 和寿 (静岡県立静岡がんセンター 呼吸器内科)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
X1-X11-11
Annex 1
Annex 2
Room A
Room B-1
Room D
Room E
S&S
スポン
Dr.Y111-1
Dr.X11-1
F1-Y111-1
Room C-1
Room C-2
Room B-2
Room 104

国立京都国際会館 2階 Room B-1

9:00-9:50 Mini-Oral Abstract Session 1-2

MO1-2 Rare Cancer1
希少がん 1

Chair : Abul Ahsan (Shaheed Surwardy Medical College, Bangladesh)

MO1-2-1 Temozolomide monotherapy in patient of neuroendocrine carcinoma with resistant to platinum chemotherapy (Final Report)

Noritoshi Kobayashi (Oncology Department, Yokohama City University Graduate School of Medicine)

プラチナベースの化学療法が不応となった神経内分泌癌に対するテモゾロミド単独化学療法の治療効果 (第二相試験最終報告)

小林 規俊 (横浜市立大学附属病院)

MO1-2-2 Surrogacy of intermediate endpoints in randomized trials of first-line treatment for advanced soft tissue sarcoma

Kazuhiro Tanaka (Department of Orthopaedic Surgery, Oita University)
田中 和宏 (大分大学整形外科)

MO1-2-3 Eribulin as a first-line treatment for patients with advanced soft tissue sarcoma: a retrospective study

Kenji Tsuchihashi (Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital / Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University)
土橋 賢司 (九州大学病院 血液・腫瘍・心血管内科 / 九州大学大学院医学研究院病態修復内科学)

MO1-2-4 IMPACT OF TREATMENT DELAYS IN EWINGS SARCOMA IN A LOW RESOURCE SETTING

Prabani S Maddumarachchi (National Cancer Institute Sri Lanka, Sri Lanka)

MO1-2-5 Microsatellite instability (MSI) profiling in patients with metastatic soft tissue sarcoma

Ayako Motoki (Graduate School of Medicine, International University of Health and Welfare, Mita Hospital Sarcoma Center)
元木 文子 (国際医療福祉大学大学院臨床医学研究分野、三田病院肉腫センター)

MO1-2-6 NCC Oncopanel in rare cancers and the impact on patient treatment

Takaaki Mizuno (Department of Thoracic Cancer, National Cancer Center Hospital / Department of Breast and Medical Oncology, National Cancer Center Hospital)
水野 孝昭 (国立がん研究センター中央病院 呼吸器内科 / 国立がん研究センター中央病院 乳腺・腫瘍内科)

9:50-10:40 Mini-Oral Abstract Session 1-3

MO1-3 Rare Cancer2
希少がん 2

Chair : Isabelle Ray-Coquard (Centre Leon Berard and University Claude Bernard Lyon, France)

MO1-3-1 Amrubicin-monotherapy for patients with platinum-refractory extrapulmonary neuroendocrine carcinoma

Rika Sakai (Department of Medical Oncology and Hematology, Kanagawa Cancer Center)
酒井 リカ (神奈川県立がんセンター 血液・腫瘍内科)

MO1-3-2 Adjuvant treatment of etoposide and cisplatin/carboplatin for stage II/III gastric neuroendocrine cell carcinoma

Mitsuhiro Furuta (Division of Gastrointestinal Oncology, Shizuoka Cancer Center)
古田 光寛 (静岡県立静岡がんセンター 消化器内科)

MO1-3-3 演題取下

MO1-3-4 Rare cancers are also not rare in Asia: The rare cancer burden in East Asia

Tomohiro Matsuda (Cntr. for Cancer Ctrl. and Info. Services, National Cancer Center)
松田 智大 (国立がん研究センターがん対策情報センター)

MO1-3-5 Comparison of molecular biological characteristics and clinical outcome of extramammary Paget's disease

Satomi Watanabe (Department of Medical Oncology, Kindai University Faculty of Medicine)
渡邊 諭美 (近畿大学医学部内科学講座腫瘍内科部門)

MO1-3-6 Efficacy and Safety of Nivolumab for Non-Cutaneous Melanoma: A Retrospective Analysis from a Single Institution

Taiji Koyama (Division of Medical Oncology/Hematology, Kobe University Hospital)
小山 泰司 (神戸大学医学部附属病院 腫瘍・血液内科)

10:40-11:30 Mini-Oral Abstract Session 1-4

MO1-4 Patient Advocacy/Suivivorship
患者支援・サバイバーシップ

Chair : Makiko Ono (Department of Medical Oncology, Cancer Institute Hospital of JFCR)
司会 : 小野 麻紀子 (がん研究会有明病院 総合腫瘍科)

MO1-4-1 Influence of financial conditions on stress in colorectal cancer patients undergoing outpatient chemotherapy

Yukiko Tatsumi (Osaka University Graduate School of Medicine)

薬物治療を受ける進行再発大腸がん患者において、経済的状況がストレスに与える影響
辰巳 有紀子 (大阪大学大学院 医学系研究科)

MO1-4-2 Meet the Expert on Rare Cancer - Social Contribution by Rare Cancer Center -

Yoko Katoh (Rare Cancer Center, National Cancer Center)
加藤 陽子 (国立がん研究センター希少がんセンター)

MO1-4-3 Prospects of Cancer Patients and Patient Association from the Viewpoint of Live Questionnaire at Participatory Symposium

Toshiyuki Sawa (Cancer center, Gifu Municipal Hospital)

参加型シンポジウムライブアンケートからみたがん患者と患者会の将来
澤 祥幸 (岐阜市民病院)

MO1-4-4 Investigation on the working status and inhibiting factors during cancer treatment in advanced NSCLC patients

Tatsuya Yoshida (Department of Thoracic Oncology, National Cancer Center Hospital /
Department of Thoracic Oncology, Aichi Cancer Center)

進行期肺がん患者における就労状況ならびに就労の阻害因子の調査

吉田 達哉 (国立がん研究センター中央病院 呼吸器内科 / 愛知県がんセンター中央病院 呼吸器内科)

MO1-4-5 Role of expert nurse for cancer genomic medicine in Keio University Hospital

Kaori Mochida (Genomics Unit, Keio Cancer, Keio University School of Medicine)

慶応義塾大学におけるがんゲノム医療に従事する看護師の役割

持田 かおり (慶応義塾大学医学部 腫瘍センター ゲノム医療ユニット)

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

Day 4 (Sun)

Annex 1

Annex 2

Room A

Room B-1

Room D

Room E

Room F

Room G

Room H

Room I

Room J

Room K

Room L

Room M

Room N

Room O

Room P

Room Q

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) 4/28-30/ Annex 1 Annex 2 Room A Room B-1 Room D Room E 4<5 2<3 D-1/D-2/D-3/D-4 D-7/D-8 D-9/D-10 Room C-1 Room C-2 Room B-2 Room 104

MO1-4-6 G8-based assessment predicts unplanned hospitalization in older patients with gastrointestinal and head/neck cancer
 Masahiro Takahashi (Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University / Department of Medical Oncology, Tohoku University Hospital)
 高橋 昌宏 (東北大学加齢医学研究所 臨床腫瘍学分野 / 東北大学病院 腫瘍内科)

15:40-16:30 Mini-Oral Abstract Session 1-5

MO1-5 Hepatobiliary/Pancreatic Cancer1 (Liver Cancer)
 肝胆胰 1 (肝臓)

Chair : Shinsuke Funakoshi (Tokyo Saiseikai Central Hospital, Division of Medical Oncology)
 司会 : 船越 信介 (東京都済生会中央病院 腫瘍内科)

MO1-5-1 TERT promoter as a sole commonly mutated gene in multinodular HCC is an indicator of good postoperative prognosis
 Yuji Iimuro (Department of Surgery, Yamanashi Central Hospital)
 飯室 勇二 (山梨県立中央病院 肝胆膵外科)

MO1-5-2 Novel Adjuvant Dendritic cell therapy targeting HSP70 for Hepatocellular Carcinoma
 Hiroto Matsui (Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine)
 松井 洋人 (山口大学大学院 消化器・腫瘍外科学)

MO1-5-3 Compromised autophagy sensitizes hepatocellular carcinoma to PARP inhibition
 Wenjing Zai (School of Basic Medical Science, Shanghai Medical College of Fudan University, China / School of Pharmacy, Fudan University)

MO1-5-4 Therapeutic efficacy and safety of lenvatinib for advanced hepatocellular carcinoma
 Tetsu Tomonari (Department of Gastroenterology and Oncology, Tokushima University Graduate School)
 友成 哲 (徳島大学病院 消化器内科)

MO1-5-5 Randomized phase II trial of sorafenib, capecitabine and oxaliplatin (SECOX) vs sorafenib in patients with advanced HCC
 Encore
 Thomas Yau (Department of Medicine, The University of Hong Kong, Hong Kong)

MO1-5-6 Comparative analysis of liver functional reserve during lenvatinib with sorafenib for advanced hepatocellular carcinoma
 Takeshi Terashima (Department of Gastroenterology, Kanazawa University Hospital)
 寺島 健志 (金沢大学附属病院)

16:30-17:20 Mini-Oral Abstract Session 1-6

MO1-6 Hepatobiliary/Pancreatic Cancer2 (Gallbladder and Biliary Tract Cancer/Pancreatic Cancer)
 肝胆胰 2 (胆嚢・胆道・膵臓)

Chair : Hiroto Matsui (Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine)
 司会 : 松井 洋人 (山口大学 消化器・腫瘍外科学)

MO1-6-1 Prognostic Relevance of Biliary drainage in Patients with Advanced Biliary Tract Cancer:Analyses of the KHBO1401 Trial
 Tomomi Kashiwada (Department of Internal Medicine, Division of Hematology, Respiratory Medicine and Oncology, Faculty of Medicine, Saga University)
 柏田 知美 (佐賀大学医学部 血液・呼吸器・腫瘍内科)

MO1-6-2	Clinical outcomes of gemcitabine, cisplatin plus S-1 in patients with advanced biliary tract cancer Yusuke Niisato (Department of Gastroenterology, National Hospital Organization Mito Medical Center) 新里 悠輔 (国立病院機構 水戸医療センター 消化器科)	Day 1 (Thu) Day 2 (Fri)
MO1-6-3	Incidence and Mortality Trends of Cholangiocarcinoma; Are Asian Patients Different From Other Ethnicities? Mohamed M Gad (Cleveland Clinic Foundation, United States / Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina)	Day 3 (Sat) X-17h-11
MO1-6-4 Encore	Whole-exome sequencing in metastatic or locally advanced pancreatic cancer patients with long-term survival Kentaro Sudo (Division of Gastroenterology, Chiba Cancer Center) 須藤 研太郎 (千葉県がんセンター 消化器内科)	Annex 1
MO1-6-5	CLINICAL UTILITY OF THE QUANTITATIVE MONITORING OF CT-DNA IN PATIENTS WITH ADVANCED PDAC UNDERGOING CHEMOTHERAPY Makoto Sugimori (Department of Gastroenterology, Yokohama City University) 杉森 慎 (横浜市立大学 消化器内科)	Annex 2 Room A
MO1-6-6	Phase I study of gemcitabine / nab-paclitaxel / S-1 in patients with advanced pancreatic cancer (GeNeS1S trial) Satoshi Sai (Department of Medical oncology/Hematology, Kobe University Hospital) 崔 諭司 (神戸大学医学部附属病院 腫瘍・血液内科)	Room B-1 Room D
17:20-18:10 Mini-Oral Abstract Session 1-7		
MO1-7	Translational Research1 TR1 Chair : Noboru Yamamoto (Department of Experimental Therapeutics) 司会 : 山本 昇 (国立がん研究センター中央病院 先端医療科)	Room E さく5
MO1-7-1	Molecular and clinicopathological characterization of URST1 as a new biomarker and therapeutic target for breast cancer Masako Nakamura (Medical Oncology Department, Shiga University of Medical Science) 中村 正子 (滋賀医科大学 臨床腫瘍学講座)	スポン D-11h-11-1
MO1-7-2	演題取下	D-11h-11-2
MO1-7-3	演題取下	D-11h-11-3
MO1-7-4	Clinical significance of TP53 variants in tumor-only next-generation sequencing as possible secondary findings Yoshihiro Yamamoto (Department of Therapeutic Oncology, Kyoto University) 腫瘍組織のみを用いた次世代シーケンス検査で検出される TP53 変異の二次的所見可能性と臨床的意義 山本 佳宏 (京都大学大学院医学研究科 腫瘍薬物治療学)	D-11h-11-4 Room C-1
MO1-7-5 Encore	NRG1-fusion positive (NRG1+) tumors: Afatinib as a novel potential treatment option Janessa J. Laskin (Division of Medical Oncology, Department of Medicine, University of British Columbia, BC Cancer, Canada)	Room C-2 Room B-2 Room 104

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
××××-11
Annex 1
Annex 2
Room A
Room B-1
Room D
Room E
×××
×××
□××××-1
□-×××-1
×-××××-1
Room C-1
Room C-2
Room B-2
Room 104

MO1-76 **Observational Study to Investigate the Implementation Rate of Re-Biopsy in EGFR-TKI-Resistant Patients (NLCTG1602)**

Jun Koshio (Department of Respiratory Medicine, Nagaoka Red Cross Hospital)

EGFR-TKI 耐性症例の re-biopsy の実施率、組織診と細胞診の Cobas 法による一致率を検討する観察研究

古塩 純 (長岡赤十字病院 呼吸器内科)

国立京都国際会館 1階 Room D

9:00-10:30 Mini Symposium 1 / ミニシンポジウム 1

MS1 Development of Combination Therapy Using I-O Agent for Upper GI Tract Cancer
上部消化管癌における免疫チェックポイント阻害薬併用療法の開発

Chairs : Manish A. Shah (Weill Cornell Medicine/New York-Presbyterian Hospital, USA)
Kohei Shitara (National Cancer Center Hospital East)

司会 : Manish A. Shah (Weill Cornell Medicine/New York-Presbyterian Hospital, USA)
設楽 紘平 (国立がん研究センター東病院)

MS1-1 Anti-PD-1 therapy as monotherapy and the development of biomarkers for patient selection in gastric and esophageal cancers

Manish A. Shah (Weill Cornell Medicine/New York-Presbyterian Hospital, USA)

MS1-2 Current status of immune checkpoint inhibitors for esophagogastric cancer

Kohei Shitara (National Cancer Center Hospital East)

上部消化管癌に対する免疫チェックポイント阻害剤の現状

設楽 紘平 (国立がん研究センター東病院)

MS1-3 Chemotherapy after progREssive disease of nivolumab (NIV) thERapy (REVIVE study)

Yukiya Narita (Aichi Cancer Center Hospital, Department of Clinical Oncology)

ニボルマブ後の化学療法における有効性と安全性の前向き観察研究

成田 有季哉 (愛知県がんセンター)

MS1-4 A Biomarker Analysis of Nivolumab in Previously Treated Advanced Gastric Cancer (WJOG10417GTR)

Hirokazu Shoji (Gastrointestinal Medical Oncology Division, National Cancer Center Hospital)

標準治療に不応不耐進行胃癌患者に対するNivolumab療法のBiomarker研究 (WJOG10417GTR)

庄司 広和 (国立がん研究センター中央病院 消化管内科)

MS1-5 An observational/translational study for nivolumab treatment in advanced gastric cancer: JACCRO GC-08 (DELIVER trial)

Encore

Yu Sunakawa (Department of Clinical Oncology, St. Marianna University School of Medicine)

切除不能進行性胃癌におけるニボルマブのバイオマーカー探索を含めた観察研究: JACCRO GC-08 (DELIVER 試験)

砂川 優 (聖マリアンナ医科大学 臨床腫瘍学)

13:40-15:10 Symposium 4 / シンポジウム 4

SY4 New Evidences of Chemotherapy in Biliary Tract and Pancreatic Cancers and Introduction them to the Practice
膵癌・胆道癌の新たな標準療法のエビデンスと臨床への影響

Chairs : Junji Furuse (Department of Medical Oncology, Kyorin University Faculty of Medicine)

Makoto Ueno (Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center)

司会 : 古瀬 純司 (杏林大学 医学部内科学腫瘍科)

上野 誠 (神奈川県立がんセンター 消化器内科)

SY4-1 New evidences of chemotherapy in biliary tract cancer

Do-Youn Oh (Medical Oncology, Seoul National University Hospital, Korea)

Day 1 (Thu)	SY4-2	Precision Oncology for Pancreatic Cancer across the United States: the Know Your Tumor® experience Lynn M. Matrisian (Pancreatic Cancer Action Network, United States)
Day 2 (Fri)	SY4-3	First-line chemotherapy for advanced biliary tract cancer, Japanese phase III studies Chigusa Morizane (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital) 森実 千種 (国立がん研究センター中央病院)
Day 3 (Sat)	SY4-4	Current Status and Future Prospective in chemotherapy for Pancreatic Cancer Masato Ozaka (Cancer Institute Hospital of Japanese Foundation for Cancer Research) 膵癌化学療法の現状と今後の展開 尾阪 将人 (がん研究会有明病院)
Annex 1	SY4-5	Second line chemotherapy for advanced pancreatic cancer patients in Japan Tatsuya Ioka (Dept of Cancer Survey and Gastrointestinal Oncology, Osaka International Cancer Institute) 井岡 達也 (大阪国際がんセンター 検診部)
Annex 2	SY4-6	Adjuvant and Neoadjuvant therapy for Pancreatic cancer Fuyuhiko Motoi (Department of Surgery, Tohoku University) 膵癌に対する術前術後補助療法 元井 冬彦 (東北大学大学院 消化器外科学)
Room A		
Room B-1		
Room D		15:40-16:30 Mini-Oral Abstract Session 1-11
Room E	MO1-11	Clinical Trial Facilitation Program 臨床試験推進プログラム Chair : Kunio Makino (TAIHO PHARMACEUTICAL CO., LTD. Medical Affairs Division) 司会 : 牧野 邦生 (大鵬薬品工業株式会社 メディカルアフェアーズ本部)
セミナー	MO1-11-1	全国ゲノムスクリーニングプロジェクトLC-SCRUM-Japanへの登録推進のための多職種連携システム Reiko Isomura (Clinical Trial Management Office, Kanagawa Cancer Center) 磯村 玲子 (神奈川県立がんセンター 治験管理室)
ワークショップ	MO1-11-2	Relationships between approved combination therapies and clinical data packages in anti-cancer drugs in Japan Shoyo Shibata (Graduate School of Business Sciences, University of Tsukuba / Education Research Center for Pharmaceutical Sciences, Faculty of Pharmacy, Keio University) 本邦における抗がん剤併用療法の承認と承認申請における臨床データパッケージの関係性に関する研究 柴田 翔洋 (筑波大学大学院 ビジネス科学研究科 / 慶應義塾大学 薬学部 薬学教育研究センター)
Day 4 (Sun)	MO1-11-3	がん臨床試験理解度評価尺度の開発 Izumi Kohara (Jichi Medical University) 小原 泉 (自治医科大学)
Room C-1	MO1-11-4	電子カルテデータの治験 / 臨床試験への利用に関する検討 Yoshihiro Aoyagi (National Cancer Center Hospital East) 青柳 吉博 (国立がん研究センター東病院)
Room C-2		
Room B-2		
Room 104		

MO1-11-5	<p>Factors that could potentially impact on the initiation time of oncology clinical trials at investigational sites</p> <p>Ayaka Sano (IQVIA Services Japan K.K.)</p> <p>がん治療薬の治験実施施設における治験開始までの期間短縮および延長に影響を与える因子の検討</p> <p>佐野 絢香 (IQVIA サービスーズ ジャパン株式会社)</p>	Day 1 (Thu)
MO1-11-6	<p>The health-related quality of life and Economic burden on Cancer Patients in Japan</p> <p>Shinya Ohno (Global Regulatory Science, Gifu Pharmaceutical University / Chugai Pharmaceutical Co., LTD.)</p> <p>日本におけるがん患者の健康関連QOL及び経済的負担に関する研究</p> <p>大野 慎也 (岐阜薬科大学 グローバルレギュラトリーサイエンス研究室/中外製薬株式会社)</p>	Day 2 (Fri)
16:30-17:20 Mini-Oral Abstract Session 1-12		
MO1-12	<p>Multidisciplinary Team Program1</p> <p>多職種連携プログラム 1</p> <p>Chair : Akihito Tsuji (Kagawa University)</p> <p>司会 : 辻 晃仁 (香川大学 医学部臨床腫瘍学講座)</p>	Day 3 (Sat)
MO1-12-1	<p>Clinical introduction of Microsatellite instability (MSI) test for the Solid Tumors at a single institute</p> <p>Izuma Nakayama (Gastroenterological chemotherapy Department, Cancer Institute Hospital of Japanese Foundation for Cancer Research)</p> <p>当院におけるMSI検査の臨床応用の実際</p> <p>中山 巖馬 (がん研究会有明病院)</p>	Annex 1
MO1-12-2	<p>BRCAAnalysis検査とPARP阻害剤「オラパリブ」の処方可能とする際に必要な院内多職種によるチーム医療とその応用</p> <p>Shingo Ishiguro (Medical Oncology Department, Ibaraki Prefectural Central Hospital)</p> <p>石黒 慎吾 (茨城県立中央病院・茨城県地域がんセンター 腫瘍内科)</p>	Annex 2
MO1-12-3	<p>がんゲノム医療コーディネーターの役割と課題</p> <p>Sadakatsu Ikeda (Cancer Center, Tokyo Medical and Dental University)</p> <p>池田 貞勝 (東京医科歯科大学 腫瘍センター)</p>	Room A
MO1-12-4	<p>Education of nurses to support cancer genome medicine -Practices in Genomic and Genetic Nursing Committee-</p> <p>Saki Hinoshita (Department of Nursing, Hyogo Cancer Center)</p> <p>がんゲノム医療に対応するための看護師の育成</p> <p>ーゲノム・遺伝看護委員会の取り組みー</p> <p>日下 咲 (兵庫県立がんセンター 看護部)</p>	Room B-1
MO1-12-5	<p>The current situation of the genome cancer board in TMDU (Tokyo Medical and Dental University)</p> <p>Hiroyuki Sakashita (Department of Clinical Oncology, Tokyo Medical and Dental University / Cancer center, Tokyo Medical and Dental University)</p> <p>東京医科歯科大学におけるゲノムキャンサーボードの現状</p> <p>坂下 博之 (東京医科歯科大学臨床腫瘍学分野/東京医科歯科大学腫瘍センター)</p>	Room D

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
Multi-Track
Annex 1
Annex 2
Room A
Room B-1
Room D
Room E
セミナー
D-1101-4
D-2101-4
F-1101-4
Room C-1
Room C-2
Room B-2
Room 104

MO1-12-6 A pilot survey on the outpatient chemotherapy unit of national university hospitals in Japan for early palliative care
 Hidenori Takahashi (Division of Community-based Medicine, University of the Ryukyus Hospital / Outpatient Chemotherapy Unit, University of the Ryukyus Hospital)
外来通院治療中のがん患者に対する早期緩和ケア提供体制の構築に向けた、全国の国立大学病院の外来化学療法室の運用実態調査
 高橋 秀徳 (琉球大学医学部附属病院 地域医療部 / 琉球大学医学部附属病院 がんセンター外来化学療法室)

17:20-18:10 Mini-Oral Abstract Session 1-13

MO1-13 Multidisciplinary Team Program2 多職種連携プログラム 2
 Chair : Shigeki Ito (Hematology & Oncology, Iwate Medical University School of Medicine)
 司会 : 伊藤 薫樹 (岩手医科大学 血液腫瘍内科)

MO1-13-1 Incidence and management of immune-related adverse events in patients with immune checkpoint inhibitor therapy
 Tsutomu Nisida (Toyonaka Municipal Hospital)
免疫チェックポイント阻害剤による免疫関連有害事象の当院の状況
 西田 勉 (市立豊中病院)

MO1-13-2 免疫チェックポイント阻害薬使用時の内分泌障害に対する院内連携の現状
 Noriko Chiba (Division of Pharmacy, Aomori Prefectural Central Hospital)
 千葉 典子 (青森県立中央病院 薬剤部)

MO1-13-3 Construction of a safety management system for Immune checkpoint inhibitors based on the multidisciplinary team
 Yumi Takahashi (National Hospital Organization Hokkaido Cancer Center Nursing Department)
多職種で行う安全な免疫チェックポイント阻害薬投与体制の構築
 高橋 由美 (北海道がんセンター 看護部)

MO1-13-4 Effect of Multi-professional Cooperation on Location for End-of-life care in Patients with Hematologic Malignancies
 Rika Kihara (Department of Hematology, Komaki City Hospital)
血液悪性腫瘍患者の終末期の療養場所に対して多職種連携が与える影響の検討
 木原 里香 (小牧市民病院 血液内科)

MO1-13-5 Oral environment and febrile neutropenia during docetaxel plus cyclophosphamide chemotherapy in breast cancer
 Shinsuke Sasada (Breast Surgery Department, Hiroshima University)
乳癌TC療法における口腔内環境と発熱性好中球減少症
 笹田 伸介 (広島大学病院 乳腺外科)

MO1-13-6 Real-World Practice of the Onco-Cardiology
 Kazuko Tajiri (Department of Cardiology, Faculty of Medicine, University of Tsukuba)
がん診療の場における循環器診療の実践
 田尻 和子 (筑波大学医学医療系 循環器内科)

9:00-9:50 Mini-Oral Abstract Session 1-8

MO1-8 Breast Cancer1
乳腺1

Chair : Chun-Yu Liu (Taipei Veterans General Hospital, Taipei, Taiwan/National Yang-Ming University, Taipei, Taiwan)

MO1-8-1 Genomic Profiling of patients with HER2 positive recurrent breast cancer resistant to anti-HER2 therapies

Hiroshi Nakagomi (Department of Breast Surgery, Yamanashi Prefectural Central Hospital)
中込 博 (山梨県立中央病院 乳腺外科)

MO1-8-2 Circulating tumor DNA predicts response and prognosis in early breast cancer patients receiving neoadjuvant chemotherapy

Shunying Li (Breast Tumor Center, Sun Yat-sen Memorial Hospital, China)

MO1-8-3 The Correlation of Nottingham Prognostic Index with Immunoexpression of ER, PR, HER2, and Ki67 in Breast Cancer Tissue

Chetana Ruangpratheep (Department of Pathology, Phramongkutklao College of Medicine, Bangkok, Thailand)

MO1-8-4 Baseline neutrophil to lymphocyte ratio is predictor of longer OS of metastatic BC patients treated with eribulin

Shota Kusuhara (Department of Breast and Medical Oncology, National Cancer Center Hospital East)
楠原 正太 (国立がん研究センター東病院 乳腺・腫瘍内科)

MO1-8-5 Expression of programmed death ligand -1 (PD-L1) and immune infiltrates in primary breast cancer

Kanako Saito (Department of Medical Oncology, Mie University Hospital)
斎藤 佳菜子 (三重大学医学部附属病院 腫瘍内科)

MO1-8-6 Development of diagnostic kit for in vitro diagnostics of the TP53 signature in early breast cancer

Shin Takahashi (Department of Medical Oncology, Tohoku University Hospital / Department of Clinical Oncology, IDAC, Tohoku University)
高橋 信 (東北大学病院 腫瘍内科 / 東北大学加齢医学研究所 臨床腫瘍学分野)

9:50-10:40 Mini-Oral Abstract Session 1-9

MO1-9 Genitourinary Cancer
泌尿器

Chair : Michiaka Nagase (Saku Central Hospital Advanced Care Center, Department of medical Oncology)
司会 : 長瀬 通隆 (佐久医療センター 腫瘍内科)

MO1-9-1 Cell-free tumor DNA in urine reflects tumor genetic profiles and predict muscle invasion in urothelial bladder cancer

Yosuke Hirotsu (Genome Analysis Center, Yamanashi Central Hospital)
弘津 陽介 (山梨県立中央病院ゲノム解析センター)

MO1-9-2 Immune microenvironment in clear cell type renal cell carcinoma with loss of PBRM1 protein expression

Yuji Miura (Department of Medical Oncology, Toranomon Hospital)
三浦 裕司 (虎の門病院 臨床腫瘍科)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
××××××
Annex 1
Annex 2
Room A
Room B-1
Room D
Room E
××××
××××
××××××
××××××
××××××
Room C-1
Room C-2
Room B-2
Room 104

- MO1-9-3 Gender Disparities among Japanese Renal Cell Carcinoma Patients Residing In the United States**
Anas M Saad (Faculty of Medicine, Ain Shams University, Egypt)
-
- MO1-9-4 Racial Disparities in Survival of Renal Cell Carcinoma**
Mohamed M Gad (Cleveland Clinic Foundation, United States / Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina)
-
- MO1-9-5 Survival of Japanese versus Non-Japanese Asian Renal Cell Carcinoma Patients; a Cohort Study**
Inas A Ruhban (Pathology department, Faculty of Medicine, Damascus University, Damascus, Syria, Egypt)
-
- MO1-9-6 Characteristics and Treatment Patterns for Non-Metastatic Castration Resistant Prostate Cancer Patients in Japan**
Ruchitbhai Shah (Pharmerit International, United States)
-
- 10:40-11:30 Mini-Oral Abstract Session 1-10
- MO1-10 Lung Cancer/Thoracic Cancer1 (NSCLC/Others1)**
呼吸器 1 (非小細胞肺がん・その他 1)
- Chair : Koichi Minato (Gunma Prefectural Cancer Center, Division of Respiratory Medicine)
司会 : 湊 浩一 (群馬県立がんセンター 呼吸器内科)
-
- MO1-10-1 The Impact of EGFR-TKIs Treatment on Tumor Immune Microenvironment in EGFR Mutation-Positive Non-Small-Cell Lung Cancer**
Kohsuke Isomoto (Kanagawa Cardiovascular and Respiratory Center)
磯本 晃佑 (神奈川県立循環器呼吸器病センター)
-
- MO1-10-2 Lack association between BIM deletion polymorphism and efficacy of EGFR-TKIs in NSCLC based on NGS**
Siyang Liu (Guangdong Provincial People's Hospital, China)
-
- MO1-10-3 Clinical impact of NCC Oncopanel for precision medicine in patients with non-small-cell lung cancer**
Takaaki Mizuno (Department of Thoracic Cancer, National Cancer Center Hospital / Cancer Medicine, Jikei University Graduate School of Medicine)
水野 孝昭 (国立がん研究センター中央病院 呼吸器内科 / 東京慈恵会医科大学 包括がん医学講座)
-
- MO1-10-4 Performance of OncomineDx Target Test as molecular diagnostics for EGFR-, ALK- and ROS1-positive lung cancer**
Shingo Matsumoto (Department of Thoracic Oncology, National Cancer Center Hospital East)
松本 慎吾 (国立がん研究センター東病院)
-
- MO1-10-5 Circulating Tumor DNA Identifies Osimertinib Resistance Mechanisms in EGFR T790M-positive lung cancer**
Ryoji Kato (Department of Medical Oncology, Kindai University Faculty of Medicine)
加藤 了資 (近畿大学医学部附属病院)
-
- MO1-10-6 The utility of image guided biopsy for mutational analysis in lung cancer**
Yoza Sato (Department of Diagnostic and Interventional Radiology, Aichi Cancer Center)
佐藤 洋造 (愛知県がんセンター中央病院 放射線診断・IVR部)

13:40-15:10 Mini Symposium 2 / ミニシンポジウム 2

MS2 How to Integrate Molecular Biomarker in Clinic for CRC?

Chairs : John L. Marshall (Georgetown University, United States)
Takayuki Yoshino (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East)

司会 : John L. Marshall (Georgetown University, United States)
吉野 孝之 (国立がん研究センター東病院)

MS2-1 Integrating precision medicine into the treatment of colorectal cancer

John L Marshall (Georgetown University, United States, United States)

MS2-2 Activity on Nationwide Cancer Genome Screening Project for Metastatic Colorectal Cancer in Japan; SCRUM-Japan GI-SCREEN

Takayuki Yoshino (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East)
吉野 孝之 (国立がん研究センター東病院)

MS2-3 JSMO Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment - Update 2019

Hiroya Taniguchi (National Cancer Center Hospital East)

大腸がん診療における遺伝子関連検査等のガイダンス改訂第4版

谷口 浩也 (国立がん研究センター東病院)

MS2-4 Potential on plasma angiogenesis biomarkers for selection of antiangiogenic inhibitors in mCRC: GI-SCREEN CRC-Ukit

Satoshi Yuki (Department of Gastroenterology and Hepatology, Hokkaido University Hospital)

血管新生阻害薬使い分けに関する血漿バイオマーカー探索の可能性: GI-SCREEN CRC-Ukit

結城 敏志 (北海道大学病院 消化器内科)

MS2-5 Therapeutic development for HER2 positive metastatic colorectal cancer

Wataru Okamoto (Cancer Treatment Center, Hiroshima University Hospital / Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East)

岡本 渉 (広島大学病院 がん治療センター / 国立がん研究センター東病院 消化器内科)

15:20-16:55 Oral Abstract Session 1-8

O1-8 Breast Cancer1
乳腺 1

Chairs : Naoki Niikura (Tokai university school of medicine, Breast and Endocrine Surgery)
Shigenori Nagai (Division of Breast Oncology, Saitama Cancer Center)

Discussant : Fumie Fujisawa (Osaka International Cancer Institute, Department of Medical Oncology)

司会 : 新倉 直樹 (東海大学 医学部 外科学系 乳腺・内分泌外科学)
永井 成勲 (埼玉県立がんセンター 乳腺腫瘍内科)

ディスカッサント: 藤澤 文絵 (大阪国際がんセンター 腫瘍内科)

O1-8-1 Updated results of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-low breast cancer from a large phase 1 study

Junji Tsurutani (Advanced Cancer Translational Research Institute, Showa University / Kindai University Faculty of Medicine)

鶴谷 純司 (昭和大学 先端がん治療研究所 / 近畿大学医学部)

Day 1 (Thu)	01-8-2	Evaluation of prognostic stage in the AJCC 8th edition from the aspect of adjuvant chemotherapy effects Takamichi Yokoe (Department of Surgery, Keio University School of Medicine) 横江 隆道 (慶應義塾大学医学部 一般・消化器外科)
Day 2 (Fri)	01-8-3 Encore	Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE Sibylle Loibl (GBG, Neu-Isenburg, Germany; Centre for Haematology and Oncology Bethanien, Frankfurt, Germany)
Day 3 (Sat)	01-8-4 Encore	Dose justification for [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-positive breast cancer Shunji Takahashi (The Cancer Institute Hospital of JFCR) 高橋 俊二 (がん研有明病院)
Annex 1	01-8-5 Encore	A phase 2 study evaluating ddAC-ddPTX supported by peg-filgrastim for patients with primary breast cancer -WJOG9016B- Yukinori Ozaki (Medical Oncology, Toranomon Hospital) 尾崎 由記範 (虎の門病院)
Annex 2	16:55-18:10 Oral Abstract Session 1-9	
Room A	01-9	Breast Cancer2 乳腺 2
Room B-1	Chairs :	Nobuhiro Shibata (Miyazaki University Hospital, Department of Clinical Oncology) Sibylle Loibl (GBG, Neu-Isenburg, Germany; Centre for Haematology and Oncology Bethanien, Frankfurt, Germany)
Room D	Discussant :	Masato Takahashi (NHO Hokkaido Cancer Center)
Room E	司会 :	柴田 伸弘 (宮崎大学医学部附属病院 臨床腫瘍科) Sibylle Loibl (GBG, Neu-Isenburg, Germany; Centre for Haematology and Oncology Bethanien, Frankfurt, Germany)
セミナー	ディスカッサント:	高橋 将人 (国立病院機構北海道がんセンター)
スタジオ	01-9-1 Encore	Randomized Phase II Study of tri-weekly nab-paclitaxel in patients with metastatic breast cancer : ABROAD Masato Takahashi (Department of Breast Surgery, NHO Hokkaido Cancer Center) 高橋 将人 (国立病院機構北海道がんセンター)
Day 4 (Sun)	01-9-2 Encore	IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC) Hope S. Rugo (Department of Medicine, University of California San Francisco)
Room C-1	01-9-3	Atezolizumab + nab-paclitaxel as first line therapy in Japanese patients with TNBC: A subgroup analysis of IMpassion130 Kenichi Inoue (Division of Breast Oncology, Saitama Cancer Center) 井上 賢一 (埼玉県立がんセンター 乳腺腫瘍内科)
Room C-2	01-9-4	A prospective real-world study of eribulin for HER2-negative recurrent breast cancer patients: final results Hirofumi Mukai (National Cancer Center Hospital East) 向井 博文 (国立がん研究センター東病院)
Room B-2		
Room 104		

AJS Precision Oncology: How Do We Use a Panel Gene Test?

Chairs : Monica M. Bertagnolli (President, American Society of Clinical Oncology (ASCO), U.S.A)
Chikashi Ishioka (Department of Clinical Oncology Institute of Development, Aging and Cancer Tohoku University)

司会 : Monica M. Bertagnolli (President, American Society of Clinical Oncology (ASCO), U.S.A)
石岡 千加史 (東北大学加齢医学研究所 臨床腫瘍学分野)

AJS-1 Next-Generation Approaches to Assessing Hereditary Cancer Risk in the Genome Era

James M. Ford (Departments of Medicine and Genetics, Stanford University, United States)

AJS-2 Genomics of Lung Cancer

Ramaswamy Govindan (Washington University School of Medicine, United States)

AJS-3 Precision Oncology in Clinical Practice in Japan

Manabu Muto (Department of Therapeutic Oncology, Kyoto University)

日本の実臨床におけるがんゲノム医療

武藤 学 (京都大学大学院医学研究科 腫瘍薬物治療学講座)

AJS-4 National Cancer Genomic Medicine Platform in Japan

Hiroyuki Mano (C-CAT, National Cancer Center)

All Japan でのがんゲノム医療体制

間野 博行 (国立がん研究センター がんゲノム情報管理センター)

PSY1 Regulatory Science in an Era of Precision Medicine



Chairs : Yasuhiro Fujiwara (Pharmaceuticals and Medical Devices Agency)
Shin-ichi Nihira (Tokyo Biochemical Foundation CHAAO unit)

司会 : 藤原 康弘 (医薬品医療機器総合機構)
仁平 新一 (東京生化学研究会 CHAAO事業)

PSY1-1 Precision Medicine: FDA Oncology Perspective

Gideon Blumenthal (Oncology Center of Excellence, U.S. Food and Drug Administration, United States)

PSY1-2 Clinical Trial Design Considerations in the Era of Targeted Therapy

Rajeshwari Sridhara (US FDA, United States)

PSY1-3 Precision Medicines in Oncology, European Regulator's Views

Pierre Démolis (Oncology Working Party, European Medicines Agency, Netherlands)

PSY1-4 Best Practices and Potential Pitfalls: Insights to the US Regulatory Landscape for Precision Oncology

Hisani Madison (Precision Medicine, R&D Oncology Unit, AstraZeneca, United States)

PSY1-5 Molecular Analysis of Pediatric Solid Tumors: Early Lessons From NCI-COG Pediatric MATCH Trial

Encore

Nita L. Seibel (For the NCI-COG Pediatric MATCH team, United States)

EJS Hereditary Cancer Treatment in Cancer Genome Era

Chairs : Solange Peters (Oncology Department CHUV, Lausanne University, Switzerland)
Hideki Shimodaira (Division of Medical Oncology, Faculty of Medicine Tohoku Medical and Pharmaceutical University)

司会 : Solange Peters (Oncology Department CHUV, Lausanne University, Switzerland)
下平 秀樹 (東北医科薬科大学医学部 腫瘍内科学教室)

EJS-1 Uses of genetic testing for cancer prevention

Diana M. Eccles (Faculty of Medicine, University of Southampton, United Kingdom)

EJS-2 Genomic Analyses of Pre-cancers to Accelerate Cancer Interception in Hereditary Colorectal Cancer Syndromes

Eduardo Vilar-Sanchez (Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, United States)

EJS-3 The Paradigm Shift in Genetic Counseling for Hereditary Cancer

Arisa Ueki (Center for Medical Genetics / Keio Cancer Center, Keio University School of Medicine)

植木 有紗 (慶應義塾大学医学部 臨床遺伝学センター・腫瘍センター)

EJS-4 Interpreting variants of uncertain significance in hereditary cancer genes in cancer genome era

Hideki Shimodaira (Division of Medical Oncology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University)

下平 秀樹 (東北医科薬科大学医学部 腫瘍内科学)

国立京都国際会館 1階 スワン

9:00-9:50 Mini-Oral Abstract Session 1-14

MO1-14 Gastrointestinal Cancer1 消化管 1

Chair : Yu Jo Chua (Medical Oncology Unit, The Canberra Hospital, Australian Capital Territory, Australia)

MO1-14-1 ENCO + BINI + CETUX in Japanese Patients With BRAF V600E-Mutant mCRC: Encore A Safety Lead-in Study to the BEACON CRC Study

Hideaki Bando (Department of Clinical Oncology, Aichi Cancer Center Hospital)
坂東 英明 (愛知県がんセンター 薬物療法部)

MO1-14-2 The genomic landscape and its prognostic significance for stage III colorectal cancer: Encore an ancillary study of JCOG0910

Atsuo Takashima (National Cancer Center Hospital)
高島 淳生 (国立がん研究センター中央病院)

MO1-14-3 演題取下

MO1-14-4 Exposure-response analysis of S-1 in patients with advanced gastric cancer

Masashi Takeuchi (Department of Surgery, Keio University School of Medicine)
竹内 優志 (慶應義塾大学医学部 一般・消化器外科)

MO1-14-5 Impact of ramucirumab plus nab-paclitaxel on peritoneal metastasis for advanced gastric cancer

Masashi Ishikawa (National Cancer Center Hospital)
石川 将史 (国立がん研究センター中央病院)

MO1-14-6 Clinical relevance of circulating tumor DNA using amplicon-based deep sequencing Encore panel in colorectal cancer patients

Hiroki Osumi (Department of Gastroenterology, Cancer Institute Hospital, Japanese Foundation of Cancer Research)
大隅 寛木 (がん研有明病院 消化器化学療法科)

9:50-10:40 Mini-Oral Abstract Session 1-15

MO1-15 Gastrointestinal Cancer2 消化管 2

Chair : Ian Chau (Royal Marsden Hospital, UK)

MO1-15-1 演題取下

MO1-15-2 Safety and efficacy of irinotecan administered after nivolumab for advanced gastric cancer

Akinori Sasaki (Department of Gastrointestinal Oncology, National Cancer Center Hospital East)
佐々木 昭典 (国立がん研究センター東病院 消化管内科)

MO1-15-3 Efficacy of Radiotherapy to Primary Tumor After Nivolumab Treatment in Patients with Advanced Gastric Cancer

Akinori Sasaki (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East)
佐々木 昭典 (国立がん研究センター東病院 消化管内科)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
メッセ
Annex 1
Annex 2
Room A
Room B-1
Room D
Room E
セミナー
スクリーン
D-101/A-1
D-201/A-1
F-101/A-1
Room C-1
Room C-2
Room B-2
Room 104

MO1-15-4	The hyperprogressive disease during nivolumab treatment or irinotecan treatment in patients with advanced gastric cancer Masahiko Aoki (National Cancer Center Hospital) 青木 雅彦 (国立がん研究センター中央病院)
MO1-15-5 Encore	Nivolumab and Radical Surgery Following Preoperative Chemoradiotherapy in MSS Locally Advanced Rectal Cancer Patients Satoshi Yuki (Department of Gastroenterology and Hapatology, Hokkaido University Hospital) 結城 敏志 (北海道大学病院 消化器内科)
MO1-15-6	Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab Ken Masuda (Gastrointestinal Medical Oncology Division, National Cancer Center Hospital) 増田 健 (国立がん研究センター中央病院 消化管内科)
10:40-11:30 Mini-Oral Abstract Session 1-16	
MO1-16	Gastrointestinal Cancer3 (Colorectal Cancer1) 消化管 3 (大腸 1)
Chair :	Hiroki Osumi (Department of Gastrointestinal Chemotherapy Cancer Institute Hospital of Japanese Foundation for Cancer Research)
司会 :	大隅 寛木 (がん研究会 有明病院 消化器内科)
MO1-16-1	Update on JACCRO CC-11 trial of 1st-line modified-FOLFOXIRI plus bevacizumab for RAS mutant metastatic colorectal cancer Masato Nakamura (Aizawa Comprehensive Cancer Center, Aizawa Hospital) 中村 将人 (社会医療法人財団慈泉会相澤病院がん集学治療センター化学療法科)
MO1-16-2	Update on phase II trial of cetuximab plus S-1/oxaliplatin (SOX) for metastatic colorectal cancer (mCRC): JACCRO CC-06 Yu Sunakawa (Department of Clinical Oncology, St. Marianna University School of Medicine) 砂川 優 (聖マリアンナ医科大学 臨床腫瘍学講座)
MO1-16-3	演題取下
MO1-16-4 Encore	Impact of prior treatment with two different fluoropyrimidines on the efficacy of CapelRI/ FOLFIRI in colorectal cancer Satoru Iwasa (National Cancer Center Hospital) 岩佐 悟 (国立がん研究センター中央病院)
MO1-16-5	Tumor growth rate of re-challenge cytotoxic chemotherapies as salvage treatment for metastatic colorectal cancer Masashi Ishikawa (National Cancer Center Hospital) 石川 将史 (国立がん研究センター中央病院)
MO1-16-6	Analysis of the reintroducing oxaliplatin in relapsed CRC treated with prior oxaliplatin-based adjuvant chemotherapy Hironaga Satake (Cancer Treatment Center, Kansai Medical University Hospital) 佐竹 悠良 (関西医科大学附属病院)

13:40-14:30 Mini-Oral Abstract Session 1-17

- MO1-17** Gastrointestinal Cancer4 (Esophageal Cancer)
消化管 4 (食道)
- Chair : Taito Esaki (NHO Kyushu Cancer Center, Clinical Research Institute)
司会 : 江崎 泰斗 (九州がんセンター 臨床研究センター)
- MO1-17-1** **A comparison of treatment response by PET scan and histopathology after NACT in SCC of esophagus**
Naveen Kumar (Surgical oncology, AIIMS, New Delhi, India)
- MO1-17-2** **Long-term results of a PII study of chemoradiotherapy with docetaxel, nedaplatin, and fluorouracil for esophageal cancer**
Hiroyuki Ohnuma (Department of Medical Oncology, Sapporo Medical University School of Medicine)
大沼 啓之 (札幌医科大学 腫瘍内科)
- MO1-17-3** 演題取下
- MO1-17-4** **Efficacy and safety of early administration of pegfilgrastim for esophageal cancer treated with DCF: A phase 2 study**
Tomoyo Yasuda (Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine)
安田 知代 (京都府立医科大学 消化器内科)
- MO1-17-5** **Prognostic impact of serum inflammatory markers in oesophageal cancer following chemoradiation**
Connie Yip (Radiation Oncology Department, National Cancer Centre Singapore, Singapore)
- MO1-17-6** **Effect of definitive radiotherapy alone for the patients with esophageal squamous cell carcinoma**
Ryo Morita (Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital / Department of Respiratory Medicine, Akita Kousei Medical Center)
守田 亮 (国立がん研究センター中央病院 消化器内科 / 秋田厚生医療センター 呼吸器内科)

14:30-15:20 Mini-Oral Abstract Session 1-18

- MO1-18** Gastrointestinal Cancer5 (Gastric Cancer1)
消化管 5 (胃 1)
- Chair : Satoru Iwasa (National Cancer Center Hospital)
司会 : 岩佐 悟 (国立がん研究センター中央病院)
- MO1-18-1** **A phase II study of modified FOLFOX-6 (mFOLFOX6) for advanced gastric cancer refractory to standard therapies**
Seiichiro Mitani (Department of Clinical Oncology, Aichi Cancer Center Hospital)
三谷 誠一郎 (愛知県がんセンター中央病院 薬物療法部)
- MO1-18-2** **Analysis of metastatic foci using in house Gastric 58 SMG panel of 351,050 nt and d/ pMMR status by IHC of MMR proteins**
Masao Hada (Division of Surgery, Yamanashi prefectural central hospital)
羽田 真朗 (山梨県立中央病院 外科)
- MO1-18-3** **Significance of Lauren's diffuse type among patients with gastric cancer classified into the genomically stable subtype**
Masayuki Nagahashi (Division of Digestive and General Surgery, Niigata University)
永橋 昌幸 (新潟大学 消化器・一般外科)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
Annex 1
Annex 2
Room A
Room B-1
Room D
Room E
e&S
スラッ
D-11/W-1
D-20-1
F-1/W-1
Room C-1
Room C-2
Room B-2
Room 104

MO1-18-4 Clinical impact of degree of intratumor HER2 heterogeneity on trastuzumab efficacy in HER2 positive gastric cancer
Takeshi Suzuki (Department of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research)
鈴木 健 (がん研有明病院 消化器化学療法科)

MO1-18-5 The efficacy of ramucirumab in patients with advanced gastric cancer who had received prior nivolumab therapy
Akie Kimura (Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine / Department of Gastroenterological Surgery, Osaka University, Graduate School of Medicine)
木村 明恵 (大阪大学大学院医学系研究科 先進薬物療法開発学寄附講座 / 大阪大学大学院医学系研究科 消化器外科)

MO1-18-6 Phase II study of capecitabine plus oxaliplatin in patients with gastric cancer resistant/intolerable to CDDP (OGSG1403)
Encore
Hirokazu Taniguchi (Department of Surgery, Minoh City Hospital)
谷口 博一 (箕面市立病院 外科)

15:20-16:10 Mini-Oral Abstract Session 1-19

MO1-19 Gastrointestinal Cancer6 (Gastric Cancer2)
消化管 6 (胃 2)
Chair : Atsuo Takashima (National Cancer Center Hospital, Gastrointestinal Medical Oncology Division)
司会 : 高島 淳生 (国立がん研究センター中央病院 消化管内科)

MO1-19-1 Activation of central/effector memory T cells in advanced gastric cancer patients treated with anti PD-1 antibody
Encore
Hirofumi Ohmura (Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences)
大村 洋文 (九州大学大学院 医学研究院 病態修復内科学)

MO1-19-2 Retrospective comparison between Nivolumab and Irinotecan for advanced gastric cancer
Takahiro Ishii (Department of Gastroenterology and Gastrointestinal oncology, National Cancer Center Hospital East)
石井 貴大 (国立がん研究センター東病院 消化管内科)

MO1-19-3 Final analysis of survival outcomes in the KSCC1501A trial of up-front therapy for HER2-negative advanced gastric cancer
Akitaka Makiyama (Department of Hematology/Oncology, Japan Community Healthcare Organization Kyushu Hospital)
牧山 明資 (JCHO九州病院)

MO1-19-4 Intraperitoneal administration of paclitaxel combined with SOX for gastric cancer with peritoneal metastasis
Hironori Yamaguchi (Dept of Clinical Oncology, Jichi Medical University)
山口 博紀 (自治医科大学 臨床腫瘍科)

MO1-19-5 Outcomes of ramucirumab plus sb-PTX or nab-PTX for advanced gastric or gastroesophageal junction cancer patients
Naoki Fukuda (Department of Medical Oncology, The Cancer Institute Hospital of JFCR)
福田 直樹 (がん研究会 有明病院 総合腫瘍科)

MO1-19-6 **Drug selection by Narrative approach in patients with advanced gastric cancer -Paclitaxel or nab-Paclitaxel?-**

Tomono Kawase (Department of Surgery, Toyonaka Municipal Hospital)
川瀬 朋乃 (市立豊中病院)

16:10-17:40 Special Presidential Session 1 / 会長特別企画 1

SPS1 A New Approach to Summarizing Treatment Effects: Are Conventional Methods for Analyzing OS and PFS Always Appropriate?
臨床試験における治療効果の要約方法の新しいアプローチ：OS や PFS を分析するために使われる統計学的手法は万能か？

Chairs : Masahiro Tsuboi (National Cancer Center Hospital East)
Taro Shibata (Biostatistics Division, Center for Research Administration and Support, National Cancer Center)

司会 : 坪井 正博 (国立がん研究センター東病院 呼吸器外科)
柴田 大朗 (国立がん研究センター 研究支援センター 生物統計部)

SPS1-1 **Review of summary measures in cancer clinical trials and the challenges in non-inferiority trials**

Shogo Nomura (Center for Research Administration and Support, National Cancer Center)

評価指標の概説・非劣性試験における問題点と課題

野村 尚吾 (国立がん研究センター研究支援センター)

SPS1-2 **Discussions on issues in superiority studies**

Takahiro Hasegawa (SHIONOGI & CO., LTD. (Data Science, Japan Pharmaceutical Manufacturers Association))

優越性試験における問題点と課題に対する議論

長谷川 貴大 (塩野義製薬 (日本製薬工業協会 データサイエンス部会))

SPS1-3 **Problems of log rank test and Cox regression from the viewpoint of clinicians**

Keiju Aokage (National Cancer Center Hospital East, Division of Thoracic Surgery)

臨床家から見たログランク検定・Cox回帰の課題

青景 圭樹 (国立がん研究センター東病院 呼吸器外科)

SPS1-4 **Clinical Meaning and Operability of Endpoints in Cancer Clinical Trials: Example of Survey on RMST Threshold**

Yasuo Ohashi (Chuo Unoversity)

がん臨床試験におけるエンドポイントの操作性と臨床的意味：RMST 閾値調査を例にして

大橋 靖雄 (中央大学理工学部人間総合理工学科)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
16:10-17:40
Annex 1
Annex 2
Room A
Room B-1
Room D
Room E
2<5
2<7
D-1111-1
D-211-1
F-1111-1
Room C-1
Room C-2
Room B-2
Room 104

グランドプリンスホテル京都 1階 ロイヤルルーム

9:00-11:30 Presidential Symposium 2 / 会長企画シンポジウム 2

PSY2 Future Tracks of Clinical Oncology and Development in South-East Asia



Chairs : Kenichi Nakamura (Clinical Research Support Office, National Cancer Center Hospital)
Khin Thin Mu (Yangon General Hospital, Myanmar)
司会 : 中村 健一 (国立がん研究センター中央病院 臨床研究支援部門)
Khin Thin Mu (Yangon General Hospital, Myanmar)

PSY2-1 Next Frontiers in Philippine Oncology and Development in the Entire Cancer Care Continuum from Prevention to Management

Clarito U. Cairo, Jr. (Department of Health, Philippines)

PSY2-2 Cancer Treatment and Research in Indonesia: Current Status and Future Track, Challenging the Era of Genomic Medicine

Sri Agustini Kurniawati (Division of Hematology and Medical Oncology, Department of Internal Medicine, Dharmais National Cancer Center Hospital, Indonesia)

PSY2-3 Systemic Treatment of Breast Cancer in Viet Nam

Pham Tuan Anh (Department of Medical Oncology, National Cancer Center of Viet Nam, Viet Nam)

PSY2-4 Establishing Comprehensive Cancer Care in Cambodia

Encore Poly Bumpa (National cancer center, Cambodia)

PSY2-5 Global Network in Medical Oncology: From the Past to the Future in Precision Medicine Era

Thanyanan Reungwetwattana (Ramathibodi Hospital, Mahidol University, Thailand)

PSY2-6 Clinical Research and Trial Infrastructure in South-East Asia (Malaysia)

Wan Zamaniah Wan Ishak (Clinical Oncology Unit, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia)

PSY2-7 Current Situation of Cancer Care and Research in Myanmar

Han Win (Department of Medical Research, Myanmar)

PSY2-8 National Cancer Grid: a model for collaboration in cancer care and research

Manju Sengar (Department of Medical Oncology, Tata Memorial Centre, India)

PSY2-9 Management of Breast Cancer in Sri Lanka

Nuradh Joseph (Ministry of Health, Sri Lanka, Sri Lanka)

14:10-16:10 Presidential Symposium 3 / 会長企画シンポジウム 3

PSY3 Issues and Perspectives for Genomic Medicine in Oncology in General Hospitals 一般病院におけるがん領域のゲノム診療の課題と展望

Chairs : Takafumi Koyama (Department of Experimental Therapeutics, National Cancer Center Hospital)
Hitoshi Arioka (Dept. of Medical Oncology, Yokohama Rosai Hospital)
司会 : 小山 隆文 (国立がん研究センター中央病院 先端医療科)
有岡 仁 (横浜労災病院 腫瘍内科)

PSY3-1 Cancer genomic medicine at designated cancer hospitals

Harukaze Yamamoto (National Hospital Organization Kumamoto Medical Center)

地域がん診療連携拠点病院におけるがんゲノム医療

山本 春風 (国立病院機構熊本医療センター)

PSY3-2	The Roles of "Core Hospital" for Cancer Genomic Medicine in Japan Kuniko Sunami (Department of Laboratory Medicine, National Cancer Center Hospital) ゲノム医療における中核拠点病院の役割 角南 久仁子 (国立がん研究センター中央病院 臨床検査科)	Day 1 (Thu)
PSY3-3	Establishing a system for cancer genomic medicine in Japan Yosuke Mukai (Cancer and Disease Control Division, Health Service Bureau, Ministry of Health, Labour and Welfare) がん領域におけるゲノム医療の提供体制について 向井 洋介 (厚生労働省 健康局 がん疾病対策課)	Day 2 (Fri)
PSY3-4	The future view for promoting cancer genome medicine, from a reviewer's perspective Takahiro Nonaka (Office of New Drug V, Pharmaceuticals & Medical Devices Agency) がんゲノム医療を推進するための今後の展望 (抗がん剤の審査の立場から) 野中 孝浩 (独立行政法人医薬品医療機器総合機構 新薬審査第五部)	Day 3 (Sat)
PSY3-5	From the viewpoint of clinical testing company Naoto Kondo (RIKEN GENESIS CO., LTD.) 検査企業の立場から 近藤 直人 (株式会社理研ジェネシス)	Annex 1
16:10-18:10 Joint Symposium 1 (JASTRO/JSMO) / 合同シンポジウム 1 (日本放射線腫瘍学会/日本臨床腫瘍学会)		Annex 2
JS1	Role of Radiation Therapy in Cancer Patients 担癌患者に対する放射線治療の役割 Chairs : Yoshikazu Kagami (Showa University School of Medicine, Division of Radiation Oncology) Shibata Hiroyuki (Department of Clinical Oncology, Akita University) 司会 : 加賀美 芳和 (昭和大学医学部放射線医学講座放射線治療学部門) 柴田 浩行 (秋田大学大学院医学系研究科 臨床腫瘍学分野)	Room A
JS1-1	Role of Highly Conformal Radiotherapy in Palliative Care Naoki Nakamura (Division of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East) 緩和医療における高精度放射線治療の役割 中村 直樹 (国立がん研究センター東病院 放射線治療科)	Room B-1
JS1-2	Work-sharing between radiotherapy and chemotherapy for the treatment of bone metastasis Hiroyuki Shibata (Department of Clinical Oncology, Akita University) 骨転移診療における放射線治療と薬物療法の棲み分け 柴田 浩行 (秋田大学大学院医学系研究科)	Room B-1
JS1-3	Role of the local treatment for patients with oligometastatic NSCLC Kazuhiko Yamada (Department of Respiratory Medicine, Shin Koga Hospital) オリゴメタスタシスに対する局所治療の役割 山田 一彦 (新古賀病院 呼吸器内科)	Room D
JS1-4	Stereotactic ablative radiotherapy for oligo-recurrence or oligo-metastases Keiichi Jingu (Department of Radiation Oncology, Tohoku University Graduate School of Medicine) オリゴメタに対する定位放射線治療 神宮 啓一 (東北大学大学院医学系研究科放射線腫瘍学分野)	Room E

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) 16:10-18:10 Annex 1 Annex 2 Room A Room B-1 Room D Room E 16:10-18:10 JS1 JS1-1 JS1-2 JS1-3 JS1-4 Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room C-1 Room C-2 Room B-2 Room 104

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
××××-11
Annex 1
Annex 2
Room A
Room B-1
Room D
Room E
×××5
××××
□××××-1
□-×××-1
×-××××-1
Room C-1
Room C-2
Room B-2
Room 104

JS1-5

Concurrent immune checkpoint inhibitor and radiotherapy
Motoo Nomura (Medical Oncology Department, Kyoto University)
免疫チェックポイント阻害剤と放射線治療の併用療法
野村 基雄 (京都大学 腫瘍内科)

グランドプリンスホテル京都 地下1階 ローズルーム

9:20-10:50 Workshop 1 / ワークショップ 1

WS1 How Do We Properly Use Various Regimens in Chemotherapy for Advanced HCC?
肝細胞癌の薬物療法の使い分け

Chairs : Masafumi Ikeda (Department of Hepatobiliary & Pancreatic Oncology, National Cancer Center Hospital East)
Yoshitaka Inaba (Dept. of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital)
司会 : 池田 公史 (国立がん研究センター東病院 肝胆膵内科)
稲葉 吉隆 (愛知県がんセンター 放射線診断・IVR部)

WS1-1 **Hepatic arterial infusion chemotherapy for hepatocellular carcinoma: current status and future perspective**

Satoshi Kobayashi (Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center)

肝細胞癌に対する肝動注化学療法の現状と展望

小林 智 (神奈川県立がんセンター 消化器内科・肝胆膵)

WS1-2 **Regorafenib for advanced hepatocellular carcinoma patients in the real world practice**

Sadahisa Ogasawara (Department of Gastroenterology, Chiba University, Graduate School of Medicine)

進行肝細胞癌の薬物治療におけるレゴラフェニブの位置づけ

小笠原 定久 (千葉大学大学院医学研究院 消化器内科学)

WS1-3 **Lenvatinib therapy for patients with unresectable hepatocellular carcinoma**

Encore ~ A nationwide multicenter study ~

Kaoru Tsuchiya (Musashino Red Cross Hospital)

切除不能肝細胞癌に対するレンパチニブ治療の実際 ~多施設共同研究の結果から~

土谷 薫 (武蔵野赤十字病院)

WS1-4 **Concept of combination therapy of TACE with molecular targeted agent**

Kazuomi Ueshima (Kindai University Faculty of Medicine)

TACEと分子標的薬との併用療法のコンセプト

上嶋 一臣 (近畿大学病院)

WS1-5 **Recent advances in systemic therapy for hepatocellular carcinoma**

Masafumi Ikeda (Department of Hepatobiliary & Pancreatic Oncology, National Cancer Center Hospital East)

肝細胞癌の全身薬物療法の最近の動向

池田 公史 (国立がん研究センター東病院 肝胆膵内科)

14:10-16:10 Symposium 5 / シンポジウム 5

SY5 Immune Therapy for Hematologic Malignancies
造血器腫瘍に対する免疫療法

Chairs : Junji Suzumiya (Shimane University Hospital Innovative Cancer Center/Hematology-Oncology)
Koji Izutsu (Department of Hematology, National Cancer Center Hospital)
司会 : 鈴宮 淳司 (島根大学医学部附属病院 先端がん治療センター / 腫瘍・血液内科)
伊豆津 宏二 (国立がん研究センター中央病院 血液腫瘍科)

SY5-1 **CAR T-Cell Therapy of B-cell Lymphomas: Current Status and Next Steps**

Stephen J. Schuster (University of Pennsylvania, United States)

Day 1 (Thu)	SY5-2	Targetable Genetics Bases of Immune Evasion in Lymphoid Malignancies Margaret A. Shipp (Dana-Farber Cancer Institute, Boston, USA)
Day 2 (Fri)	SY5-3	ALL treatment using Bispecific Ab Max S. Topp (Universitätsklinikum Würzburg, Würzburg, Germany)
Day 3 (Sat)	SY5-4	CAR T cell therapy for multiple myeloma Naoki Hosen (Department of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine) 多発性骨髄腫に対するCAR T細胞療法 保仙 直毅 (大阪大学大学院医学系研究科癌幹細胞制御学)
Annex 1	SY5-5	The role of immuno-checkpoint inhibitors in Hodgkin lymphoma Dai Maruyama (Department of Hematology, National Cancer Center Hospital) ホジキンリンパ腫治療における免疫チェックポイント阻害剤の役割 丸山 大 (国立がん研究センター中央病院)
Annex 2	SY5-6	The importance of immune responses in the treatment of hematologic malignancies Hiroyoshi Nishikawa (Division of Cancer Immunology, Research Institute/EPOC, National Cancer Center / Department of Immunology, Nagoya University Graduate School of Medicine) 血液悪性疾患治療における免疫反応の重要性 西川 博嘉 (国立がん研究センター 研究所 腫瘍免疫研究分野 / EPOC 免疫TR分野 / 名古屋大学大学院医学系研究科 微生物・免疫学講座 分子細胞免疫学)
Room A	Encore	
Room B-1		
Room D		
Room E	16:10-18:10	Joint symposium 2 on Rare Cancers in Asia (JCA/JSCO/JSMO/RCC) / 合同シンポジウム (希少がん) 2 (日本癌学会 / 日本癌治療学会 / 日本臨床腫瘍学会 / 希少がん患者会ネットワーク)
Room E	JS2	Rare Cancer in Asia: Current Status and Construction of Medical Network アジアでの希少がん：現状及び診療のネットワーク構築について 
Room E	Chairs :	Tatsunori Shimoi (Department of Breast and Medical Oncology, National Cancer Center Hospital) Eiso Hiyama (Hiroshima University N-BARD)
Room E	Discussant :	Isabelle Ray-Coquard (Centre Leon Berard and University Claude Bernard Lyon, France)
Room E	司会 :	下井 辰徳 (国立がん研究センター中央病院 乳腺・腫瘍内科) 檜山 英三 (広島大学 自然科学研究支援開発センター)
Room E	ディスカッション :	Isabelle Ray-Coquard (Centre Leon Berard and University Claude Bernard Lyon, France)
Room C-1	JS2-1	Challenges and Prospects of International Network: Rare Cancers Europe to Rare Cancers Asia Paolo Casali (Istituto Tuomri, Milan, Italy)
Room C-2	JS2-2	Rare Cancer Burden in Asia - International coordination is a pressing issue Tomohiro Matsuda (National Cancer Center) アジアでの希少がんの負担 - 国際協調が喫緊の課題である 松田 智大 (国立がん研究センター)
Room B-2	JS2-3	The current status of pathological diagnosis of soft tissue tumors and its issues in the future Yoshinao Oda (Department of Anatomic Pathology, Kyushu University) 軟部腫瘍病理診断の現状と今後の課題 小田 義直 (九州大学大学院医学研究院形態機能病理学)
Room 104		

JS2-4	Unmet Needs of Rare Cancer Patients and New Initiatives of RCJ Yoshiyuki Majima (Rare Cancers Japan/PanCAN Japan) 希少がん患者のアンメットニーズ及びRCJのイニシアチブ 眞島 喜幸 (日本希少がん患者会ネットワーク/パンキャンジャパン)
JS2-5	Efforts on Rare Cancers and Other Diseases in Hong Kong Herbert HF Loong (The Chinese University of Hong Kong, HK)
JS2-6	Rare Cancers China Programs starting up Hongfei Gu (chinese Organization for Rare Disorders, China)
JS2-7	The building and utilization of nation wide networking for rare cancer in Japan Makoto Kodaira (Kodaira Hospital) 全国的な希少がんネットワークの構築と活用 公平 誠 (公平病院)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
キックオフ
Annex 1
Annex 2
Room A
Room B-1
Room D
Room E
セミナー
スワップ
Day 4 (Sun)
Day 5 (Mon)
Day 6 (Tue)
Day 7 (Wed)
Room C-1
Room C-2
Room B-2
Room 104

グランドプリンスホテル京都 地下2階 ゴールドルーム

9:00-11:00 Symposium 6 / シンポジウム 6

SY6 Cancer Immunotherapy; A Paradigm Shift in the First-line Treatment of Lung Cancer 肺癌薬物療法のパラダイムシフト〜初回治療総入れ替え元年

Chairs : Kazuhiko Nakagawa (Department of Medical Oncology, Kindai University Faculty of Medicine)
Isamu Okamoto (Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University)
司会 : 中川 和彦 (近畿大学医学部 内科学腫瘍内科部門)
岡本 勇 (九州大学 呼吸器科)

SY6-1 Cancer immunotherapy; A paradigm shift in the first-line treatment of lung cancer

Roy S. Herbst (Yale School of Medicine | Yale Cancer Center | Smilow Cancer Hospital at Yale-New Haven, United States)

SY6-2 Current status of immune-checkpoint inhibitors in the first-line treatment of metastatic non-small cell lung cancer

Kentaro Tanaka (Respiratory Medicine Department, Kyushu University Hospital)
田中 謙太郎 (九州大学病院 呼吸器科)

SY6-3 Is Earlier Better? Immunotherapy for Resectable Lung Cancer

Patrick M. Forde (Johns Hopkins University School of Medicine, United States)

SY6-4 The role of immune checkpoint inhibitor and future perspective for unresectable stage III non-small cell lung cancer

Takaaki Tokito (Division of Respiriology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine)
時任 高章 (久留米大学医学部内科学講座呼吸器神経膠原病内科部門)

SY6-5 Development of immune checkpoint inhibitors for thoracic cancer (SCLC, malignant mesothelioma, thymic epithelioid tumor)

Yasushi Goto (National Cancer Center Hospital)

免疫チェックポイント阻害薬の胸部悪性腫瘍での開発

後藤 悌 (国立がん研究センター中央病院)

14:10-16:10 Joint Symposium 3 (JCS/JSMO) / 合同シンポジウム 3 (日本循環器学会 / 日本臨床腫瘍学会)

JS3 Cardio-Oncology Learned from Case Discussion 症例提示で学ぶ腫瘍循環器学

Chairs : Tohru Minamino (Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences)
Shingo Yano (Division of Clinical Oncology and Hematology, Jikei University School of Medicine)
司会 : 南野 徹 (新潟大学大学院医歯学総合研究科 循環器病態学分野教授)
矢野 真吾 (東京慈恵会医科大学附属病院 血液・腫瘍内科)

JS3-1 A case of heart failure after radiation therapy for mediastinum.

Jun Sato (Department of Experimental Therapeutics, National Cancer Center Hospital)

縦隔に対する放射線治療後に心不全を発症した一例

佐藤 潤 (国立がん研究センター中央病院 先端医療科)

JS3-2	<p>The importance of early detection of cancer therapeutic-related cardiac dysfunction in the managements of heart failure</p> <p>Chisato Izumi (National Cerabral and Cardiovascular Center)</p> <p>がん治療関連心不全の診療における心機能低下の早期発見の重要性</p> <p>泉 知里 (国立循環器病研究センター)</p>	Day 1 (Thu)
JS3-3	<p>An endometrial cancer patient with sudden loss of consciousness</p> <p>Yoshinori Imamura (Medical Oncology/Hematology, Kobe University Hospital)</p> <p>今村 善宣 (神戸大学医学部附属病院 腫瘍・血液内科)</p>	Day 2 (Fri)
JS3-4	<p>Management of atrial fibrillation in patients with cancer</p> <p>Yuji Okura (Department of Onco-cardiology, Niigata Cancer Center Hospital)</p> <p>大倉 裕二 (新潟県立がんセンター 腫瘍循環器科)</p>	Day 3 (Sat)
JS3-5	<p>Acute coronary syndromes before or during chemotherapy</p> <p>Kazuya Shimoda (Department of Gastroenterology and Hematology, University of Miyazaki)</p> <p>下田 和哉 (宮崎大学 医学部内科学講座 消化器血液学分野 (血液内科))</p>	Multi-day
JS3-6	<p>Therapeutic strategies for ischemic heart disease</p> <p>Daisuke Sueta (Department of Cardiovascular Medicine, Kumamoto University Hospital)</p> <p>虚血性心疾患の治療戦略</p> <p>末田 大輔 (熊本大学病院 循環器内科)</p>	Annex 1
16:10-18:10 Symposium 7 / シンポジウム 7		Annex 2
SY7	<p>Future Prospects of Immune Checkpoint Inhibitors</p> <p>免疫チェックポイント阻害薬の展望</p> <p>Chairs : Makoto Nishio (Department of Thoracic Medical Oncology, the Cancer Institute Hospital, Japanese Foundation for Cancer Research)</p> <p>Yoshikazu Kamiya (National Hospital Organization Higashinagoya National Hospital)</p> <p>司会 : 西尾 誠人 (がん研究会有明病院 呼吸器センター)</p> <p>神谷 悦功 (東名古屋病院 血液・腫瘍内科)</p>	Room A
SY7-1	<p>TUMOR AND HOST FACTORS REGULATING ANTI-TUMOR IMMUNITY AND IMMUNOTHERAPY EFFICACY</p> <p>Thomas Gajewski (University of Chicago, United States)</p>	Room B-1
SY7-2	<p>Combination Immuno-therapy in Melanoma</p> <p>Yoshio Kiyohara (Dermatology Division, Shizuoka Cancer Center)</p> <p>メラノーマの免疫併用療法</p> <p>清原 祥夫 (静岡県立静岡がんセンター 皮膚科)</p>	Room D
SY7-3	<p>Immune checkpoint inhibitors: a perspective of established and potential combination therapy</p> <p>Hidehito Horinouchi (Department of Thoracic Oncology, National Cancer Center Hospital)</p> <p>免疫チェックポイント阻害剤：広がる併用療法の可能性</p> <p>堀之内 秀仁 (国立がん研究センター中央病院呼吸器内科)</p>	Room E
SY7-4	<p>The management of immune-related adverse events</p> <p>Shuichi Hironaka (Department of Medical Oncology and Hematology, Oita University Faculty of Medicine)</p> <p>免疫チェックポイント阻害薬の有害事象対策</p> <p>廣中 秀一 (大分大学医学部)</p>	Room F

国立京都国際会館 1階 Room C-1

17:00-17:50 Mini-Oral Abstract Session 1-20

MO1-20 Translational Research8
TR8

Chair : Masahiko Nishiyama (Higashi-Sapporo Hospital)
司会 : 西山 正彦 (東札幌病院)

MO1-20-1 **Lenvatinib + PD-1 blockade activates CD8 T cell by decrease of tumor-associated macrophage and activation of IFN pathway**

Encore

Yu Kato (Oncology Business Group, Eisai Co. Ltd.)

腫瘍内マクロファージの減少及びIFNパスウェイ活性化に基づくレンパチニブとPD-1阻害剤併用治療のCD8T細胞賦活化作用

加藤 悠 (エーザイ株式会社オンコロジービジネスグループ)

MO1-20-2 **Safety, PK and preliminary efficacy of talazoparib in Japanese patients with advanced solid tumors; Phase 1 Study**

Yoichi Naito (National Cancer Center Hospital East)

日本人進行固形がんに対するtalazoparibの第1相試験

内藤 陽一 (国立がん研究センター東病院)

MO1-20-3 **HER2 mRNA expression level is preserved in liver metastasis compared with corresponding primary colorectal cancer**

Hidekazu Kuramochi (Tokyo Women's Medical University, Yachiyo Medical Center)

倉持 英和 (東京女子医科大学八千代医療センター)

MO1-20-4 **Expression of Olfactomedin-4 in pancreatic cancer and its clinical significance**

Encore

Ryotaro Ohkuma (Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University / Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology & Therapeutics, Showa University)

大熊 遼太郎 (昭和大学医学部内科学講座 腫瘍内科学部門 / 昭和大学臨床薬理研究所 臨床腫瘍診断学講座)

MO1-20-5 **Characterization of URST4 as a new cancer biomarker and therapeutic target for oral cancer**

Ming Zhu (Medical Oncology Department, Shiga University of Medical Science)

祝 銘 (滋賀医科大学 臨床腫瘍学講座)

MO1-20-6 **Identification of OASEP1 as a biomarker and therapeutic target for oral cancer**

Atsushi Takano (Center for Antibody and Vaccine Therapy, Institute of Medical Science, University of Tokyo / Department of medical oncology, Shiga University of Medical Science)

高野 淳 (東京大学医学部研究所附属病院 抗体ワクチンセンター / 滋賀医科大学 臨床腫瘍学講座)

17:10-18:00 Distinguished Expert Lecture 1

DL1 My Lung Cancer World: Yesterday, Today and Tomorrow

Chair : Yoshiro Nakahara (Department of Thoracic Oncology, Kanagawa Cancer Center)
司会 : 中原 善朗 (神奈川県立がんセンター 呼吸器内科)

My Lung Cancer World: Yesterday, Today and Tomorrow

Thanyanan Reungwetwattana (Ramathibodi Hospital, Mahidol University, Thailand)

Day 1 (Thu) 国立京都国際会館 2階 Room B-2

10:30-11:20 Distinguished Expert Lecture 2

DL2 Precision Medicine in Triple Negative Breast Cancer: The Future is Coming

Chair : Kanako Saito (Department of Medical Oncology, Mie University Hospital)
司会 : 斎藤 佳菜子 (三重大学医学部附属病院 腫瘍内科)

Precision Medicine in Triple Negative Breast Cancer: The Future is Coming

Qiang Liu (Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, China)

14:10-15:00 Distinguished Expert Lecture 3

DL3 Breast Cancer in Young and Premenopausal Women

Chair : Yumi Yoshii (Oncology Center, Nara Medical University)
司会 : 吉井 由美 (奈良県立医科大学附属病院 腫瘍センター)

Breast Cancer in Young and Premenopausal Women

Sibylle Loibl (GERman Breast Group; University Frankfurt, Germany)

15:10-16:00 Distinguished Expert Lecture 4

DL4 Checkpoint Inhibition and Other Immunotherapies in the Management of Sarcomas: Are We There Yet?

Chair : Rika Sakai (Department of Hematology and Medical Oncology, Kanagawa Cancer Center)
司会 : 酒井 リカ (地方独立行政法人神奈川県立病院機構 神奈川県立がんセンター 血液・腫瘍内科)

Checkpoint Inhibition and Other Immunotherapies in the Management of Sarcomas: Are We There Yet?

Herbert HF Loong (The Chinese University of Hong Kong, Hong Kong)

16:10-17:00 Distinguished Expert Lecture 5

DL5 Challenges of Current Management in Nasopharyngeal Carcinoma from a Perspective of a High Incidence Developing Country

Chair : Fumihiko Matsumoto (Department of Otorhinolaryngology-Head and Neck Surgery, Juntendo University Hospital)
司会 : 松本 文彦 (順天堂大学医学部附属病院 耳鼻咽喉・頭頸科)

Challenges of Current Management in Nasopharyngeal Carcinoma from a Perspective of a High Incidence Developing Country

Pei Jye Voon (Radiotherapy and Oncology Department, Hospital Umum Sarawak, Malaysia)

DL6 International Collaboration in Cancer Clinical Trials: The Australasian Gastrointestinal Cancer Trials Group Experience

Chair : Masayuki Nagahashi (Division of Digestive and General Surgery Niigata University Graduate School of Medical and Dental Sciences)

司会 : 永橋 昌幸 (新潟大学 消化器・一般外科 (第一外科))

International Collaboration in Cancer Clinical Trials: The Australasian Gastrointestinal Cancer Trials Group Experience

Yu jo Chua (Medical Oncology Unit, The Canberra Hospital, Australian Capital Territory, Australia)

Day 1 (Thu) 国立京都国際会館 1F Room 104

9:00-10:00 Meet the Experts 1

ME1 Targeting Biliary Tract Cancers

Moderators: Naomi Kiyota (Kobe University Hospital Cancer Center)
Meiko Nishimura (Division of Medical Oncology, Hyogo Cancer Center)
モデレーター: 清田 尚臣 (神戸大学医学部附属病院 腫瘍センター)
西村 明子 (兵庫県立がんセンター 腫瘍内科)

Targeting Biliary Tract Cancers

Bruce A. Chabner (Harvard Medical School and the Massachusetts General Hospital, U.S.A.)

10:00-11:00 Meet the Experts 2

ME2 Evolving Strategies for Enhancing the Impact of Immunotherapy in Breast Cancer

Moderators: Fumikata Hara (The Cancer Institute Hospital of JFCR, Breast Medical Oncology)
Junji Tsurutani (Advanced Cancer Translational Research Institute, Department of Medical Oncology, Showa University)
モデレーター: 原文堅 (公益財団法人がん研究会 がん研有明病院乳腺センター 乳腺内科)
鶴谷 純司 (昭和大学 先端がん治療研究所、医学部 内科学講座 腫瘍内科部門)

Evolving Strategies for Enhancing the Impact of Immunotherapy in Breast Cancer

Hope S. Rugo (UCSF Helen Diller Family Comprehensive Cancer Center, U.S.A.)

14:10-15:10 Meet the Experts 3

ME3 Frailty and Challenges of Immunotherapy in Older Patients

Moderators: Kimikazu Yakushijin (Medical Oncology and Hematology, Kobe University Hospital)
Yoshimi Fujishima (Department of Medical Oncology/Hematology, Kobe University Graduate School of Medicine, Kobe, Japan)
モデレーター: 薬師神 公和 (神戸大学医学部附属病院 腫瘍・血液内科)
藤島 佳未 (神戸大学医学部附属病院 腫瘍・血液内科)

Frailty and Challenges of Immunotherapy in Older Patients

Etienne GC Brain (Department of Medical Oncology, Institut Curie - Hôpital René Huguenin, France)

15:10-16:10 Meet the Experts 4

ME4 New Therapeutic Strategies for EGFR Mutant Lung Cancer

Moderators: Hidetoshi Hayashi (Department of medical oncology, Kindai University)
Koji Haratani (Kindai University Faculty of Medicine, Department of Medical Oncology)
モデレーター: 林 秀敏 (近畿大学病院)
原谷 浩司 (近畿大学医学部 腫瘍内科)

New Therapeutic Strategies for EGFR Mutant Lung Cancer

Pasi A. Jänne (Lowe Center for Thoracic Oncology; Dana Farber Cancer Institute, U.S.A.)

16:10-17:10 Meet the Experts 5

ME5 Development of Immunotherapy in Gastro-esophageal Cancer in the Worldwide Arena

Moderators: Akira Fukutomi (Division of Gastrointestinal Oncology, Shizuoka Cancer Center)
Nobumasa Mizuno (Department of Gastroenterology, Aichi Cancer Center Hospital)

モデレーター: 福富 晃 (静岡県立静岡がんセンター 内科)
水野 伸匡 (愛知県がんセンター 消化器内科部)

Development of Immunotherapy in Gastro-esophageal Cancer in the Worldwide Arena

Ian Chau (Royal Marsden Hospital, UK)

17:10-18:10 Meet the Experts 6

ME6 Treatment Strategies for Newly Diagnosed Elderly Patients with Multiple Myeloma

Moderators: Hisakazu Nishimori (Department of Hematology and Oncology, Okayama University Hospital)
Kimikazu Yakushijin (Medical Oncology and Hematology, Kobe University Hospital)

モデレーター: 西森 久和 (岡山大学病院 血液・腫瘍内科)
薬師神 公和 (神戸大学医学部附属病院 腫瘍・血液内科)

Treatment Strategies for Newly Diagnosed Elderly Patients with Multiple Myeloma

Thierry R. Facon (Lille University Hospital, France)

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

キコウ-1

Annex 1

Annex 2

Room A

Room B-1

Room D

Room E

さく5

スラフ

Day 1 (Thu)

Day 2 (Fri)

Room C-1

Room C-2

Room B-2

Room 104

国立京都国際会館 ニューホール

12:40-13:35 Poster Session 1-1 / ポスターセッション 1-1

P1-1 Gastrointestinal Cancer1 (Colorectal Cancer1)
消化管 1 (大腸 1)

Chair : Naoki Muguruma (Tokushima University Graduate School of Biomedical Sciences)
司会 : 六車 直樹 (徳島大学大学院 医歯薬学研究部 消化器内科学)

P1-001 **MicroRNA-9 methylation reflect epigenetic drift and identify patients with risk for UC-associated colorectal neoplasia**
Yoshinaga Okugawa (Department of Gastrointestinal and Pediatric Surgery, Mie University)
奥川 喜永 (三重大学大学院医学系研究科)

P1-002 **Impact of fluoropyrimidine switching in sequential treatment of first- and second-line in unresectable colorectal cancer**
Yusuke Nagata (The Jikei University School of Medicine)
永田 祐介 (東京慈恵会医科大学附属病院)

P1-003 **Three cases of FOLFOX plus bevacizumab therapy for hemodialytic patients with metastatic colorectal cancer**
Chikako Funasaka (Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital)
船坂 知華子 (都立駒込病院 腫瘍内科)

P1-004 **FOLFIRI in combination with Ramcirumab in unresectable colorectal cancer. A single center retrospective analysis**
Akiko Hasegawa (Osaka International Cancer Institute)
長谷川 晶子 (大阪国際がんセンター)

P1-005 **FOLFIRI plus ramucirumab or aflibercept in patients with bevacizumab beyond PD refractory metastatic colorectal cancer**
Hiroki Yoshita (Department of Gastroenterology and Hematology, Faculty of medicine, University of Toyama)
吉田 啓紀 (富山大学附属病院)

P1-006 **Clinical Experience of FOLFOXIRI therapy for patients with advanced, recurrent colorectal cancer**
Kosuke Sagara (National Hospital Organization Kyushu Cancer Center)
相良 浩輔 (九州がんセンター)

P1-007 **The difference in the effects on chemotherapy following primary tumor resection and colostomy in colorectal cancer**
Yusuke Nagata (The Jikei University School of Medicine)
永田 祐介 (東京慈恵会医科大学附属病院)

P1-008 **Chemotherapy for recurrence of postoperative colorectal cancer in our institute**
Takayuki Sone (Department of Gastroenterology, Sapporo City General Hospital)
曾根 孝之 (市立札幌病院 消化器内科)

P1-009 **A case of chemotherapy for unresectable sigmoid colon cancer with severe cardiac dysfunction**
Tsunenori Tamai (General Practice Department, National Hospital Organization Saitama Hospital)
玉井 恒憲 (国立病院機構埼玉病院 総合診療科)

P1-010 A case report and retrospective examination of primary appendiceal adenocarcinoma in our hospital

Kazutaka Iijima (Department of Gastroenterology, Ibaraki Prefectural Central Hospital/Ibaraki Prefecture Regional Cancer Center)
 飯島 一飛 (茨城県立中央病院・茨城県地域がんセンター 消化器内科)

12:40-13:35 Poster Session 1-2 / ポスターセッション 1-2

P1-2 Gastrointestinal Cancer2 (Colorectal Cancer2)
消化管 2 (大腸 2)

Chair : Osamu Muto (Dept. of Clinical Oncology Akita Red Cross Hospital)
 司会 : 武藤 理 (秋田赤十字病院 腫瘍内科)

P1-011 Endoscopic features and histologic diagnosis of immune check point inhibitor associated colitis

Akira Maekawa (Department of Gastrointestinal Oncology, Osaka International Cancer Institute)
 前川 聡 (大阪国際がんセンター 消化管内科)

P1-012 Primary tumor location and benefit of anti-EGFRs as second or later line treatment in KRAS-RAS wild type mCRC patients

Ayumi Saito (Medical Oncology Department, Kameda Medical Center)
 齋藤 亜由美 (亀田総合病院 腫瘍内科)

P1-013 Real-world outcome of second-line FOLFIRI plus RAM with or without prior bevacizumab for metastatic colorectal cancer

Takeshi Suzuki (Department of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research)
 鈴木 健 (がん研有明病院 消化器化学療法科)

P1-014 Relation between efficacy and relative dose intensity of ramucirumab plus FOLFIRI for metastatic colorectal cancer

Satoru Yamaga (Department of Hematology/Oncology, Japan Community Healthcare Organization Kyushu Hospital)
 山家 寛 (地域医療機能推進機構 九州病院 血液・腫瘍内科)

P1-015 Predictive factors for early mortality after regorafenib or trifluridine/tipiracil initiation in colorectal cancer

Encore

Toshiki Masuishi (Department of Clinical Oncology, Aichi Cancer Center Hospital)
 舩石 俊樹 (愛知県がんセンター)

P1-016 TAS-102 plus bevacizumab with metastatic colorectal cancer in salvage line

Hiroshi Osawa (Edogawa Hospital)
 大澤 浩 (江戸川病院)

P1-017 Retrospective analysis of Trifluridine/tipiracil + Bevacizumab for mCRC, a single center experience

Tomohiro Matsushima (Department of Gastroenterology, Saitama Cancer Center)
 松島 知広 (埼玉県立がんセンター)

P1-018 The efficacy of capecitabine as a salvage treatment in the colorectal cancer patients

Ho Young Nam (Wonju Severance Christianity Hospital, Korea)

P1-019 Efficacy and feasibility of systemic chemotherapy in elderly patients (>80 years old) with metastatic colorectal cancer

Yuji Miyamoto (Gastroenterological Surgery Department, Kumamoto University)

P1-020 Primary small bowel adenocarcinoma : a case report
 Mari Sato (Department of Gastroenterology, Saka General Hospital)
 佐藤 麻理 (坂総合病院 消化器センター)

12:40-13:35 Poster Session 1-3 / ポスターセッション 1-3

P1-3 Gastrointestinal Cancer3 (Gastric Cancer - Immune Checkpoint Inhibitors1)
 消化管3 (胃-免疫チェックポイント阻害薬1)

Chair : Satoshi Kato (Division of Clinical Oncology Iwate Prefectural Central Hospital)
 司会 : 加藤 誠之 (岩手県立中央病院 がん化学療法科)

P1-021 Efficacy and Safety of Chemotherapy Following Anti-PD-1 Antibody Therapy for Gastric Cancer

Mitsunari Yamada (Department of Gastroenterology and Hepatology, Kindai University)
 山田 光成 (近畿大学 消化器内科)

P1-022 Clinical response to subsequent chemotherapy after nivolumab in patients with advanced gastric cancer

Kai Tsugaru (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine)
 津軽 開 (慶應義塾大学医学部 消化器内科)

P1-023 Abscopal effect in a patient with gastric cancer followed by nivolumab and radiotherapy: serum immune response analysis

Yasuyoshi Sato (Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo / Department of Immunotherapeutics, The University of Tokyo Hospital)
 佐藤 靖祥 (東京大学大学院医学系研究科 消化管外科学 / 東京大学医学部附属病院 免疫細胞治療学)

P1-024 Retrospective analysis for efficacy and safety of nivolumab in advanced gastric cancer patients with malignant ascites

Hirosumi Suzuki (Division of Gastroenterology, University of Tsukuba Hospital)
 鈴木 宏清 (筑波大学附属病院 消化器内科)

P1-025 Nivolumab for poor performance status patients : retrospective analysis

Toshihiko Matsumoto (Himeji red cross hospital)
 松本 俊彦 (姫路赤十字病院)

P1-026 Efficacy of nivolumab for advanced gastric cancer

Ichiro Moriyama (Innovative Cancer Center, Shimane University Hospital)
 森山 一郎 (島根大学医学部附属病院 先端がん治療センター)

P1-027 Validation of nivolumab monotherapy for patients with AGC as the late-line chemotherapy: a retrospective study

Tetsuya Kusumoto (Department of Gastroenterological Surgery and Clinical Research Institute Cancer Research Division, National Kyushu Medical Center)
 楠本 哲也 (九州医療センター 消化管外科・がん臨床研究部)

P1-4 Hepatobiliary/Pancreatic Cancer1 (Unfit Patients)
肝胆膵1 (Unfit Patients)

Chair : Ayumu Hosokawa (Department of Clinical Oncology, University of Miyazaki Hospital)
 司会 : 細川 歩 (宮崎大学医学部附属病院 臨床腫瘍科)

P1-028 The efficacy of S-1 monotherapy after refractory to combination therapy with 5-FU for unresectable pancreatic cancer

Akiko Todaka (Shizuoka Cancer Center)
 戸高 明子 (静岡県立静岡がんセンター)

P1-029 Gemcitabine plus nab-paclitaxel for elderly patients with advanced pancreatic cancer
Ruiko Yamaguchi (Department of Medical Oncology and Gastroenterology, Ishikawa Prefectural Central Hospital)

高齢進行膵癌患者に対する Gemcitabine + nab-paclitaxel療法の有効性と安全性
 山口 暁子 (石川県立中央病院 腫瘍内科 消化器内科)

P1-030 膵臓癌に対する FOLFIRINOX療法におけるオキサリプラチンの減量と予後の関係

Akane Higami (Shiga General Hospital Resident center)
 樋上 明音 (滋賀県立総合病院 レジデントセンター)

P1-031 当院における切除不能膵癌に対する FOLFIRINOX、GEM+nab-PTX 両治療施行についての検討

Yosuke Saragai (Department of Gastroenterology and Hepatology, Okayama University)
 皿谷 洋祐 (岡山大学病院)

P1-032 当科における膵癌化学療法の現状 (FOLFIRINOX療法とGEM/nab-PTX療法について)

Yoshihiro Tahara (Department of Clinical Oncology, University of Miyazaki Hospital)
 田原 良博 (宮崎大学医学部附属病院 臨床腫瘍科)

P1-033 Efficacy and safety of chemotherapy in elderly patients with unresectable pancreatic cancer

Dai Inoue (Department of Gastroenterology, Tokyo Metropolitan Tama Medical Center)
 高齢者膵癌患者に対する化学療法の安全性・有効性の検討
 井上 大 (東京都立多摩総合医療センター)

P1-034 切除不能膵癌に対する化学療法症例の検討

Masakuni Fujii (Okayama Saiseikai General Hospital)
 藤井 雅邦 (岡山済生会総合病院 内科)

P1-035 Selection of treatments for elderly patients with pancreatic cancer

Junko Tahara (Department of Medicine, Institute of Gastroenterology, Tokyo Women's Medical University)
 田原 純子 (東京女子医科大学)

12:40-13:35 Poster Session 1-5 / ポスターセッション 1-5

- P1-5** Hepatobiliary/Pancreatic Cancer2 (Gallbladder and Biliary Tract Cancer/Pancreatic Cancer - Systemic Chemotherapy)
肝胆膵 2 (胆嚢・胆道・膵臓-全身薬物療法)
- Chair : Masahiro Hirakawa (National Hospital Organization Hokkaido Cancer Center, Department of gastroenterology)
- 司会 : 平川 昌宏 (独立行政法人国立病院機構 北海道がんセンター 消化器内科)
-
- P1-036** **Retrospective analysis of predict prognostic factor with gemcitabine, cisplatin for patients with biliary tract cancer**
Toru Otsuru (Department of Frontier Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University)
大鶴 徹 (大阪大学大学院医学系研究科先進癌薬物療法開発学寄附講座)
-
- P1-037** **Statins use is associated with reduced risk of cholangiocarcinoma: A systematic review and meta-analysis**
Gaurav Nepal (Maharajgunj Medical Campus, Tribhuvan University Institute of Medicine, Nepal)
-
- P1-038** **Chemotherapy for unresectable biliary tract cancer -a single-institution retrospective study**
Ryosuke Taguchi (National Hospital Organization Kyushu Cancer Center)
田口 綾祐 (国立病院機構九州がんセンター)
-
- P1-039** **当院における肝内胆管癌術後薬物療法の現状**
Akihiro Matsumi (Department of Gastroenterology and Hepatology, Okayama University)
松三 明宏 (岡山大学 消化器肝臓内科)
-
- P1-040** **Efficacy of liposomal Irinotecan and Impact on Survival of Advanced Pancreatic Cancer: A Single Institutional Experience**
Yung-Yeh Su (National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan / National Cheng Kung University Hospital, National Cheng Kung University, Tainan)
-
- P1-041** **The association between UGT1A1 polymorphisms and treatment toxicities from liposomal irinotecan (nal-IRI; Onivyde)**
Nai-Jung Chiang (National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan / National Cheng Kung University Hospital, Tainan)
-
- P1-042** **2nd line Modified FOLFIRINOX for metastatic pancreatic adenocarcinoma refractory to nab-paclitaxel plus gemcitabine**
Masashi Sawada (Cancer Institute Hospital of Japanese Foundation of Cancer Research)
澤田 雅志 (がん研究会 有明病院 肝胆膵内科)
-
- P1-043** **Gemcitabine plus nab-paclitaxel after FOLFIRINOX failure in patients with unresectable pancreatic carcinoma**
Yasufumi Otsuki (Department of Medical Oncology, Tohoku University Hospital / Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University)
大槻 泰史 (東北大学病院 腫瘍内科 / 東北大学 加齢医学研究所 臨床腫瘍学分野)

P1-6

Lung Cancer/Thoracic Cancer1 (Lung Cancer/Thymic Tumor/Malignant Pleural Mesothelioma)
呼吸器 1 (肺がん、胸腺腫瘍、悪性胸膜中皮腫)

Chair : Kazuma Kishi (Toho University School of Medicine)

司会 : 岸 一馬 (東邦大学医療センター大森病院)

P1-044

Encore

Phase 2 study of low-dose afatinib maintenance treatment for patients with EGFR-mutated NSCLC (NJLCG1601)

Hisashi Tanaka (Department of Respiratory Medicine, Hirosaki University)

EGFR遺伝子変異陽性非小細胞肺癌患者に対する低用量アファチニブ維持療法を検討する第II相試験
田中 寿志 (弘前大学 呼吸器内科)

P1-045

Encore

A Phase II Study of Nedaplatin and nab-PTX with Previously Untreated Advanced Squamous Cell Lung Cancer (KRSG1302)

Tomohide Sugiyama (Department of Medical Oncology, Division of Thoracic Oncology, Tochigi Cancer Center / Kanto Respiratory Disease Study Group (KRSG))

未治療進行肺扁平上皮癌に対するネダプラチンと nab-パクリタキセル併用療法第II相試験 (KRSG1302)

杉山 智英 (栃木県立がんセンター 呼吸器内科 / 関東呼吸器研究会)

P1-046

PF-06439535 (a bevacizumab biosimilar) for non-small cell lung cancer: subgroup analysis

Yoshio Okano (Division of Pulmonary Medicine, National Hospital Organization Kochi Hospital)

非小細胞肺癌患者を対象としたPF-06439535 (ベバシズマブのバイオシミラー) の臨床試験 : サブグループ解析

岡野 義夫 (国立病院機構高知病院呼吸器センター内科)

P1-047

Treatment outcome of radiation therapy for thymic malignancies

Yumiko Minagawa (Department of Radiation Oncology, Shonan Kamakura General Hospital)

胸腺腫瘍に対する強度変調放射線治療の検討

皆川 由美子 (湘南鎌倉総合病院 放射線腫瘍科)

P1-048

Encore

Phase II study of amrubicin in previously treated patients with malignant pleural mesothelioma

Daiki Ogawara (Department of Respiratory Medicine, Sasebo City General Hospital)

既治療切除不能悪性胸膜中皮腫に対するアムルビシン療法の第II相試験

小河原 大樹 (佐世保市総合医療センター 呼吸器内科)

P1-049

当院における悪性胸膜中皮腫に対するニボルマブ投与症例の検討

Hirotoishi Ishigaki (Division of Respiratory Medicine Department of Internal Medicine, Hyogo College of Medicine)

石垣 裕敏 (兵庫医科大学 内科学講座呼吸器科)

12:40-13:35 Poster Session 1-7 / ポスターセッション 1-7

- | | |
|--|---|
| P1-7 | Lung Cancer/Thoracic Cancer2 (NSCLC - Chemotherapy1)
呼吸器 2 (非小細胞肺がん-化学療法1) |
| Chair : Kyoichi Kaira (Saitama Medical University, International Medical Center)
司会 : 解良 恭一 (埼玉医科大学国際医療センター包括的がんセンター 呼吸器内科) | |
| P1-050 | A retrospective study of docetaxel treatment after immune-checkpoint inhibitor for non-small cell lung cancer
Tatsuro Fukuhara (Miyagi Cancer Center)
非小細胞肺癌における免疫チェックポイント阻害剤投与後のドセタキセル治療の効果と安全性の後方視的研究
福原 達朗 (宮城県立がんセンター) |
| P1-051 | 当院における Docetaxel+Ramucirumab 投与症例の検討
Hiroki Izuno (Department of Thoracic Oncology,Kansai Medical University Hospital / First Department of Internal Medicine,Kansai Medical University)
泉野 弘樹 (関西医科大学附属病院 呼吸器腫瘍内科 / 関西医科大学 内科学第一講座) |
| P1-052 | 非小細胞肺癌に対する RAM + DTX 療法のペグフィリグラスチム併用時の FN 発現割合に関する多施設共同前向き観察研究 (CJLSG1602)
Tepei Yamaguchi (Department of Thoracic Oncology, Aichi Cancer Center Hospital)
山口 哲平 (愛知県がんセンター中央病院 呼吸器内科) |
| P1-053 | 非小細胞肺癌に対する S-1 療法の治療効果と治療前血清腫瘍マーカーとの関連
Yusuke Kagawa (Department of Respiratory Medicine, Aichi Cancer Center Hospital)
香川 友祐 (愛知県がんセンター中央病院) |
| P1-054 | 当院における高齢者非小細胞性肺癌に対する化学療法についての検討
Kayoko Kibata (Department of Thoracic Oncology,Kansai Medical University Hospital / First Department of Internal Medicine, Kansai Medical University)
木畑 佳代子 (関西医科大学附属病院 呼吸器腫瘍内科 / 関西医科大学 内科学第一講座) |
| P1-055 | 75 歳以上の高齢者を含む非小細胞肺癌患者に対するペバシズマブの使用経験
Aya Yamamoto (Department of Thoracic Surgery, Kansai rosai hospital)
山本 亜弥 (関西労災病院 呼吸器外科) |
| P1-056 | IV期非小細胞肺癌の長期生存例の特徴と、全生存期間と相関する患者背景因子の検討
Junji Koyama (Department of Respiratory Medicine and Allergy, Tosei General Hospital)
神山 潤二 (公立陶生病院 呼吸器・アレルギー疾患内科) |
| P1-057 | Management of Brain Metastases in Advanced Non-Small-Cell Lung Cancer
Yuki Nakatani (Department of Medical Oncology, Osaka City General Hospital)
初診時に脳転移を有する進行・再発非小細胞肺癌の検討
中谷 有貴 (大阪市立総合医療センター 腫瘍内科) |

12:40-13:35 Poster Session 1-8 / ポスターセッション 1-8

- | | |
|---|--|
| P1-8 | Lung Cancer/Thoracic Cancer3 (Diagnosis)
呼吸器 3 (検査・診断) |
| Chair : Kenji Sugio (Department of Thoracic and Breast Surgery, Oita University)
司会 : 杉尾 賢二 (大分大学 医学部 呼吸器・乳腺外科学講座) | |
| P1-058 | Immediate results and features of video-assisted thoracoscopic pneumonectomy in lung cancer
Saidrakhim N. Lukmonov (Oncology Department, Tashkent Medical Academy, Uzbekistan) |

- P1-059 Validation of the immunohistochemical expression of PD-L1 on using EBUS-TBNA samples in lung cancer**
Hiroki Matsuoka (Respiratory Medicine Department, Kanazawa University Hospital)
松岡 寛樹 (金沢大学附属病院 呼吸器内科)
-
- P1-060 Mutation profile analysis using the OncoPrint™ Lung cfDNA Assay in advanced NSCLC patients with driver mutation**
Yuichi Sakamori (Department of clinical oncology, Kyoto University)
OncoPrint™ Lung cfDNA Assay を用いたドライバー遺伝子変異陽性の進行期非小細胞肺癌の遺伝子変異の検討
阪森 優一 (京都大学 腫瘍内科)
-
- P1-061 肺癌Biopsy検体別のDNA/RNA抽出量とNGSシークエンス成功率の比較検討**
Naoki Furuya (Division of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine)
古屋 直樹 (聖マリアンナ医科大学 呼吸器内科)
-
- P1-062 CTで発見された肺結節の判定基準と経過観察：長崎県における多施設共同研究**
Hiroyuki Yamaguchi (Department of Respiratory medicine, Nagasaki University Hospital)
山口 博之 (長崎大学病院 呼吸器内科)
-
- P1-063 Galectin-3 expression in patients with resected NSCLC treated with platinum-based adjuvant chemotherapy**
Seichiro Kusuhara (Respiratory Medicine Department, Kitasato University Hospital)
楠原 政一郎 (北里大学病院 呼吸器内科)

12:40-13:35 Poster Session 1-9 / ポスターセッション 1-9

- P1-9 Lung Cancer/Thoracic Cancer4 (NSCLC - TKIs)**
呼吸器 4 (非小細胞肺癌 - TKI)
Chair : Haruko Daga (Department of Medical Oncology, Osaka City General Hospital)
司会 : 駄賀 晴子 (大阪市立総合医療センター 腫瘍内科)
-
- P1-064 Driver gene mutations and target therapy of primary pulmonary lymphoepithelioma-like carcinoma**
Kai Yin (Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, China)
-
- P1-065 Phase II trial of afatinib in elderly patients aged over 75 years with EGFR mutated non-small cell lung cancer (NSCLC)**
Toshiyuki Harada (JCHO Hokkaido Hospital)
原田 敏之 (北海道病院)
-
- P1-066 A comparison of patients with advanced NSCLC harboring uncommon EGFR mutations before and after the approval of afatinib**
Ryo Ko (Department of Respiratory Medicine, Juntendo University Hospital)
高 遼 (順天堂大学医学部附属順天堂医院 呼吸器内科)
-
- P1-067 Effectiveness and toxicity of osimertinib in NSCLC with EGFR mutation: a retrospective analysis in a single institution**
Yuki Akazawa (Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital)
赤澤 結貴 (刀根山病院)

- P1-068 High level of serum C-reactive protein predicts poor outcome in EGFR-TKI-treated patients with EGFR-mutated NSCLC**
 Nobuyuki Koyama (Department of Clinical Oncology, Tokyo Medical University Hachioji Medical Center)
 小山 信之 (東京医科大学八王子医療センター 臨床腫瘍科)
-
- P1-069 Tumor tissue and plasma level of AXL and GAS6 in EGFR mutation positive non-small cell lung cancer**
 Yoshikane Nonagase (Department of Medical Oncology, Kindai University Faculty of Medicine)
 野長瀬 祥兼 (近畿大学医学部内科学腫瘍内科部門)
-
- P1-070 A phase 2 trial assessing osimertinib activity against leptomeningeal carcinomatosis in EGFR-mutant lung cancer**
 Motohiro Tamiya (Department of Thoracic Oncology, Osaka International Cancer Institute)
 田宮 基裕 (大阪国際がんセンター 呼吸器内科)
-
- P1-071 Successful desensitization with crizotinib after crizotinib-induced liver injury in ROS1-rearranged lung adenocarcinoma**
 Takayo Ota (Department of Medical Oncology, Izumi City General Hospital)
 大田 隆代 (和泉市立総合医療センター 腫瘍内科)
-
- P1-072 Osimertinib is an initial treatment for three advanced NSCLC patients harboring uncommon EGFR mutation**
 Shunta Mori (National Hospital Organization Shikoku Cancer Center)
 森 俊太 (国立病院機構 四国がんセンター)
-
- P1-073 Re-administration of EGFR-TKI to mutated EGFR NSCLC patients after remission of osimertinib induced ILD**
 Kenichi Chikamori (NHO Yamaguchi-Ube Medical Center)
 近森 研一 (山口宇部医療センター)

12:40-13:35 Poster Session 1-10 / ポスターセッション 1-10

- P1-10 Lung Cancer/Thoracic Cancer5 (NSCLC - Chemotherapy2)**
 呼吸器 5 (非小細胞肺癌—化学療法 2)
 Chair : Toshio Kubo (Center for Clinical Oncology, Okayama University Hospital)
 司会 : 久保 寿夫 (岡山大学病院 腫瘍センター)
-
- P1-074 Phase I/II trial of biweekly nab-paclitaxel in patients with previously treated advanced non-small cell lung cancer**
 Ryohei Saito (Department of Pulmonary Medicine, Sendai Kousei Hospital)
 齊藤 亮平 (仙台厚生病院 呼吸器内科)
-
- P1-075 Phase 3 MAPLE Study Comparing ABP 215 and Bevacizumab in Advanced NSCLC: Totality of Evidence in Biosimilar Development**
 Encore
 Yuichiro Ohe (National Cancer Center Hospital, Tokyo, Japan)
-
- P1-076 High serum soluble-CD27 level correlates with poor performance status and survival in patients with advanced lung cancer**
 Jumpei Kashima (Department of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital)
 加島 淳平 (がん・感染症センター 東京都立駒込病院)
-
- P1-077 Changes in TROP2 expression in lung cancer patients receiving anticancer treatments**
 Encore
 Shota Omori (Division of Thoracic Oncology, Shizuoka Cancer Center)
 大森 翔太 (静岡県立静岡がんセンター 呼吸器内科)

- P1-078** **Bevacizumab and S-1 chemotherapy for patients with previously treated advanced non-squamous non-small cell lung cancer**
 Tsukasa Hasegawa (Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research)
 長谷川 司 (がん研究会有明病院 呼吸器内科)
-
- P1-079** **Impact of cytotoxic chemotherapy on PD-L1 expression in patients with NSCLC negative for EGFR mutation and ALK fusion**
 Hitomi Sakai (Department of Medical Oncology, Kindai University Faculty of Medicine)
 酒井 瞳 (近畿大学医学部内科学腫瘍内科)
-
- P1-080** **Clinical characteristics and outcomes of peritoneal carcinomatosis in non-small-cell lung cancer**
 Tetsuo Tani (Tachikawa Hospital / Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine)
 谷 哲夫 (国家公務員共済組合連合会 立川病院 / 慶應義塾大学医学部呼吸器内科)
-
- P1-081** **Combined chemoradiotherapy regimens of paclitaxel and carboplatin for non-small cell lung cancer stage IIIB**
 Lan Anh thi Dinh (Medical Oncology Department, VietNam National Cancer Hospital, Viet Nam)
-
- P1-082** **Clinical experience of pneumonitis with durvalumab after chemoradiotherapy in patients with locally advanced NSCLC**
 Hiroto Inoue (Division of Gastrointestinal Oncology, Shizuoka Cancer Center)
 井上 博登 (静岡県立静岡がんセンター 消化器内科)
-
- P1-083** **Significance of immunologic biomarkers for stage III non-small cell lung cancer patients treated with chemoradiotherapy**
 Takehiro Tozuka (Department of Pulmonary Medicine and Oncology Graduate School of Medicine Nippon Medical School)
 戸塚 猛大 (日本医科大学大学院医学研究科呼吸器内科学分野)

12:40-13:35 Poster Session 1-11 / ポスターセッション 1-11

- P1-11** **Hematologic Malignancies1 (Leukemia)**
 血液 1 (白血病)
- Chair : Yasushi Takamatsu (Division of Medical Oncology, Hematology and Infectious Diseases, Department of Internal Medicine, Fukuoka University School of Medicine)
 司会 : 高松 泰 (福岡大学医学部 腫瘍・血液・感染症内科)
-
- P1-084** **Antileukemic activity and mechanism of ardisianone-a crucial role of mitochondrial stress in apoptosis and necroptosis**
 She-Hung Chan (Cosmetic Science Department, Providence University, Taiwan)
-
- P1-085** **Efficacy and safety of lenalidomide as monotherapy and multitherapy in acute myeloid leukemia: A meta-analysis**
 Md Salman Hussain (Department of Pharmaceutical Medicine, Jamia Hamdard, India)
-
- P1-086** **ISSUES PERTAINING TO TYROSINE KINASE INHIBITORS TREATMENT ADHERENCE AMONG PATIENTS WITH CHRONIC MYELOID LEUKEMIA**
 Chee Chean Dang (Pharmacy Department (Haematology), Hospital Melaka, Malaysia)
-
- P1-087** **Ibrutinib treatment for patients with relapse/refractory and treatment-naive CLL/SLL**
 Shuichi Ota (Department of hemtology, Sapporo hokuyu hospital)
 太田 秀一 (札幌北楡病院 血液内科)

P1-088 Relative adrenal insufficiency post-discontinuation of topical steroids in a patient with acute lymphoblastic leukemia

Sakiko Uho (Integrated Clinical Education Center Kobe University Hospital)

急性リンパ性白血病患者においてステロイド軟膏中止後に発症した相対的副腎不全の一例
宇保 早希子 (神戸大学医学部附属病院 総合臨床教育センター)

12:40-13:35 Poster Session 1-12 / ポスターセッション 1-12

P1-12 Hematologic Malignancies2 (Lymphoma1)
血液 2 (リンパ腫 1)

Chair : Yukio Kobayashi (Department of Hematology, International University of Health and Welfare, Mita Hospital)

司会 : 小林 幸夫 (国際医療福祉大学三田病院 血液内科)

P1-089 Association between comorbidity and relative dose intensity in patients with diffuse large B-cell lymphoma

Masakazu Yamamoto (Department of Hematology Okitama Public General Hospital, Yamagata, Japan)

DLBCL 患者における併発症と相対治療強度の関連
山本 雅一 (公立置賜総合病院)

P1-090 Clinical analysis of elderly patients with low risk diffuse large B-cell lymphoma

Hiroto Kaneko (Department of Hematology, Aiseikai Yamashina Hospital)

低リスク群高齢びまん性大細胞型B細胞性リンパ腫の臨床像解析
兼子 裕人 (愛生会山科病院)

P1-091 Clinical feature of very elderly malignant lymphoma patients unfit for chemotherapy

Takenori Takahata (Department of Medical Oncology, Hirosaki University Graduate school of Medicine)

高畑 武功 (弘前大学大学院医学研究科腫瘍内科学講座)

P1-092 Retrospective analysis of clinical course of elderly diffuse large B-cell lymphoma (DLBCL) patients in our hospital

Kei Takenaka (Hematology and Oncology, Kita-Harima Medical Center)

自施設における超高齢DLBCL患者の治療選択、治療経過の後方視的解析
竹中 圭 (北播磨総合医療センター)

P1-093 Clinical outcomes of ibrutinib in patients with mantle-cell lymphoma in a single institution

Hiroto Adachi (Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan)

安達 弘人 (都立駒込病院 腫瘍内科)

P1-094 濾胞性リンパ腫で治療後2年以内に再発 (POD24) 症例の臨床学的特徴と治療の検討

Naoto Imoto (Department of Hematology, Toyohashi Municipal Hospital)

井本 直人 (豊橋市民病院)

P1-095 Treatment Outcome for Primary Cervix Large B-cell Lymphoma: A Clinical Analysis of 37 Cases

Xiaojian Liu (Fudan University, China)

P1-096 **Glucose tolerance change before and after R-CHOP therapy in 19 elderly patients with DLBCL**

Shoko Marshall (Tokyo Womens Medical University Medical Center East)

高齢DLBCL患者19名に対するR-CHOP療法前後の血糖値変化について

マーシャル 祥子 (東京女子医科大学東医療センター)

12:40-13:35 Poster Session 1-13 / ポスターセッション 1-13

P1-13 **Hematologic Malignancies3 (Lymphoma2)**
血液3 (リンパ腫2)

Chair : Takayuki Ikezoe (Department of Hematology, Fukushima Medical University)

司会 : 池添 隆之 (福島県立医科大学 血液内科学講座)

P1-097 **Peripheral T cell lymphoma not otherwise specified induced by fingolimod treatment for multiple sclerosis**

Hidetsugu Kawai (Department of Hematology / Oncology, Tokai University School of Medicine)

川井 英嗣 (東海大学医学部 血液・腫瘍内科)

P1-098 **The prognostic significance of pretreatment parameters of FDG PET in patients with diffuse large B-cell lymphoma (DLBCL)**

Takeshi Yoshida (Chemotherapy Center, Isesaki Municipal Hospital)

吉田 武史 (伊勢崎市民病院 化学療法センター)

P1-099 **Treatment with bendamustine and rituximab for patients with previously untreated follicular lymphoma**

Toshiki Yamada (Department of Hematology, Gifu Prefectural General Medical Center)

山田 俊樹 (岐阜県総合医療センター)

P1-100 **Impact of Charlson comorbidity index on survival in patients with diffuse large B-cell lymphoma who received R-CHOP**

Atsushi Inagaki (Department of Hematology and Oncology, Nagoya City West Medical Center)

稲垣 淳 (名古屋市立西部医療センター 血液・腫瘍内科)

P1-101 **Bendamustine plus rituximab therapy for patients with Mantle-cell lymphoma in our institute, 20 cases**

Yuki Takeuchi (Department of Hematology and Oncology, Anjo Kosei Hospital)

竹内 裕貴 (安城更生病院)

P1-102 **Emergency treatment for diffuse large B cell lymphoma of pituitary region complaining visual disturbance**

Takeshi Sugimoto (Department of Hematology and Oncology, Kita-Harima Medical Center)

杉本 健 (北播磨総合医療センター 血液腫瘍内科)

P1-103 **STUDY PHARMACOKINETIC BEHAVIOR OF MTX-HD AND RESCUE WITH LEUCOVORINE IN HUMAN PLASMA LC AND RMNC13, CHILDREN HOSPITAL**

Guillermo O. Rocabado Calizaya (Department of Onco Hematology, Children's Hospital "Dr. Ovidio Aliaga Uria", La Paz- Bolivia, Bolivia, Plurinational State of)

12:40-13:35 Poster Session 1-14 / ポスターセッション 1-14

P1-14 Hematologic Malignancies4 (Leukemia/Myeloma)
血液 4 (白血病・骨髄腫)

Chair : Kenji Ishitsuka (Department of Hematology and Rheumatology, Kagoshima University Hospital)
司会 : 石塚 賢治 (鹿児島大学病院 血液・膠原病内科)

P1-104 Targeting of versican, a proteoglycan in bone marrow microenvironment by microRNAs inhibit multiple myeloma progression

Nidhi Gupta (Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India)

P1-105 Multiple Myeloma in Patient with Co-existing Chronic Renal Failure on Hemodialysis: A Case Report

Noorwati Sutandyo (Hematology and Medical Oncology Department, Dharmais National Cancer Centre Hospital, Indonesia)

P1-106 The characteristics of CD30-positive HTLV-1-infected cells and the effects of Brentuximab Vedotin

Ryouichi Horie (Division of Hematology, Department of Laboratory Sciences, School of Allied Health Sciences, Kitasato University)
堀江 良一 (北里大学 医療衛生学部 医療検査学科 血液学)

P1-107 Rapid improvement of secondary myelodysplastic syndrome from essential thrombocytosis (ET) treated by Azacitidine (AZA)

Masahide Yamazaki (Keiju General Hospital)
山崎 雅英 (恵寿総合病院)

P1-108 An unexpected but successful pregnancy for young lady with CML

Hirofumi Yokota (Anjo Kosei Hospital)
横田 裕史 (安城更生病院)

12:40-13:35 Poster Session 1-15 / ポスターセッション 1-15

P1-15 Genitourinary Cancer1
泌尿器 1

Chair : Shin Takahashi (Tohoku University Hospital, Department of Medical Oncology)
司会 : 高橋 信 (東北大学病院 腫瘍内科)

P1-109 Clinical course of hemodialysis patients with metastatic renal cell carcinoma: a single-center retrospective analysis

Taro Yamanaka (Department of Medical Oncology, Toranomon Hospital)
山中 太郎 (虎の門病院 臨床腫瘍科)

P1-110 Clinical characteristic and clinical outcomes of renal cell carcinoma in Ramathibodi hospital

Piyaporn Srikaew (Medical oncology unit, Suratthani hospital, Thailand)

P1-111 Evaluation of blood pressure control on axitinib treatment after nivolumab therapy in renal cell cancer

Kenichi Suzuki (Hoshi University, Division of Applied Pharmaceutical, Education and Research)
腎がんにおいてニボルマブ治療後にアキシチニブを開始した際の血圧管理の評価
鈴木 賢一 (星薬科大学実務教育研究部門)

- P1-112 Efficacy of molecular targeted therapy for non clear renal cell carcinoma**
Ryuichi Mizuno (Department of Urology, Keio university, school of medicine)
進行性非淡明型腎細胞癌に対する分子標的治療の検討
水野 隆一 (慶應義塾大学医学部泌尿器科)
-
- P1-113 The evaluation of prognosis factor with inflammatory markers for patients with metastatic renal cell carcinoma using TKI**
Naoto Sassa (Department of Urology, Nagoya University)
転移性進行性腎細胞癌の炎症性マーカーによる予後予測
佐々 直人 (名古屋大学 泌尿器科)
-
- P1-114 Urinary spermine level as novel additional diagnostic marker of prostate cancer**
Veronika V Bentrad (Department of Tumor Biochemistry and Oncopharmacology, R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Ukraine)
-
- P1-115 Ra-223 for the treatment for bone metastatic castration-resistant prostate cancer: a single-center experience**
Hiroaki Iida (Departments of Urology Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Toyama, Japan)
当科における去勢抵抗性前立腺癌に対するRa-223の初期経験
飯田 裕朗 (富山大学大学院医学薬学研究部腎泌尿器科学講義)
-
- P1-116 The prognostic value of nadir PSA level and time to nadir in high risk mHNPC patients**
Akihiro Asai (Sasebo City General Hospital)
浅井 昭宏 (佐世保市総合医療センター)
-
- P1-117 Treatment outcome of neuroendocrine prostate cancer**
Hiroaki Iwamoto (Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science)
前立腺神経内分泌癌の治療成績
岩本 大旭 (金沢大学大学院医学系研究科 集学的治療分野泌尿器科)
-
- P1-118 Surgical tactics in urethra resection for retroperitoneal tumors**
Firdavs Gayratovich Ulmasov (National cancer research center of Uzbekistan, Uzbekistan)

12:40-13:35 Poster Session 1-16 / ポスターセッション 1-16

- P1-16 Genitourinary Cancer2 (Case Reports)**
泌尿器 2 (症例報告)
- Chair : Rio Honma (Tonan Hospital, Department of Medical Oncology)
司会 : 本間 理央 (斗南病院 腫瘍内科)
-
- P1-119 Pathological Complete Response of Squamous Cell Carcinoma of Urinary Bladder After Neoadjuvant Cisplatin/Gemcitabine**
Amorn Tamtai (Oncology Unit, Department of Internal Medicine, Lampang Hospital, Lampang, Thailand)
-
- P1-120 Gemcitabine/Cisplatin therapy for an urothelial carcinoma patient undergoing hemodialysis: a case report**
Yumiko Goto (Department of Hospital Pharmacy of Aichi Medical University)
血液透析施行中の尿路上皮癌患者に対しGemcitabine/Cisplatin療法を行った一例
後藤 裕美子 (愛知医科大学病院 薬剤部)

-
- P1-121** **Assessment of bladder preservation therapy for locally advanced bladder cancer patients at Toyohashi Municipal Hospital**
Akiyuki Yamamoto (Toyohashi Municipal Hospital)
豊橋市民病院における局所進行膀胱癌に対する膀胱温存療法の評価
山本 晃之 (豊橋市民病院)
-
- P1-122** **Pembrolizumabによる肝障害と原病増悪の鑑別が困難であった尿路上皮癌**
Tatsuyuki Kawahara (General Internal Medicine 4, Kawasaki Medical School)
河原 辰由樹 (川崎医科大学総合医療センター 総合内科学4)
-
- P1-123** **ステロイド抵抗性ニボルマブ関連多関節炎に対して抗IL-6受容体抗体で治療した再発腎癌の一例**
Hiroko Yukawa (Department of Medical Oncology, Yokohama Rosai Hospital)
湯川 裕子 (横浜労災病院 腫瘍内科)
-

P1-17 Rare Cancer1 (Soft Tissue Sarcoma)
希少がん 1 (悪性軟部腫瘍)

Chair : Makoto Endo (Department of Orthopaedic Surgery, Kyushu University)
司会 : 遠藤 誠 (九州大学病院 整形外科)

P1-124 高齢男性の乳房に発生し、術後早期に再発した粘液線維肉腫 (mixofibrosarcoma) の一例
Karin Hirakawa (Resident, Tokai University)
平川 歌倫 (東海大学医学部付属病院 臨床研修部)

P1-125 3 cases of undifferentiated embryonal sarcoma of the liver (UESL) in adult
Motoko Arakaki (Department of Breast and Medical Oncology, National Cancer Center Hospital)
新垣 誉子 (国立がん研究センター中央病院 乳腺・腫瘍内科)

P1-126 The clinical efficacy of eribulin to soft tissue sarcoma patients: differences in histological subtypes
Kenji Nakano (Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research)
仲野 兼司 (がん研究会有明病院 総合腫瘍科)

P1-127 The efficacy of second-line chemotherapy for angiosarcoma patients receiving taxane regimen: a retrospective study
Munehiro Ito (Department of Breast and Medical Oncology, National Cancer Center Hospital)
伊藤 宗洋 (国立がん研究センター中央病院 乳腺・腫瘍内科)

P1-128 Distribution of clinical characteristics of soft tissue sarcoma in six provinces in China
Maomao Cao (Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China)

P1-129 Retrospective analysis of trabectedin therapy for soft tissue sarcoma
Kuniki Kawaguchi (Department of Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research)
川口 城毅 (がん研究会有明病院 総合腫瘍科)

P1-130 A retrospective study of weekly paclitaxel in patients with advanced or recurrent angiosarcoma
Tetsuya Urasaki (Department of Medical Oncology, the Cancer Institute Hospital of Japanese Foundation for Cancer Research)
進行・再発血管肉腫症例に対する weekly paclitaxel 療法の後方視的検討
浦崎 哲也 (がん研究会有明病院 総合腫瘍科)

P1-131 Efficacy of chemotherapy for metastatic and recurrence Synovial Sarcoma, a retrospective study at single institution
Takuji Seo (National Cancer Center Hospital)
滑膜肉腫における転移・再発症例の治療成績
瀬尾 卓司 (国立がん研究センター中央病院)

P1-132 骨肉腫再発に対して化学療法が奏効し、完全切除に至った一例
Shohei Ueno (Department of Hematology, Oncology & Cardiovascular medicine, Kyushu University Hospital)
上野 翔平 (九州大学病院 血液・腫瘍・心血管内科)

P1-133 A case of relapsed hemangiopericytoma surviving for 14 months treated with soft-tissue sarcoma therapies

Takahiro Yamaguchi (Hematology, University of Occupational and Environmental Health, Japan / Palliative care and Hematology, Wakamatsu Hospital of UOEH, Japan)

軟部肉腫治療により14ヶ月の生存延長が得られた再発hemangiopericytomaの1例

山口 享宏 (産業医科大学病院血液内科 / 産業医科大学若松病院緩和ケア血液腫瘍科)

12:40-13:35 Poster Session 1-18 / ポスターセッション 1-18

P1-18 Rare Cancer2 (Soft Tissue Sarcoma/Others) 希少がん2 (悪性軟部腫瘍・その他)

Chair : Shintaro Iwata (Department of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital)
 司会 : 岩田 慎太郎 (国立がん研究センター中央病院 骨軟部腫瘍・リハビリテーション科)

P1-134 the case of an uterus sarcoma treated effectively with Doxorubicin after Eribulin 4 cycles after PD of Docetaxel+Gemzal

Chigusa Shimono (Medical Oncology Department, Chemotherapy Center, Suita Tokushukai Hospital)

Docetaxel+GemzalがPD後にEribulin4サイクル施行後Doxorubicinが著効した子宮肉腫の症例

下野 千草 (吹田徳洲会病院 腫瘍内科・化学療法センター)

P1-135 A case of undifferentiated pleomorphic sarcoma showing rapid abdominal metastasis

Toshihiko Hoashi (Department of Dermatology, Nippon Medical School)

急速に腹腔内転移を生じた未分化多型肉腫の1例

帆足 俊彦 (日本医科大学付属病院皮膚科)

P1-136 An adult-onset ethmoidal sinus rhabdomyosarcoma

Kota Shigeto (Department of Medicine, Division of Gastroenterology, Kurume University)

成人発症の篩骨洞横紋筋肉腫の1例

重藤 宏太 (久留米大学医学部 内科学部講座 消化器内科部門)

P1-137 Isoliquiritigenin induces cell death programs and reduces ECM accumulation in uterine leiomyoma

Shih-Min Hsia (School of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taiwan)

P1-138 Bevacizumab markedly reduces the size of active cystic part of tumor

Fumiyuki Yamasaki (Department of Neurosurgery, Hiroshima University Hospital)

山崎 文之 (広島大学病院 脳神経外科)

P1-139 Comparison of QOL Scales in Patients with Brain Tumors

Natsuko Tsushita Satomi (Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital)

脳腫瘍患者における最適なQOL評価尺度の検討

里見 (津下) 奈都子 (国立がん研究センター中央病院 脳脊髄腫瘍科)

P1-140 Dasatinib in patients with gastrointestinal stromal tumors who failed to Imatinib and sunitinib

Ye Zhou (Department of Gastric Surgery, Fudan University Shanghai Cancer Center, China)

- P1-141** **ROLE OF PTH LEVEL AND PARATHYROID SCAN IN THE DIAGNOSIS OF PARATHYROID TUMORS IN PATIENTS WITH NODULES IN THYROID AREA**
 Linh Van Phung (Oncology Department, Nguyen Dinh Chieu Hospital, Province Ben Tre, Viet Nam)
-
- P1-142** **イマチニブで病勢コントロールが可能であった転移性隆起性皮膚線維肉腫の3症例**
 Ryoko Higashiyama (National Cancer Center Hospital)
 東山 量子 (国立がん研究センター中央病院)
-
- P1-143** **Bexarotene therapy for CTCL in Japan: The results of a phase 1/2 (B-1101) and a phase 2 (B-1201) studies**
 Toshihisa Hamada (Department of Dermatology, Takamatsu Red Cross Hospital / Department of Dermatology, Okayama University Hospital)
 濱田 利久 (高松赤十字病院 皮膚科 / 岡山大学病院 皮膚科)
-
- P1-144** **Results of treatment of patients with retroperitoneal tumors**
 Saidrakhim N. Lukmonov (Oncology Department, Tashkent Medical Academy, Uzbekistan)

12:40-13:35 Poster Session 1-19 / ポスターセッション 1-19

- P1-19** **Rare Cancer3**
 希少がん3
 Chair : Hiroo Ishida (Division of Medical Oncology, Showa University Koto Toyosu Hospital)
 司会 : 石田 博雄 (昭和大学江東豊洲病院 腫瘍内科)
-
- P1-145** **INVESTIGATION OF RADIOACTIVE IODINE-REFRACTORY DIFFERENTIATED THYROID CARCINOMA AT HOCHIMINH CITY ONCOLOGY HOSPITAL**
 Nguyen Huynh Khanh An (Department Nuclear Medicine, HCM Oncology Hospital, Viet Nam)
-
- P1-146** **Scheduled cessation in treatment using lenvatinib for differentiated thyroid carcinoma**
 Yasuhiro Ito (Department of Surgery, Kuma Hospital / Department of Clinical Trial, Kuma Hospital)
 伊藤 康弘 (隈病院外科 / 隈病院治験臨床試験管理科)
-
- P1-147** **Mechanism of antitumor effect of Sorafenib in anaplastic thyroid cancer cell lines**
Encore Sae Ishihara (Department of Breast Endocrine Surgery, Osaka City University Graduate School of Medicine)
 石原 沙江 (大阪市立大学大学院医学研究科 乳腺内分泌外科)
-
- P1-148** **Combination therapy with tetrahydropyran-adyamycin + ifosfamide + etoposide for advanced soft tissue sarcoma**
 Hisaki Aiba (Nagoya City University Graduate School of Medical Sciences)
 相羽 久輝 (名古屋市立大学病院 整形外科)
-
- P1-149** **Pneumothorax as an adverse event in patients with lung metastasis of soft tissue sarcoma under eribulin treatment**
 Kohichi Takada (Department of Medical Oncology, Sapporo Medical University)
 高田 弘一 (札幌医科大学 腫瘍内科)
-
- P1-150** **Multimodal Treatment of Extragonadal Choriocarcinoma With Multiple Brain and Lung Metastases: A Case Report**
 Mao Uematsu (Medical Oncology Department, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital)
 植松 真生 (がん・感染症センター 都立駒込病院 腫瘍内科)

- P1-151** **Usefulness of bone marrow examination for diagnosis of cancer of unknown primary origin**
Naoko Hatanaka (Rinku General Medical Center)
畑中 奈保子 (りんくう総合医療センター)
- P1-152** **Primary splenic angiosarcoma with multiple bone metastasis**
Takashi Hamada (Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine)
濱田 高志 (日本大学医学部附属板橋病院 血液膠原病内科)
- P1-153** **Primary Mediastinal Malignant Mixed (Non-seminomatous) Germ Cell Tumor Presenting as Superior Vena Cava Syndrome**
Emilio Jose S. Gravador (St. Luke's Medical Center - Global City, Philippines / Department of Medicine)
- P1-154** **Various immuno-related adverse events after IPI+NIVO therapy; a case report of metastatic choroidal melanoma**
Yumi Yoshii (Department of Medical Oncology, Osaka City General Hospital / Oncology Center, Nara Medical University)
吉井 由美 (大阪市立総合医療センター 腫瘍内科 / 奈良県立医科大学 腫瘍センター)

12:40-13:35 Poster Session 1-20 / ポスターセッション 1-20

P1-20 Translational Research1 (PK/PD, Others)
TR1 (PK/PD・その他)

Chair : Yoshihiko Segawa (Dpt. of Medical Oncology, Saitama Medical University, International Medical Center)

司会 : 畷川 芳彦 (埼玉医科大学国際医療センター 腫瘍内科)

- P1-155** **Preliminary Results of Safety and PK of Telisotuzumab Vedotin (T) in Japanese Patients with Advanced Solid Tumors**
Haruyasu Murakami (Shizuoka Cancer Center Hospital, Shizuoka, Japan)
- P1-156** **Preliminary results from fight-102: a phase 1 study of pemigatinib in Japanese patients with advanced malignancies**
Yasutoshi Kuboki (National Cancer Central Hospital East, Kashiwa, Chiba, Japan)
- P1-157** **Pharmacogenetic profile associated with toxicity of fluoropyrimidines in colorectal cancer patients from Kazakhstan**
Dmitriy Babenko (Scientific and research center, Karaganda Medical University, Kazakhstan)
- P1-158** **Missense mutation code c 2059 C to T in MLH 1 can be an Swedish founder mutation confirmed by using haplotype analysis**
Tao Liu (Department of Molecular medicine and surgery, Karolinska University, Sweden)
- P1-159** **PPARb regulates and stabilizes HIF-1a to enhance epithelial mesenchymal transition and metastasis**
Mei-Ling Sheu (Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan)
- P1-160** **IL-6 Induces and Releasing of MMP-9 in Murine Bone Marrow Neutrophils by Activating STAT3 Pathway**
Quanfu-Ma (Hubei Maternal and Child Health Hospital, China)

12:40-13:35 Poster Session 1-21 / ポスターセッション 1-21

P1-21 Translational Research2
TR2

Chair : Natsuko Chiba (Department of Cancer Biology, Institute of Development, Aging and Cancer, Tohoku University)
司会 : 千葉 奈津子 (東北大学加齢医学研究所 腫瘍生物学分野)

P1-161 **p16 and BRAF Immunohistochemistry as a screening assay in MLH1 deficient colorectal cancer**

Matuross Soukavanitch (Medical Oncology Department, Mahidol University, Thailand)

P1-162 演題取下

P1-163 **The clinical significance of EGFL6 as a cancer biomarker and its role in colorectal cancer**

Pan Shioh-Lin (Graduate Institute of Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taiwan / Ph.D. Program in Biotechnology Research and Development, College of Pharmacy, Taipei Medical University / TMU Biomedical Commercialization Center, Taipei Medical University)

P1-164 **Diagnostic potential of serum methylation levels of MAL gene for detection of early stage colorectal cancer**

Yanqun Liu (Colorectal Surgery, Singapore General Hospital, Singapore)

P1-165 **Resistin facilitates VEGF-A-dependent angiogenesis by inhibiting miR-16-5p in human chondrosarcoma cells**

Encore

Shih-Wei Wang (Department of Medicine, Mackay Medical College, Taiwan)

P1-166 演題取下

P1-167 **anti-PDGF-CC antibodies as tools for investigating tissue expression and PDGFR signalling in vivo**

Encore

Hong Li (Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden)

P1-168 **Natural Extracts from Plectranthus amboinicus Inhibit NLRP3 Inflammasome Activation through Multiple Signaling Pathways**

Wohn-Jenn Leu (School of Pharmacy, National Taiwan University, Taiwan)

12:40-13:35 Poster Session 1-22 / ポスターセッション 1-22

P1-22 Translational Research3
TR3

Chair : Tadaaki Yamada (Kyoto Prefectural University of Medicine)
司会 : 山田 忠明 (京都府立医科大学 呼吸器内科)

P1-169 **A novel CSF1R-c-kit dual antagonist eliminates tumor associated macrophage without elevating intratumoral MDSC level**

Ji Wang (Adlai Nortye Biopharma Co., Ltd., China)

P1-170 **Signal detection of chemotherapy-related cardiac dysfunction on small molecule tyrosine kinase inhibitors**

Takahito Mizuno (Department of Pharmacy, Tosei General Hospital / Graduate School of Pharmacy, Meijo University)

水野 貴仁 (公立陶生病院 / 名城大学 薬学研究科)

- P1-171** **Exploration of biomarkers for the choice of chemotherapy in colorectal cancer patients**
 Yoshihiko Fujita (Department of Genome Biology Kindai University Faculty of Medicine)
 藤田 至彦 (近畿大学医学部ゲノム生物学教室)
-
- P1-172** **PARP1 Controls KLF4-Mediated Telomerase Expression in Cancer Cells**
Encore Shu-Chun Teng (Department of Microbiology, College of Medicine, National Taiwan University, Taiwan)
-
- P1-173** **The combination of SGLT1 inhibitors circumvents acquired resistance to EGFR TKIs in NSCLC**
 Wei-Chien Huang (Graduate Institute of Biomedical Sciences, China Medical University, Taiwan)
-
- P1-174** **Improved efficacy of mitochondrial disrupting agents upon inhibition of biogenesis in triple-negative breast cancer**
 Pei-Yi Chu (Department of Pathology, Show Chwan Memorial Hospital, Taiwan / School of Medicine, College of Medicine, Fu Jen Catholic University / National Institute of Cancer Research, National Health Research Institutes)
-
- P1-175** **Repositioning of Sildenafil as a Chemosensitizer to Vincristine against Human Castration-Resistant Prostate Cancer**
 Juiling Hsu (School of Pharmacy, National Taiwan University, Taipei, Taiwan)
-
- P1-176** **T-cell receptor (TCR) sequencing for pharmacodynamic and response biomarkers of checkpoint blockade (CB)**
Encore Simon Papillon-Cavanagh (Bristol-Myers Squibb, Princeton, NJ, United States / Simon Papillon-Cavanagh and Alice M. Walsh are co-lead authors)
-
- P1-177** **Clinical and biological significance of thymopoietin- α in gastric cancer**
 Kai-Yuan Lin (Department of Medical Research, Chi Mei Medical Center, Taiwan / Department of Biotechnology, Cha Nan University of Pharmacy and Science)

12:40-13:35 Poster Session 1-23 / ポスターセッション 1-23

P1-23 Translational Research4 (Trials in Progress)
 TR4 (Trials in Progress)

- Chair : Hidekazu Hirano (National Cancer Center Hospital, Gastrointestinal Medical Oncology Division)
 司会 : 平野 秀和 (国立がん研究センター中央病院 (消化管内科))
-
- P1-178** **切除不能進行・再発胃癌患者の二次化学療法中における末梢神経障害と薬剤効果を検討する前向き多施設共同観察研究**
 Hiroaki Tanioka (Department of Clinical Oncology, Kawasaki Medical School Hospital)
 谷岡 洋亮 (川崎医科大学附属病院 臨床腫瘍科)
-
- P1-179** **免疫チェックポイント阻害薬の治験における免疫関連有害事象の対応について～CRCの立場から～**
 Ayumi Kiyokawa (Division of Clinical Trials, Chiba Cancer Center)
 清川 歩美 (千葉県がんセンター 治験臨床試験推進部)
-
- P1-180** **Randomized phase II study of osimertinib plus ramucirumab vs. osimertinib alone for EGFR mutation +ve nSqNSCLC: TORG1833**
 Takeshi Honda (Department of Internal Medicine, Division of Medical Oncology, Teikyo University School of Medicine)
EGFR変異陽性NSCLCに対するオシメルチニブ+ラムシルマブとオシメルチニブのランダム化第II相試験: TORG1833
 本田 健 (帝京大学医学部内科学講座 腫瘍内科)

- P1-181** **インターネット社会において、患者向けセミナーを開催する意義**
Kenta Kachi (CROee Inc. / Oncolo)
可知 健太 (株式会社クロエ / がん情報サイト「オンコロ」)
- P1-182** **Nivolumab + chemotherapy vs chemotherapy in EGFR-mutated NSCLC after 1L or 2L EGFR-TKIs (CheckMate 722)**
Keunchil Park (Samsung Medical Center at Sungkyunkwan University School of Medicine, Korea)
- P1-183** **CheckMate 592: a phase 2 exploratory study of biomarkers of efficacy for 1L nivolumab + ipilimumab in advanced NSCLC**
Encore
Nobuhisa Ohtsuka (Bristol-Myers Squibb, Japan)

12:40-13:35 Poster Session 1-24 / ポスターセッション 1-24

- P1-24** **Translational Research5 TR5**
Chair : Kenji Tsuchihashi (Department of Hematology, Oncology and Cardiovascular medicine)
司会 : 土橋 賢司 (九州大学病院 血液・腫瘍・心血管内科)
- P1-185** **Liquid biopsy for detection of actionable mutation in various cancer patients**
Shunji Takahashi (Cancer Institute Hospital, Japanese Foundation for Cancer Research)
高橋 俊二 (がん研究会 有明病院 総合腫瘍科)
- P1-186** **Efficacy of inhibition of BAD Ser99 phosphorylation by a novel small molecule in cisplatin resistant ovarian cancer**
Yanxin Wang (Cancer Science Institute of Singapore, National University of Singapore, Singapore)
- P1-187** **Association study of the ABCB1 rs1128503 polymorphism with the development of taxane-induced peripheral neuropathy**
Yuko Tanabe (Department of Medical Oncology, Toranomon Hospital / Department of Department of Breast and Medical Oncology, National Cancer Center Hospital)
タキサン誘発末梢神経障害の発現と ABCB1 rs1128503 の関連解析
田辺 裕子 (虎の門病院 臨床腫瘍科 / 国立がん研究センター中央病院 乳腺・腫瘍内科)
- P1-188** **Quantitative and spatial mass spectrometry evaluation of oncometabolite 2-hydroxyglutarate in gliomas**
Mitsuhiro Hayashi (Division of Molecular Pharmacology, National Cancer Center Research Institute)
脳腫瘍におけるオンコメタボライト 2-ヒドロキシグルタル酸の定量的および空間的評価
林 光博 (国立がん研究センター研究所、分子薬理研究分野)
- P1-189** **Role of Curcumin in reducing toxicity and adverse effects in locally advanced and metastatic breast cancer patients**
Shekhar Goyal (ATRCTRI, S.P. Medical College & AG of Hospitals, Bikaner, Rajasthan, India / Amity Institute of Molecular Medicine & Stem Cell Research (AIMMSCR), Amity University, Noida, (UP) India)
- P1-190** **L-Lysine increased the cytotoxicity effect of doxorubicin in MDA-MB-231 and MDA-MB-468 breast cancer cell lines**
Javad Chehri (Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Islamic Republic of / Moscow State Academy of Veterinary Medicine, Biotechnology (K.I. Skryabin), Russia)

P1-191 **WK0202, A Strong NQO1 Substrate, Improves Febrile Neutropenia and Myelosuppression Recovery after Anti-Cancer Therapy**
 Dipendra Khadka (Department of Medicine, Wonkwang University School of Medicine, Korea)

P1-192 **演題取下**

P1-193 **レゴラフェニブの血中濃度と有害事象およびABCG2、OATP1B1 遺伝子多型との関連**
 Kei Irie (Faculty of Pharmaceutical Sciences, Kobe Gakuin University / Department of Pharmacy, Kobe City Hospital Organization, Kobe City Medical Center General Hospital)
 入江 慶 (神戸学院大学薬学部 / 神戸市立医療センター中央市民病院 薬剤部)

P1-194 **兵庫県立がんセンターにおけるがんゲノム診療**
 Takuma Onoe (Department of Medical Oncology, Hyogo Cancer Center)
 尾上 琢磨 (兵庫県立がんセンター 腫瘍内科)

12:40-13:35 Poster Session 1-25 / ポスターセッション 1-25

P1-25 Translational Research6 TR6

Chair : Junichiro Yuda (Department of Hematology and Experimental Therapeutics)
 司会 : 湯田 淳一郎 (国立がん研究センター東病院 血液腫瘍科 / 先端医療科)

P1-195 **Development of new treatment using CMG for oxaliplatin-resistant colorectal cancer with KRAS mutation**
 Masashi Kanai (Department of Medical Oncology, Kyoto University Hospital)
オキサリプラチン抵抗性のKRAS変異大腸癌に対するCMG注射製剤を用いた新規治療法の開発
 金井 雅史 (京都大学医学部附属病院 腫瘍内科)

P1-196 **Interim analysis: Ph1 study of cemiplimab, a human monoclonal antibody to programmed death (PD)-1, in Japanese patients**
 Shigehisa Kitano (National Cancer Center Hospital, Department of Experimental Therapeutics, Tokyo, Japan)

P1-197 **Single siRNA directed modulation of HPV18 oncogenes by post transcriptional and transcriptional gene silencing**
Encore
 Madeeha Mudassir (Department of Biochemistry, All India Institute of Medical Sciences, India)

P1-198 **A phase 1 study of niraparib in Japanese patients with advanced solid tumors**
 Ryota Shibaki (Department of Experimental Therapeutics, National Cancer Center Hospital)
 柴木 亮太 (国立がん研究センター中央病院 先端医療科)

P1-199 **New molecular and therapeutic insight into KRAS-driven pancreatic cancer**
 Yoshihito Kano (Department of Laboratory Medicine and Pathobiology, University of Toronto / Department of Clinical Oncology, Tokyo Medical and Dental University)
KRASチロシンリン酸化モデルに基づく膵癌新規分子機構と治療戦略
 加納 嘉人 (トロント大学 Laboratory Medicine & Pathobiology / 東京医科歯科大学 臨床腫瘍学)

P1-200 **Phase 1 study of IDO1 inhibitor navoximod (GDC-0919) in Japanese patients with advanced solid tumors**
 Noboru Yamamoto (Department of Experimental Therapeutics, National Cancer Center)
IDO1阻害剤Navoximod(GDC-0919) の日本人固形癌を対象とした第1相臨床試験
 山本 昇 (国立がん研究センター中央病院)

P1-201 **The clinical significance of PD-L1 expression intensity in the relapse of non-small cell lung cancer**
 Koji Teramoto (Department of Medical Oncology, Shiga University of Medical Science / Cancer Center, Shiga University of Medical Science Hospital)

非小細胞肺がんの再発におけるPD-L1発現強度の意義
 寺本 晃治 (滋賀医科大学 臨床腫瘍学講座 / 滋賀医科大学医学部附属病院 腫瘍センター)

P1-202 **Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer**
Encore

Haruka Kuno (Department of Pulmonary Medicine, Japanese Red Cross Kyoto Daini Hospital)
EGFR遺伝子変異陽性肺癌における免疫チェックポイント阻害剤の有効性に関する後方視的多施設共同研究
 久野 はるか (京都第二赤十字病院 呼吸器内科)

P1-203 **Roles of FGFR inhibition on murine RCC cells in antitumor activity of combination of lenvatinib plus anti-PD-1 antibody**
Encore

Yusuke Adachi (Eisai Co., Ltd)
マウス腎癌細胞におけるLenvatinibとPD-1抗体の併用におけるFGFR阻害作用の役割
 安達 雄亮 (エーザイ株式会社)

12:40-13:35 Poster Session 1-26 / ポスターセッション 1-26

P1-26 Palliative Care/Symptom Management1
 緩和ケア・支持療法 1

Chair : Naotoshi Sugimoto (Department of medical Oncology, Osaka International Cancer Institute)
 司会 : 杉本 直俊 (大阪国際がんセンター 腫瘍内科)

P1-204 **白金製剤アナフィラキシー既往患者に対する白金製剤の再投与についての検討**
 Keiichi Uchiyama (Post graduate education division, Fujita Health University / Clinical Oncology, Fujita Health University)
 内山 桂一 (藤田医科大学 臨床研修センター / 藤田医科大学 臨床腫瘍科)

P1-205 **化学療法施行中に薬剤性肺障害を来した症例の検討**
 Hiroshi Soeda (Medical Oncology Department, Mitsui Hospital)
 添田 大司 (三井病院 腫瘍内科)

P1-206 **演題取下**

P1-207 **2 Fast 2 Furious: A pitfall in immune checkpoint blockade?**
 Hadi bin Ab. jalil (Clinical Oncology Department, University Malaya Medical Centre, Malaysia)

P1-208 **デノスマブ投与後に重度の低カルシウム血症が遷延した一例**
 Yousuke Katata (Medical oncology Department, Kawasaki Medical School)
 堅田 洋佑 (川崎医科大学附属病院)

P1-209 **利尿作用のある生薬を含む漢方薬が癌性胸膜炎の緩和に有用であった2症例の検討**
 Tomoharu Yoshiya (Hatsukaichi Memorial Hospital)
 吉屋 智晴 (廿日市記念病院)

12:40-13:35 Poster Session 1-27 / ポスターセッション 1-27

P1-27 Palliative Care/Symptom Management2 (Cancer-Associated Thromboembolism)
緩和ケア・支持療法 2 (血栓・抗凝固療法)

Chair : Yoshihiro Torimoto (Oncology Center, Asahikawa Medical University Hospital)
司会 : 鳥本 悦宏 (旭川医科大学病院 腫瘍センター)

P1-210 Fluoropyrimidine-based chemotherapy for gastrointestinal cancer in patients with direct oral anticoagulants or warfarin

Yuki Matsubara (Kouseiren Takaoka Hospital)

ワルファリンまたはDOAC使用例における消化器癌化学療法の検討

松原 裕樹 (厚生連高岡病院)

P1-211 Analysis of gastrointestinal cancer and cancer associated thrombosis

Koji Nakashima (University of Miyazaki Hospital, Department of Clinical oncology)

消化器癌とがん関連血栓症の検討

中島 孝治 (宮崎大学医学部附属病院 臨床腫瘍科)

P1-212 胃がん関連血栓症予測因子の検討

Sara Horie (Tokyo Saiseikai Central Hospital)

堀江 沙良 (済生会中央病院 内科)

P1-213 消化器癌患者に合併した静脈血栓症に対する抗凝固療法の現状

Masami Miyagawa (Department of Gastroenterology and Hepatology, Kyoto City Hospital)

宮川 昌巳 (京都市立病院 消化器内科)

P1-214 Efficacy of recombinant human soluble thrombomodulin in cancer patients with disseminated intravascular coagulation

Masako Sugita (KOGA General Hospital)

当院における悪性腫瘍患者に対するトロンボモジュリン製剤 (rTM) の有用性の検討

杉田 昌子 (古賀総合病院)

P1-215 Safety and effectiveness of direct oral anticoagulants for venous thromboembolism in patients with active cancer

Misato Ogata (Department of Medical Oncology, Kobe City Medical Center General Hospital)

緒方 美里 (神戸市立医療センター中央市民病院 腫瘍内科)

P1-216 Cancer-associated cerebral infarction, a single center experience

Misao Fukuda (Department of Oncology, Kameda Medical Center)

福田 美佐緒 (亀田総合病院 腫瘍内科)

12:40-13:35 Poster Session 1-28 / ポスターセッション 1-28

P1-28 Palliative Care/Symptom Management3
緩和ケア・支持療法 3

Chair : Emi Kubo (National Cancer Center Japan)

司会 : 久保 絵美 (国立がん研究センター中央病院)

P1-217 Practical Trials of Steroid Sparing in Moderate-emetic-risk Gastrointestinal Cancer Chemotherapy

Yasutaka Inoue (Department of Pharmacy, Sapporo City General Hospital)

Steroid Sparingを考える-実践的導入事例の検討-

井上 靖隆 (市立札幌病院 薬剤部)

P1-218 Chemotherapy Induced Nausea and Vomiting and Quality of Life of Patients On Moderate And Highly Emetogenic Chemotherapy
 Eznal Izwadi Bin Mohd Mahidin (Department of Radiotherapy and Oncology, Hospital Sultan Ismail, Johor Bahru, Johor, Malaysia)

P1-219 入院カルボプラチンレジメンにおける制吐療法の検討
 Daisuke Ueki (National Hospital Organization Tokyo National Hospital)
 植木 大介 (国立病院機構 東京病院)

P1-220 Cost-effectiveness of aprepitant in patients who treated with cisplatin-containing highly emetogenic chemotherapy
Encore
 Ikuto Tsukiyama (Faculty of Pharmacy, Meijo University / Gifu Prefectural Tajimi Hospital)
シスプラチン含有化学療法誘発性の悪心・嘔吐に対するアプレピタントの費用効果分析
 柴山 郁人 (名城大学薬学部 / 岐阜県立多治見病院)

P1-221 Capsaicin application for prevention of chemotherapy induced neuropathy from paclitaxel or oxaliplatin, phase II study
 Chutima Upachar (Department of Medicine, Bhumibol Adulyadej Hospital, Royal Thai Air Force, Thailand)

P1-222 Effectiveness and safety of using hydromorphone for gastrointestinal cancer pain
 Koichi Taira (Osaka City University Graduate School of Medicine)
 平良 高一 (大阪市立大学 消化器内科)

P1-223 高度腹水を有する切除不能・進行再発癌に対する腹水濾過再静注療法併用化学療法の後方視的検討
 Atsujiro Nishioka (Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University)
 西岡 敦二郎 (佐賀大学医学部 血液・呼吸器・腫瘍内科)

P1-224 Investigation of efficacy and safety of cancer ketogenic diet
 Keisuke Hagihara (Department of Advanced Hybrid Medicine, Osaka University Graduate School of Medicine)
癌ケトン食療法の有用性と安全性の検討
 萩原 圭祐 (大阪大学大学院医学系研究科 先進融合医学共同研究講座)

12:40-13:35 Poster Session 1-29 / ポスターセッション 1-29

P1-29 Palliative Care/Symptom Management4
緩和ケア・支持療法 4
 Chair : Masahiro Tabata (Clinical Oncology Center, Okayama University Hospital)
 司会 : 田端 雅弘 (岡山大学病院 腫瘍センター)

P1-225 ラムシルマブ (RAM) 投与患者における蛋白尿発現に与えるリスク因子についての検討
 Tomoya Tanaka (Department of Pharmacy, Ako City Hospital)
 田中 智也 (赤穂市民病院 薬剤部)

P1-226 Successful treatment of immune checkpoint inhibitor-related severe hepatitis with mycophenolate mofetil
 Yoshimi Fujishima (Department of Medical Oncology/Hematology, Kobe University Hospital)
免疫チェックポイント阻害剤による重篤な肝炎に対して mycophenolate mofetil が奏効した 1 例
 藤島 佳未 (神戸大学医学部附属病院 腫瘍・血液内科)

P1-227 EGFR阻害薬による爪囲炎のケアに関連した予防因子の検討：前向き観察研究
 Asako Ryu (nursing Division, National Cancer Center Hospital)
 柳 朝子 (国立がん研究センター中央病院看護部)

- P1-228** **An investigation about the efficacy of measuring serum procalcitonin in patients with advanced urological cancer**
Hiroshi Yaegashi (Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science)
進行泌尿器癌患者における血清プロカルシトニン測定の有用性に関する検討
八重樫 洋 (金沢大学大学院 医薬保健学域医学類 泌尿器集学的治療学)
- P1-229** **外来化学療法を受ける術後再発・切除不能膀胱癌患者のQOLの様相**
Kanako Iwami (Hiroshima Prefectural Hospital)
岩見 加奈子 (県立広島病院)
- P1-230** **Comparison Between Low and Normal Muscle Mass to Quality of Life in Breast Cancer Patients A Preliminary Study**
Andree Kurniawan (Internal Medicine Department, Faculty of Medicine, Pelita Harapan University, Indonesia)

12:40-13:35 Poster Session 1-30 / ポスターセッション 1-30

- P1-30** **Cross-sectional Program1 (Complications)**
臓器横断プログラム 1 (合併症)
Chair : Keigo Komine (Department of Medical Oncology, Tohoku Unuversity Hospital)
司会 : 小峰 啓吾 (東北大学病院 腫瘍内科)
- P1-231** **Chemo port usage and complications in University of Malaya Medical Centre**
FOOK YEW HENG (Radiotherapy and Oncology Unit, University Malaya Medical Centre, Malaysia)
- P1-232** **Feasibility study of a short infusion with bevacizumab**
Akiko Konomatsu (Department of Pharmacy, Nippon Medical School Musashikosugi Hospital)
ヒト化モノクローナル抗体 (ベパシズマブ) における投与速度短縮の安全性試験
此松 晶子 (日本医科大学武蔵小杉病院 薬剤部)
- P1-233** **Association of serum levels of KL-6 with the development of anti-PD-1-related pneumonitis in patients with solid tumors**
Kazuaki Harada (Department of Medical Oncology, Kushiro Rosai Hospital, Kushiro, Japan / Department of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan)
原田 一顕 (釧路労災病院 腫瘍内科 / 釧路労災病院 内科)
- P1-234** **Five cases of trousseau syndrome occurred during chemotherapy**
Toshimitsu Tanaka (Multidisciplinary treatment cancer center, Kurume University Hospital / Department of Medicine, Division of Gastroenterology, Kurume University)
化学療法中に発症したトルソー症候群 5 例の検討
田中 俊光 (久留米大学病院がん集学治療センター / 久留米大学医学部内科学講座消化器内科部門)
- P1-235** **The incidence of Immuno-related adverse events induced by Nivolumab in solid tumors**
Ayumi Fujimoto (Pharmaceutical Department, Osaka City General Hospital)
固形癌でのニボルマブによる免疫関連副作用の発現状況
藤本 亜弓 (大阪市立総合医療センター 薬剤部)
- P1-236** **Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy**
Momoko Takahashi (Medical Oncology Department, Toranomon Hospital)
高橋 萌々子 (虎の門病院 臨床腫瘍科)

P1-237 The roles of essential amino acid tryptophan in cancer related sarcopenia
Sorano Ninomiya (First Department of Internal Medicine, Gifu University Graduate School of Medicine)
二宮 空暢 (岐阜大学医学部附属病院第一内科)

P1-238 悪性腫瘍患者における静脈血栓塞栓症 (VTE) の検討
Hiroya Ashimine (Medical Oncology Department, Kameda Medical Center)
安次嶺 宏哉 (亀田総合病院 腫瘍内科)

P1-239 Antibiotic therapy augments the efficacy of gemcitabine-containing regimens for advanced cancer: A retrospective study
Hiroo Imai (Department of Medical Oncology, Tohoku University Hospital / Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University)
抗生剤併用によるゲムシタピン療法の治療効果の改善に関する後方視的解析
今井 源 (東北大学病院 腫瘍内科 / 東北大学加齢医学研究所臨床腫瘍学分野)

P1-240 Risk of hepatitis B virus reactivation in patients with solid tumors receiving systemic chemotherapy
Yuka Kobayashi (Nagaoka Chuo General Hospital)
固形がん化学療法におけるHBVのリスク
小林 由夏 (長岡中央総合病院)

12:40-13:35 Poster Session 1-31 / ポスターセッション 1-31

P1-31 Cross-sectional Program2 (Special Populations/Epidemiology)
臓器横断プログラム2 (特殊病態・疫学)

Chair : Takashi Ogura (Department of Clinical Oncology, St.Marianna University School of Medicine)
司会 : 小倉 孝氏 (聖マリアンナ医科大学 臨床腫瘍学講座)

P1-241 Features of adolescent and young adult cancer patients in Japan
Yuka Aida (Department of Medical Oncology, Faculty of Medicine, University of Tsukuba)
日本におけるAYA世代がんの特徴
會田 有香 (筑波大学医学医療系 腫瘍内科学)

P1-242 Investigation of clinical sequencing for patients with advanced cancer refractory to standard treatments
Yasuki Hijikata (Department of General Medicine, IMSUT Hospital)
当科における既治療抵抗性進行がんに対する臨床シーケンスの検討
土方 康基 (東京大学医科学研究所附属病院 総合診療科)

P1-243 演題取下

P1-244 Cancer Incidence and Mortality rate in Cancer Center, Mittaphab Hospital, Laos, data from Hospital-based cancer Registry
Douangprachanh Sathathone (Obstetric-Gynecology Department, Cancer Center, Mittapharb Hospital, Lao People's Democratic Republic)

**P1-245 東日本大震災前後における福島県の部位別年齢階級別罹患率の動向
～がん検診を行っている5部位について～ (第2報)**
Eisaku Sasaki (Department of Medical Oncology, Fukushima Medical University)
佐々木 栄作 (福島県立医科大学 腫瘍内科学講座)

P1-246 Clinical Profile of HIV-Infected Patients with Malignancy at Dharmais National Cancer Center Hospital

Sri Agustini Kurniawati (Division of Hematology and Medical Oncology, Department of Internal Medicine, Dharmais National Cancer Center Hospital, Indonesia)

12:40-13:35 Poster Session 1-32 / ポスターセッション 1-32

**P1-32 Multidisciplinary Team Program 1 (Interdisciplinary Approach/Local Cooperation Systems)
多職種連携 1 (チーム医療・地域連携)**

Chair : Masami Kawahara (Aichi Gakuin University, School of Pharmacy)

司会 : 河原 昌美 (愛知学院大学薬学部)

**P1-247 化学療法中の患者と看護師間での有害事象の認識の差の実態調査
～CTCAE評価法を用いて～**

Nanako Hakozaiki (Nursing department, Fukuoka Wajiro Hospital)

箱崎 奈々子 (福岡和白病院 看護部)

P1-248 がん患者に対する看護師の精神腫瘍科連携システムの構築を目指して

Miwako Saitou (National Cancer Center Hospital, Department of Nursing)

齋藤 美和子 (国立がん研究センター中央病院 看護部)

P1-249 地域におけるがん化学療法チーム医療研修—都道府県がん診療連携拠点病院の取り組み—

Miwako Nakamura (Department of Nursing, Kyushu University Hospital / Kyushu University Hospital, Health Networking Center / Kyushu University Hospital, Cancer Center)

中村 美和子 (九州大学病院 看護部 / 九州大学病院 医療連携センター / 九州大学病院 がんセンター)

P1-250 地域の中核病院の肺がん実地診療におけるがんリハビリテーション

Takamoto Saijo (General Internal Medicine, Toda Central General Hospital)

西條 天基 (戸田中央総合病院 一般内科)

P1-251 Retrospective analysis about intervention for the patients who have children under 18 years old in our hospital

Kiyomi Misawa (Nursing Department, The Cancer Institute Hospital of JFCR / Palliative Care Center, The Cancer Institute Hospital of JFCR)

がん専門病院における18歳以下の子どもをもつがん患者へのかかわりに関する実態調査

三澤 貴代美 (がん研究会有明病院 看護部 / がん研究会 有明病院 緩和ケアセンター)

P1-252 An effect of adhesive barrier-forming solution for chemotherapy-induced oral mucositis and cooperation with dentistry

Takashi Shibata (Japanese Red Cross Nagoya Daini Hospital, Department of Pharmacology)

化学療法由来の口内炎に対するハイドロゲル創傷被覆・保護剤の効果及び歯科との連携

柴田 剛志 (名古屋第二赤十字病院 薬物療法内科)

P1-253 内服抗がん剤診察前面談における多職種での取り組み

Yoriko Kawashima (Omihachiman Community Medical Center)

川嶋 頼子 (近江八幡市立総合医療センター 看護部)

P1-254 Expectations and challenges for TeamOncology workshops

Chihiro Kondoh (Department of Medical Oncology, Toranomon Hospital)

がんチーム医療ワークショップへの期待と課題

近藤 千紘 (虎の門病院 臨床腫瘍科)

12:40-13:35 Poster Session 1-33 / ポスターセッション 1-33

P1-33 Multidisciplinary Team Program2 (Controlling Occupational Exposure to Chemotherapy)
多職種連携 2 (抗がん剤曝露対策)

Chair : Toshiaki Nakayama (Saitama Children's Medical Center Department of Pharmacy)
司会 : 中山 季昭 (埼玉県立小児医療センター 薬剤部)

P1-255 Investigation of anticancer agent exposure in the angiography room and future problem
Yumi Takahashi (Department of Nursing, Saiseikai Niigata Hospital)

放射線科血管造影 (アンギオ) 室の抗がん剤曝露調査と今後の課題
高橋 由美 (済生会新潟病院 看護部)

P1-256 当院における清掃担当者の抗がん剤職業性曝露の現状と課題
Yoko Hamada (Department of Nursing, Japanese Red Cross Ishinomaki Hospital)
濱田 陽子 (石巻赤十字病院 看護部)

P1-257 抗がん剤調製に可視化手法を用いての多職種連携による院内曝露対策の取り組み
Yuko Hasebe (Suwa Red Cross Hospital)
長谷部 優子 (諏訪赤十字病院)

P1-258 An action for correspondence common knowledge at the environmental pollution with the anticancer drug
Michie Takahashi (hakodate goryoukaku hospital)

抗がん薬での環境汚染時の対応周知へ向けた取り組み
高橋 美知枝 (函館五稜郭病院)

P1-259 抗がん剤の腔内・動脈内注入時における曝露対策への取り組み
Naoko Kurushima (Kita-Harima Medical Center)
久留嶋 尚子 (北播磨総合医療センター)

P1-260 閉鎖式輸液ラインの病棟導入に向けた取り組み
Mika Murata (Southern TOHOKU Reserch Institute for Neuroscience Nursing Department)
村田 美佳 (一般財団法人脳神経疾患研究所附属総合南東北病院看護部)

P1-261 CSTD導入における手技習得に向けた指導方法の検討
Rie Hirayama (fukuokawajiro hospital)
平山 理恵 (福岡和白病院)

P1-262 がん化学療法中の患者への曝露対策指導についての実態調査
Yuta Ueda (National Hospital Organization Iwakuni Clinical Center)
植田 悠太 (独立行政法人国立病院機構岩国医療センター)

12:40-13:35 Poster Session 1-34 / ポスターセッション 1-34

P1-34 Multidisciplinary Team Program3 (Immunotherapy-Related Toxicities)
多職種連携 3 (免疫チェックポイント阻害薬の副作用)

Chair : Tohru Hashida (Kobe City Medical Cnter General Hospital)
司会 : 橋田 亨 (神戸市立医療センター中央市民病院 薬剤部)

P1-263 Correlation between immune-related adverse events and the efficacy of immune checkpoint inhibitors
Masaaki Yanai (Department of Respiratory Medicine, Matsue City Hospital / Division of Medical Ontology and Molecular Respirology, Tottori University Faculty of Medicine)

免疫チェックポイント阻害薬による免疫関連有害事象の発現と治療効果についての検討
矢内 正晶 (松江市立病院 / 鳥取大学医学部附属病院 分子制御内科学)

- P1-264 Countermeasures for immune-related Adverse Events (irAE) caused by nivolumab, pembrolizumab and Atezolizumab**
 Yumiko Saeki (Department of pharmacy, Matsue city hospital)
当院におけるirAE発現状況と対策
 佐伯 由美子 (松江市立病院 薬剤部)
-
- P1-265 当院で免疫チェックポイント阻害薬を受ける患者の免疫関連有害事象発現時の症状の実態**
 Kazuko Nakajima (Chemotherapy/Supportive-care Center, Shizuoka Cancer Center)
 中島 和子 (静岡県立静岡がんセンター 化学療法・支持療法センター)
-
- P1-266 免疫チェックポイント阻害薬有害事象対策
 ～当院におけるチーム医療の取り組みと展望～**
 Chitose Yokomizo (Iizuka Hospital Cancer Multidisciplinary Therapy Center)
 横溝 千登勢 (飯塚病院 がん集学治療センター)

12:40-13:35 Poster Session 1-35 / ポスターセッション 1-35

- P1-35 Clinical Trial Facilitation Program1 (Clinical Research)**
臨床試験推進プログラム 1 (臨床研究)
 Chair : Tomohiro Nishina (National Hospital Organization Shikoku Cancer Center, Department of Gastrointestinal Medical Oncology)
 司会 : 仁科 智裕 (国立病院機構四国がんセンター 消化器内科)
-
- P1-267 Cost-effectiveness of pegfilgrastim in prostate cancer patients receiving cabazitaxel**
 Yu Kondo (Department of Pharmacy, Toyota Kosei Hospital)
カバジタキセル療法を受ける前立腺がん患者におけるペグフィルグラスチムの費用対効果
 近藤 有 (JA愛知厚生連豊田厚生病院薬剤部)
-
- P1-268 The potential and problem on precision medicine depends on onco-panel for geneprofiling**
 Yoshinari Okada (Department of Surgery, Tane General Hospital / Clinical Research, Innovation and Education Center, Tohoku University Hospital)
遺伝子パネル検査による高精度医療の可能性と課題
 岡田 佳也 (多根総合病院 外科 / 東北大学病院 臨床研究推進センター)
-
- P1-269 国際共同試験の地域間における治験実施計画書からの逸脱の検討**
 Hiromi Sasamoto (IQVIA Services Japan, Medical Scientific Services)
 笹本 博美 (IQVIAサービシーズジャパン株式会社 メディカル・サイエンティフィック・サービシーズ)
-
- P1-270 抗がん剤治験における治験実施計画書に関する、治験実施施設からの医学的質問事項のパイロット的検討**
 Hiromi Sasamoto (IQVIA Services Japan, Medical Scientific Services)
 笹本 博美 (IQVIAサービシーズジャパン株式会社 メディカル・サイエンティフィック・サービシーズ)
-
- P1-271 Trial of cost-effectiveness analysis of postoperative adjuvant therapy for lung cancer -Analysis with Uracil-Tegafur-**
 Takanori Miyoshi (General Thoracic Surgery, Yuai Memorial Hospital)
肺癌術後補助療法の費用対効果分析の試み -Uracil-Tegafurでの分析-
 三好 孝典 (友愛記念病院 呼吸器外科)

P1-272 Proposal of ideal vial sizes to cost reduction of wasted drug for trastuzumab
 Nobuhiko Nakamura (Education and Research Center for Clinical Pharmacy, Kyoto Pharmaceutical University)
トラスツズマブにおける無駄となる薬剤のコスト削減に対する最適なバイアル規格の提案
 中村 暢彦 (京都薬科大学 臨床薬学教育研究センター)

P1-273 Building and operating of strategic support organization for Practical Research for Innovative Cancer Control
 Yoshinori Makino (National Cancer Center)
革新的がん医療実用化研究事業の戦略的サポートを行う機関の構築と運営
 牧野 好倫 (国立がん研究センター)

P1-274 Establishment of support system for clinical trials under the Clinical Trials Act in National Cancer Center Hospital
 Eiko Yorikane (National Cancer Center Hospital)
国立がん研究センター中央病院における臨床研究法上の特定臨床研究支援体制
 寄兼 映子 (国立がん研究センター中央病院 臨床研究支援部門 研究企画推進部)

12:40-13:35 Poster Session 1-36 / ポスターセッション 1-36

P1-36 Case Reports/Series1 (Hematologic Malignancies)
 症例報告 1 (血液)

Chair : Masahiro Yokoyama (Division of Hematology Oncology, Cancer Institute Hospital)
 司会 : 横山 雅大 (がん研究会有明病院 血液腫瘍科)

P1-275 診断前に緊急ストーマ造設術を行い、早期に高用量多剤併用化学療法を導入出来た回盲部病変を有するバーキットリンパ腫の1例
 Takefumi Katsuragi (Department of Internal Medicine, Kitakyushu General Hospital)
 葛城 武文 (北九州総合病院 内科)

P1-276 肺腺癌の術後に大細胞性血管内リンパ腫が急速に進行し呼吸不全に至った一例
 Ayako Shiono (Department of Respiratory Medicine, International Medical Center, Saitama University Hospital)
 塩野 文子 (埼玉医科大学国際医療センター 呼吸器内科)

P1-277 Clinical outcome of carfilzomib for relapsed multiple myeloma. A single institution experience
 Eiju Negoro (Cancer Care Promotion Center, University of Fukui Hospital / Department of Hematology and Oncology, University of Fukui)
 根来 英樹 (福井大学医学部附属病院 がん診療推進センター / 福井大学 血液・腫瘍内科)

P1-278 Id therapy for elderly relapsed/refractory Multiple Myeloma
 Kenjiro Tomo (Department of Medical Oncology, Japanese Red Cross Otsu Hospital)
高齢者再発難治多発性骨髄腫におけるId療法の有用性
 塘 賢二郎 (大津赤十字病院 化学療法科)

P1-279 サリドマイド治療中に消化管穿孔を合併した多発性骨髄腫
 Kozue Yoshida (Department of Hematology, Iwate Prefectural Isawa Hospital)
 吉田 こず恵 (岩手県立胆沢病院 血液内科)

P1-280 A Case of Primary Bone Marrow Diffuse Large B-Cell Lymphoma with Hemophagocytic Syndrome (HPS)

Kisato Nosaka (Kumamoto University Hospital)

血球貪食症候群を合併した骨髄原発びまん性大細胞型B細胞リンパ腫

野坂 生郷 (熊本大学病院 血液内科)

12:40-13:35 Poster Session 1-37 / ポスターセッション 1-37

P1-37 Case Reports/Series2 (Hepatobiliary/Pancreatic Cancer)

症例報告 2 (肝胆臓)

Chair : Yoshiharu Motoo (Department of Medical Oncology, Kanazawa Medical University)

司会 : 元雄 良治 (金沢医科大学 腫瘍内科学)

P1-281 Bleeding sinonasal metastasis as a presentation of metastatic hepatocellular carcinoma

Kanta Makphanchareonkit (Division of Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand)

P1-282 新潟大学医歯学総合病院での膵臓癌患者の患者背景、治療選択と成績の変化

Yoshifumi Matsumoto (Medical Oncology Department, Niigata University)

松本 吉史 (新潟大学医歯学総合病院)

P1-283 NAC (GEM+nabPTX) and Antithrombotic Therapy (Dabigatran) for Borderline Resectable Pancreatic Cancer with SMV Thrombosis

Norio Emoto (Kokura Memorial Hospital)

SMV血栓を認めるborderline resectable膵頭部癌に対し、術前GEM+nabPTX療法と抗血栓療法を施行し、根治手術が可能となった一例

江本 憲央 (小倉記念病院)

P1-284 Clinical analysis of 27 cases with elderly unresectable advanced pancreas cancer

Mariko Kobayashi (Division of Gastroenterology, Tsukuba Memorial Hospital)

切除不能であった75歳以上進行膵癌 27例の臨床的検討

小林 真理子 (筑波記念病院)

P1-285 A case of unresectable pancreatic cancer with massive ascites received chemotherapy following CART

Hayato Mikuni (Division of Gastroenterology, Fuji City General Hospital / Division of Gastroenterology and Hepatology, The Jikei University School of Medicine)

大量悪性腹水貯留した切除不能膵癌にCARTを行うことで化学療法が継続できた一例

三國 隼人 (富士市立中央病院 消化器内科 / 東京慈恵会医科大学 消化器・肝臓内科)

P1-286 A case of intraductal papillary mucinous carcinoma treated by chemotherapy

Atsushi Kubo (Department of Gastroenterology, Takamatsu Red Cross Hospital)

IPMC (Stage4) に対して化学療法を施行した一例

久保 敦司 (高松赤十字病院 消化器内科)

P1-287 A Case of Gallbladder Cancer Harboring Same ERBB2 Mutation on the Primary Site and the Metachronous Metastasis

Chiaki Inagaki (Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine)

稲垣 千晶 (大阪大学大学院医学系研究科 先進薬物療法開発学寄附講座)

P1-38

Case Reports/Series3 (Colorectal Cancer/Small Bowel Cancer/Others)

症例報告 3 (直腸・小腸・その他)

Chair : Yasuo Hamamoto (Keio Cancer Center, Keio University School of Medicine)

司会 : 浜本 康夫 (慶應義塾大学 医学部 腫瘍センター)

P1-288

Complete pathological response after preoperative chemotherapy for locally advanced rectal cancer: a case report

Ryoichi Miyamoto (Department of Gastroenterological Surgery, Tsukuba Medical Center Hospital)

術前化学療法が奏効し切除可能となった局所進行直腸癌の1例

宮本 良一 (筑波メディカルセンター病院 消化器外科)

P1-289

Long-term survival of metastatic rectal cancer treated by low-dose regorafenib as salvage chemotherapy

Takashi Seki (Department of Surgery, Anjo Kosei Hospital)

低用量 Regorafenib 療法が有用であった StageIV 直腸癌の長期生存例

関 崇 (安城更生病院 外科)

P1-290

Synchronous para-aortic lymph node metastases of rectal cancer successfully treated using multidisciplinary therapy

Takahiro Kamiga (Department of Surgery, Shirakawa Kosei General Hospital)

集学的治療で根治術が可能となった同時性大動脈周囲リンパ節転のある直腸癌の1例

神賀 貴大 (白河厚生総合病院 外科)

P1-291

Imatinibによる術前化学療法が有用であった巨大直腸GISTの3症例

Hitoshi Fujii (Department of Surgery, Iwate Medical University)

藤井 仁志 (岩手医科大学)

P1-292

A case of tumor resection without bowel resection for multiple intestinal lipomatosis

Yasunori Yoshimoto (Tobata Kyoritsu Hospital)

多発小腸脂肪腫に対して腸管切除せずに腫瘍切除を行った1例

吉本 裕紀 (戸畑共立病院)

P1-293

虫垂 goblet cell carcinoid に対して化学療法の奏功が得られた1例

Atsushi Shirakawa (Department of Gastroenterology, Kyoto Second Red Cross Hospital)

白川 敦史 (京都第二赤十字病院 消化器内科)

P1-294

腸管MALTリンパ腫の二例

Masato Hoshikawa (Department of gastroenterology, Kishiwada Tokusuyukai Hospital)

星川 聖人 (医療法人徳洲会 岸和田徳洲会病院 消化器内科)